Methods for extending healthy lifespan and treating age-related diseases

JP2023547468A5Inactive Publication Date: 2024-11-01NATIONAL UNIVERSITY OF SINGAPORE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526223
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-29
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapeutic interventions targeting individual aging pathways are associated with significant side effects and do not effectively address the complex interplay of aging hallmarks, leading to an unmet clinical need for treatments and prevention of age-related diseases.

Method used

Inhibition of interleukin-11 (IL-11)-mediated signaling using agents such as antibodies or small molecules to target multiple aging pathways, including frailty, age-related changes in body composition, and age-related diseases.

Benefits of technology

This approach effectively reduces frailty, improves body composition, and extends healthy lifespan by inhibiting IL-11 signaling, addressing multiple aging pathways with reduced side effects compared to existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to the diagnosis, treatment, and prevention of age-related diseases and increasing healthy lifespan. Provided are methods for treating or preventing age-related diseases / conditions, particularly methods for treating or preventing frailty, comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signaling. Also provided are agents capable of inhibiting interleukin-11 (IL-11)-mediated signaling for use in such methods. Further provided is the use of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signaling in the manufacture of a medicament for use in such methods.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure relates to the diagnosis, treatment, and prevention of age-related diseases, as well as to increasing healthy life expectancy. [Background technology]

[0002] Age-related functional decline is common across multiple organs and physiological systems, resulting in an overall increased vulnerability to stressors, decreased resilience, and frailty. The manifestation of frailty is a major factor in shortening healthy lifespan (i.e., the lifespan of a healthy organism). Significant contributors to frailty are age-related declines in muscle mass, often accompanied by increased body fat mass. The accumulation of senescent cells increases reactive oxygen species, and sterile inflammation is a significant pathology in the aging process.

[0003] The key pathologies underlying aging are classified as “aging traits,” of which there are nine (Lopez-Otin et al., 2013)—specifically, telomere reduction, genomic instability, mitochondrial dysfunction, cellular senescence, stem cell depletion, loss of protein balance, disregulated nutrient sensing, epigenetic changes, and altered intercellular communication. Among these, the traits with the strongest evidence that can be genetically or therapeutically manipulated to mitigate age-related diseases and / or extend lifespan include nutrient sensing (Liu and Sabatini, 2020), loss of protein balance (Kaushik and Cuervo, 2015), and cellular senescence (Dolgin, 2020). Altered intercellular communication, particularly increased chronic inflammation and IL-6 upregulation, are also important characteristics that can be targeted to prevent, treat, and / or reverse the aging process (Furman et al., 2019; Ferrucci and Fabbri, 2018; Ershler and Keller, 2000).

[0004] Most of the data on pathways and key genes that promote one or more of the characteristics of aging comes from genetic studies in insects, flies, and mice. Cross-species data point to crucial roles for insulin / IGF-1 signaling (IIS), the mammalian target of rapamycin 1 (mTORC1), AMP-activated kinase (AMPK), and the MEK / ERK pathway (Slack et al., 2015; Liu and Sabatini, 2020; Burkewitz, Zhang, and Mair, 2014). Attempts have been made to target aging alone, but this does not address other characteristics and does not affect the major aging pathways (IIS, ERK, mTORC1, AMPK).

[0005] Therapeutic targeting of IIS at the insulin, its receptor, or IRS1 level is associated with significant toxicity. Inhibition of IIS-downstream mTORC, nutrient sensing, and other age-related processes is possible using immunosuppressive rapamycin, which has a lesser but still significant toxicity profile. Across species, rapamycin and rapamycin-like drugs (rapalogs) can improve healthy lifespan and extend lifespan (Zhang, Zhang and Wang, 2021; Fernandes and Demetriades, 2021). Activation of AMPK with metformin is an alternative approach that has been successfully used to improve healthy lifespan and extend lifespan (Burkewitz, Zhang and Mair, 2014). Notably, metformin depletes cellular energy stores and activates the nutrient-sensing LKB1 kinase upstream of AMPK rather than directly activating AMPK itself (Shaw et al., 2005). Experiments in flies have shown that therapeutic inhibition of MEK / ERK signaling with trimetinib can extend lifespan (Slack et al., 2015). Overall, to date, therapeutic interventions have targeted individual pathways involved in aging, and are associated with major side effects. There is no drug that inhibits all pathways.

[0006] There is an unmet clinical need for the development of therapies for the treatment and prevention of age-related diseases and conditions. [Overview of the project]

[0007] In a first aspect, the Disclosure provides a method for treating or preventing an age-related disease / condition, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling, wherein the age-related disease / condition is selected from: frailty, age-related increase in body fat, sarcopenia, age-related hyperlipidemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related hepatic steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related kidney disease, and age-related skin disease.

[0008] This disclosure also provides agents capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods of treating or preventing age-related diseases / conditions selected from: frailty, age-related increase in body fat mass, sarcopenia, age-related hyperlipidemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related hepatic steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related kidney disease, and age-related skin disease.

[0009] This disclosure also provides the use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in methods of treating or preventing age-related diseases / conditions selected from: frailty, age-related increase in body fat mass, sarcopenia, age-related hyperlipidemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related hepatic steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related kidney disease, and age-related skin disease.

[0010] This disclosure also provides agents capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods of treating or preventing weakness. This disclosure also provides the use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in treating or preventing weakness.

[0011] The disclosure also provides a method for treating or preventing weakness, which includes administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling to a target.

[0012] This disclosure also provides agents capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods of treating or preventing age-related changes in body composition. This disclosure also provides the use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in methods of treating or preventing age-related changes in body composition.

[0013] The disclosure also provides a method for treating or preventing age-related changes in body composition, which includes administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling to a target.

[0014] This disclosure also provides agents capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods to extend the healthy lifespan of subjects. This disclosure also provides the use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in extending the healthy lifespan of subjects.

[0015] The present disclosure also provides a method of extending the healthspan of a subject, the method comprising administering to the subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signaling.

[0016] In some embodiments, the agent is selected from the group consisting of an antibody or an antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer, or a small molecule. In some embodiments, the agent is an agent capable of blocking or reducing the binding of interleukin 11 (IL-11) to the interleukin 11 receptor (IL-11R).

[0017] In some embodiments, the agent is capable of binding to interleukin 11 (IL-11) or the interleukin 11 receptor (IL-11R). In some embodiments, the agent is an antibody or an antigen-binding fragment thereof.

[0018] In some embodiments, the agent is an anti-IL-11 antibody antagonist of IL-11-mediated signaling, or an antigen-binding fragment thereof. In some embodiments, the agent is an anti-IL-11Rα antibody antagonist of IL-11-mediated signaling, or an antigen-binding fragment thereof.

[0019] In some embodiments, the agent is a decoy receptor for IL-11. In some embodiments, the agent is a competitive inhibitor of IL-11. In some embodiments, the agent is capable of blocking or reducing the expression of interleukin 11 (IL-11) or the interleukin 11 receptor (IL-11R).

[0020] In some embodiments, the agent is an antisense oligonucleotide capable of blocking or reducing the expression of IL-11. In some embodiments, the agent is an antisense oligonucleotide capable of blocking or reducing the expression of IL-11Rα.

[0021] In some embodiments, the method involves administering a drug to a subject in whom the expression of interleukin-11 (IL-11) or the IL-11 receptor (IL-11R) is upregulated. [Brief explanation of the drawing]

[0022] [Figure 1] Graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on weakness in 110-week-old mice. [Figure 2] Graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on the body temperature of 110-week-old mice. [Figure 3] Figure 3A shows graphs and tables illustrating the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on changes in body fat mass. Figure 3B shows graphs and tables illustrating the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on changes in lean body mass. [Figure 4] Figure 4A is a graph and table showing the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on the mass of the soleus muscle as a percentage of body weight. Figure 4B is a graph and table showing the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on the mass of the gastrocnemius muscle as a percentage of body weight. [Figure 5] These images show the levels of IL-11 protein in the livers of 3-month-old and 28-month-old mice, as determined by Western blotting. [Figure 6A]This graph shows the effect of treatment with the anti-IL-11Rα antagonist antibody X209 or isotype-matched control IgG on P21 / Cdkn1a levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 6B] This graph shows the effect of treatment with the anti-IL-11Rα antagonist antibody X209 or isotype-matched control IgG on Il1b levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 6C] This graph shows the effect of treatment with the anti-IL-11Rα antagonist antibody X209 or isotype-matched control IgG on IL-11 levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 6D] This graph shows the effect of treatment with the anti-IL-11Rα antagonist antibody X209 or isotype-matched control IgG on Tgfb mRNA levels at day 7 of AML12 cells induced to undergo the cellular senescence program. [Figure 7A] This graph shows the effect of treatment with the anti-IL-11 antagonist antibody X203 or isotype-matched control IgG on P21 / Cdkn1a levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 7B] This graph shows the effect of treatment with the anti-IL-11 antagonist antibody X203 or isotype-matched control IgG on Il1b levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 7C] This graph shows the effect of treatment with the anti-IL-11 antagonist antibody X203 or isotype-matched control IgG on IL-11 levels at day 7 in AML12 cells induced to undergo a cellular senescence program. [Figure 7D] This graph shows the effect of treatment with the anti-IL-11 antagonist antibody X203 or isotype-matched control IgG on Tgfb mRNA levels at day 7 in AML12 cells induced to undergo the cellular senescence program. [Figure 8] These images show the levels of IL-11 protein in the liver, ventricles (heart), kidneys, soleus muscle, and gastrocnemius muscle of 110-week-old or 12-week-old male and female mice, as determined by Western blotting. [Figure 9] The graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on blood urea nitrogen (BUN) levels. The dotted line represents the mean BUN levels of 12-week-old male (51.3 mg / dl) and female (31.8 mg / dl) C57B1 / 6J mice. [Figure 10] The graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on serum creatinine levels. The dotted line represents the mean serum creatinine levels of 12-week-old male (0.92 mg / dl) and female (0.77 mg / dl) C57B1 / 6J mice. [Figure 11] The graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on serum triglyceride levels. The dotted line represents the mean serum triglyceride levels of 12-week-old male (54 mg / dl) and female (37 mg / dl) C57B1 / 6J mice. [Figure 12] The graphs and tables show the effect of treatment with the anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on liver triglyceride levels. The dotted line represents the mean liver triglyceride levels of 12-week-old male (165 mg / g) and female (130 mg / g) C57B1 / 6J mice. [Figure 13] The graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on serum cholesterol levels. The dotted line represents the mean serum cholesterol levels of 12-week-old male (149 mg / dl) and female (90 mg / dl) C57B1 / 6J mice. [Figure 14]The graphs and tables show the effect of treatment with anti-IL-11 antagonist antibody X203 or isotype-matched control IgG from 55 weeks of age on serum β-hydroxybutyrate levels. The dotted line represents the mean serum β-hydroxybutyrate levels of 12-week-old male (0.159 mM) and female (0.236 mM) C57B1 / 6J mice. [Figure 15] These are Western blot images showing the levels of p-LKB1, LKB1, p-mTOR, and mTOR in primary human cardiac fibroblasts stimulated with IL11 (10 ng / ml) for 15 minutes, 2 hours, 4 hours, 6 hours, or 24 hours. [Figure 16] IL-11 stimulates ERK-mediated phosphorylation of LKB1 serine 325 (S325) and P90RSK-mediated phosphorylation of LKB1 serine 428 (S428), subsequently inactivating AMPK and activating mTOR, P70RSK, and S6RP. (16A) A549 cells were infected with AAV8 encoding human LKB1 for 24 hours (infection multiplicity = 20) and then stimulated with IL-11 (10 ng / ml) for the indicated times (15 minutes, 2 hours, 4 hours, 6 hours, or 24 hours). Cell lysates were immunoblotted for the indicated proteins. (16B) Schematic diagram of the activation of ERK (direct) and P90RSK (indirect) by IL-11 signaling and its downstream effects on aging characteristics. P or p; phosphorylated amino acid. [Figure 17] Human hepatic stellate cells (17A) and hepatocytes (17B) were infected with AAV8 encoding human LKB1 for 24 hours (infection multiplicity = 20), and then stimulated with IL11 (10 ng / ml) for 2 hours. Cell lysates were immunoblotted for the indicated proteins. [Figure 18] Western blot images showing the levels of p-LKB1, LKB1, p-AMPK, and AMPK in unstimulated (BL+DMSO) or IL11-stimulated primary human cardiac fibroblasts for 24 hours in the presence of DMSO, rapamycin, wartmannin, or U0126. IL11 (10 ng / ml), rapamycin (10 nM), wartmannin (1 μM), U0126 (10 μM). [Figure 19]Western blot images showing the levels of p-ERK, ERK, p-P90RSK, P90RSK, p-LKB1, LKB1, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, SMA, and GAPDH in unstimulated (BL) or primary human cardiac fibroblasts stimulated for 24 hours with IL11 or TGFβ1 in the presence of X203, X209, or IgG(11E10) isotype controls. IL11 / TGFβ1 (10 ng / ml), IgG / X203 / X209 (2 μg / ml). [Figure 20] Western blot images showing the levels of p-ERK, ERK, p-P90RSK, P90RSK, p-LKB1, LKB1, p-AMPK, AMPK, p-acetyl-CoA carboxylase (p-ACC), acetyl-CoA carboxylase (ACC), p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, and S6RP in unstimulated (BL) or primary human hepatocytes stimulated for 24 hours with IL11, 0.5% BSA, or palmitate (saturated fatty acid) in the presence of X203, X209, or IgG(11E10) isotype controls. IL11 (10 ng / ml), IgG / X203 / X209 (2 μg / ml), and palmitate (0.5 mM) conjugated in free BSA (0.5% BSA solution) in a 6:1 ratio. [Figure 21] These are Western blot images showing the levels of p-ERK, ERK, p-P90RSK, P90RSK, p-LKB1, LKB1, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, SMA, and GAPDH in unstimulated (BL+DMSO) or IL11-stimulated primary human hepatic astrocytosis cells stimulated for 24 hours in the presence of DMSO or U0126 (10 μM). [Figure 22]These are Western blot images showing the levels of p-ERK, ERK, p-P90RSK, P90RSK, p-LKB1, LKB1, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, and S6RP in unstimulated primary human hepatocytes stimulated for 24 hours with (BL+DMSO) or IL11 in the presence of DMSO or U0126 (10 μM). [Figure 23] These are Western blot images showing the levels of p-LKB1, LKB1, p-AMPK, and AMPK in unstimulated (BL) or primary human hepatocytes or primary human hepatic astrocytocytes stimulated for 24 hours with increasing concentrations of IL-11 or IL-6 (1.25, 2.5, 5, 10, or 20 ng / ml). [Figure 24] (24A) Schematic diagram of the anti-aging experiment for the data shown in (24A)B-F. As described by Tripathi et al. (2020), aged AML12 was induced by treating cells with a sublethal concentration of H2O2 (0.75 mM) for 1 hour each day for 7 days, followed by a 23-hour recovery period. During the 23-hour recovery period, IgG / X2O9 (2 μg / ml) was added to the culture for 10 days; cells were harvested on day 10 for RNA extraction and subsequent qPCR experiments. (24B) Relative mRNA expression of Cdkn2a(p16), (24C) Cdkn1a(p21), (24D) Il1β, (24E) Il8 and (24F) Il11. [Figure 25] (25A)Schematic diagram of the aging reversal experiment for the data shown in B-D. Aged AML12 was generated for 7 days as described above. At the end of the 72-hour aging induction period, IgG / X203 / X209 (2 μg / ml) was added to the culture; cells were harvested on day 10 for RNA extraction and subsequent qPCR experiments. (25B)Relative mRNA expression of Cdkn1a(p21), (25C)Il1β and (25D)Il11. [Figure 26]This figure shows IL-11 expression in kidney cells of aged mice. The image (gray; right column) shows EGFP expression throughout the kidney of a 110-week-old IL11:EGFP reporter mouse: cortex, medulla, papillary processes, and renal blood vessels. EGFP staining was not observed in age-matched control kidneys from wild-type mice (left column). The scale represents 50 μm. [Figure 27] This figure shows IL-11 expression in ventricular and atrium cells of aged mice. EGFP expression (gray) is observed in the hearts of aged (110-week-old) IL11:EGFP reporter mice, particularly in the interstitium and perivascular regions. In the atria, specific staining is observed in the epicardium of aged IL11:EGFP mice. EGFP staining was not observed in age-matched controls or young (10-week-old) IL11:EGFP reporter mice. The scale represents 50 μm. [Figure 28] This figure shows IL-11 expression in lung cells of aged mice. EGFP expression (gray) is observed in the lungs of aged (110-week-old) IL11:EGFP reporter mice, particularly around the bronchioles. No EGFP staining was observed in age-matched controls or young (10-week-old) IL11:EGFP reporter mice. The scale represents 50 μm. [Figure 29] This figure shows IL-11 expression in spleen cells of aged mice. EGFP expression (gray) was observed in spleen cells of aged (110-week-old) IL11:EGFP reporter mice, and was also observed at a much lower level in spleens of younger (10-week-old) IL11:EGFP mice. No EGFP staining was observed in age-matched control spleens from wild-type mice. [Figure 30] These are Western blot images showing IL-11 levels in abdominal adipose tissue of 12 and 110-week-old wild-type male and female mice. [Figure 31]The livers of aged Il11ra1-deficient mice exhibit lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to wild-type mice. Images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, p16, p21, and GAPDH in the livers obtained from 10 or 110-week-old male Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, as determined by Western blotting (n=3 / group). [Figure 32] The gastrocnemius muscle of aged Il11ra1-deficient mice exhibits lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to wild-type mice. The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p16, p21, and GAPDH in the gastrocnemius muscle obtained from 10 or 110-week-old male Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, as determined by Western blotting. [Figure 33] The soleus muscle of aged Il11ra1-deficient mice exhibits lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to wild-type mice. The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, p16, p21, and GAPDH in the soleus muscle obtained from 10 or 110-week-old male Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, as determined by Western blotting. [Figure 34]Abdominal fat of aged Il11ra1-deficient mice exhibits lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to wild-type mice. The images show levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p16, p21, and GAPDH in abdominal fat obtained from 10 or 110-week-old male Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, as determined by Western blotting. [Figure 35] Aged Il11ra1 knockout mice had lower body weight compared to wild-type controls. Graphs and tables show the body weight of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice; two-way ANOVA. [Figure 36] Aged Il11ra1 knockout mice had less body fat compared to wild-type controls. Graphs and tables show the percentage of body fat (body fat mass (g) / body weight (g)) in 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, determined by echo-MRI; two-way ANOVA. [Figure 37] Aged Il11ra1 knockout mice had a higher percentage of lean muscle mass compared to wild-type controls. Graphs and tables show the percentage of lean muscle mass (muscle mass (g) / body weight (g) expressed as %) of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, determined by echo-MRI; two-way ANOVA. [Figure 38]Aged Il11ra1 knockout mice showed reduced frailty compared to wild-type controls. Graphs and tables show frailty scores of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, blinded and performed using the protocol published by Rizzo et al. (2018), Healthspan and lifespan measures in aging mice: Optimization of testing protocols, replicabability, and rater reliability, Current Protocols in Mouse Biology, 8, e45.doi:10.1002 / cpmo.45; two-way ANOVA. [Figure 39] Aged Il11ra1 knockout mice showed reduced body temperature compared to wild-type controls. Graphs and tables show body temperature of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice; two-way ANOVA. [Figure 40] Aged Il11ra1 knockout mice had less abdominal fat and more muscle (soleus and gastrocnemius) compared to wild-type controls. Graphs and tables show (40A) abdominal fat, (40B) soleus muscle, and (40C) gastrocnemius muscle mass as a percentage of body weight for 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice; two-way ANOVA. [Figure 41] Aged Il11ra1 knockout mice had less fibrosis across organs compared to wild-type controls. Graphs and tables show collagen content in (38A) abdominal fat, (38B) gastrocnemius muscle, (38C) soleus muscle, and (38D) liver of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, determined by hydroxyproline assay; binary ANOVA. [Figure 42]Aged Il11ra1 knockout mice had less fibrosis across organs compared to wild-type controls. Graphs and tables show collagen content in the (42A) atria, (42B) ventricles, (42C) kidneys, and (42D) lungs of 110-week-old male and female Il11ra1+ / + (wild-type, expressing Il11ra1) or Il11ra1- / - (Il11ra1 knockout) mice, determined by a hydroxyproline assay; two-way ANOVA. [Figure 43] The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, p16, p21, and GAPDH in the livers of 12-week-old control male mice (n=3), IgG (n=5), and / or X203-treated male mice (n=5), as determined by Western blotting. [Figure 44] Figure 43 shows the semi-quantitative densitometry analysis (one-way ANOVA with Tukey correction) of the Western blot image. [Figure 45] The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p16, p21, and GAPDH in the gastrocnemius muscle obtained from 12-week-old control male mice (n=3), IgG (n=5), and / or X203-treated male mice (n=5), as determined by Western blotting. [Figure 46] Figure 45 shows the semi-quantitative densitometry analysis (one-way ANOVA with Tukey correction) of the Western blot image. [Figure 47] The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K, p70S6K, p-S6RP, S6RP, p16, p21, and GAPDH in the soleus muscle obtained from 12-week-old control male mice (n=3), IgG (n=5), and / or X203-treated male mice (n=5), as determined by Western blotting. [Figure 48] Figure 47 shows the semi-quantitative densitometry analysis (one-way ANOVA with Tukey correction) of the Western blot image. [Figure 49] The images show the levels of p-ERK, ERK, p-LKB, LKB, p-AMPK, AMPK, p-mTOR, mTOR, p16, p21, and GAPDH in abdominal fat obtained from 12-week-old control male mice (n=3), IgG (n=5), and / or X203-treated male mice (n=5), as determined by Western blotting. [Figure 50] Figure 49 shows the semi-quantitative densitometry analysis (one-way ANOVA with Tukey correction) of the Western blot image. [Figure 51] Neutralizing IL-11 antibodies reduce serum IL-6 protein levels in aged mice. The graph shows the effect of treatment with anti-IL11(X203) or IgG isotype controls on serum IL-6 levels in aged (110-week-old) male and female mice. The dotted line shows the mean serum IL-6 levels of 12-week-old control male (0.159 pg / ml) and female (0.236 pg / ml) mice. Data were analyzed by two-way ANOVA. [Figure 52] Neutralizing IL-11 antibodies reduce multiple inflammatory markers in the kidneys of aged mice. Wild-type C57BL6 / J mice were treated with intraperitoneal injection of anti-IL11 (X203; 40 mg / kg, once every 3 weeks) or isotype IgG control (11E10; 40 mg / kg, once every 3 weeks) from 55 weeks to 110 weeks of age. Mice were sacrificed at 110 weeks of age, organs were collected, rapidly frozen, and RNA was extracted using standard procedures. Samples were analyzed by quantitative RT-PCR (QPCR) using primers specific to Ccl2, Ccl5, Tnfα, Il1β, Il11, Il6, or Gapdh. [Figure 53]Neutralizing IL-11 antibodies reduce multiple inflammatory markers in the liver of aged mice. Wild-type C57BL6 / J mice were treated with intraperitoneal injection of anti-IL11 (X203; 40 mg / kg, once every 3 weeks) or isotype IgG control (11E10; 40 mg / kg, once every 3 weeks) from 55 weeks to 110 weeks of age. Mice were sacrificed at 110 weeks of age, organs were collected, rapidly frozen, and RNA was extracted using standard procedures. Samples were analyzed by quantitative RT-PCR (QPCR) using primers specific to Ccl2, Ccl5, Tnfα, Il1β, Il11, Il6, or Gapdh. [Figure 54] Neutralizing IL-11 antibody reduces multiple inflammatory markers in the skeletal muscle (soleus muscle) of aged mice. Wild-type C57BL6 / J mice were treated with intraperitoneal injection of anti-IL11 (X203; 40 mg / kg, once every 3 weeks) or isotype IgG control (11E10; 40 mg / kg, once every 3 weeks) from 55 weeks to 110 weeks of age. Mice were sacrificed at 110 weeks of age, organs were harvested, rapidly frozen, and RNA was extracted using standard procedures. Samples were analyzed by quantitative RT-PCR (QPCR) using primers specific to Ccl2, Ccl5, Tnfα, Il1β, Il11, Il6, or Gapdh. [Modes for carrying out the invention]

[0023] Interleukin-11 and IL-11 receptors Interleukin-11 (IL-11), also known as a lipid synthesis inhibitor, is a multifaceted cytokine and a member of the IL-6 family of cytokines, which includes IL-6, IL-27, IL-31, oncostatin, leukemia inhibitor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor (CNTF), and neuropoietin (NP-1).

[0024] Interleukin-11 (IL-11) is expressed in various cell types. The IL-11 genome sequence is mapped to the centromere regions of chromosomes 19 and 7 and is transcribed along with classical signal peptides that ensure efficient secretion from cells. The IL-11 activator protein complex, cJun / AP-1 located within its promoter sequence, is important for the fundamental transcriptional regulation of IL-11 (Du and Williams, Blood 1997, Vol 89: pp. 3897-3908). Immature human IL-11 is a 199-amino acid polypeptide, while mature IL-11 encodes a 178-amino acid protein (Garbers and Scheller, Biol. Chem. 2013; 394(9): pp. 1145-1161). The human IL-11 amino acid sequence is available under UniProt accession number P20809 (P20809.1 GI:124294; Sequence ID No. 1). Recombinant human IL-11 (oprelbequine) is also commercially available. IL-11 from other species, including mice, rats, pigs, cattle, some species of bony fish, and primates, has also been cloned and sequenced.

[0025] In this specification, “IL-11” means IL-11 derived from any species and includes isoforms, fragments, variants, or homologs of IL-11 derived from any species. In preferred embodiments, the species is human (Homo sapiens). Isoforms, fragments, variants, or homologs of IL-11 may, if necessary, be characterized by having at least 70%, preferably one of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with respect to the amino acid sequence of immature or mature IL-11 derived from a given species, e.g., human. Isoforms, fragments, variants, or homologs of IL-11 may optionally be characterized by their ability to bind to IL-11Rα (preferably derived from the same species) and stimulate signaling in cells expressing IL-11Rα and gp130 (as described, e.g., Curtis et al., Blood, 1997, 90(11); or Karpovich et al., Mol. Hum. Reprod. 2003 9(2): pp. 75-80). Fragments of IL-11 may be of any length (in terms of the number of amino acids), but may optionally be at least 25% of the length of mature IL-11, and may have one of the largest lengths of 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of mature IL-11. The IL-11 fragment may have a minimum length of 10 amino acids and a maximum length of one of 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 195 amino acids.

[0026] IL-11 signals via homodimers of ubiquitously expressed glycoprotein 130 (gp130; also known as glycoprotein 130, IL-6ST, IL-6-beta, or CD130). gp130 is a transmembrane protein that forms one subunit of the IL-6 receptor family and type I cytokine receptor. Specificity is obtained via individual interleukin-11 receptor subunit alpha (IL-11Rα), which is not directly involved in signal transduction, but the initial cytokine binding event to the α-receptor leads to the final complex formation with gp130.

[0027] Human gp130 (containing a 22-amino acid signal peptide) is a 918-amino acid protein, with the mature form being 866 amino acids, comprising a 597-amino acid extracellular domain, a 22-amino acid transmembrane domain, and a 277-amino acid intracellular domain. The extracellular domain of this protein contains the cytokine-binding module (CBM) of gp130. The CBM of gp130 contains the Ig-like domain D1 of gp130, as well as the fibronectin type III domains D2 and D3. The amino acid sequence of human gp130 is available under UniProt accession number P40189-1 (SEQ ID NO: 2).

[0028] Human IL-11Rα is a 422-amino acid polypeptide (UniProt Q14626; SEQ ID NO: 3) and shares approximately 85% nucleotide and amino acid sequence identity with mouse IL-11Rα. Two isoforms of IL-11Rα with different cytoplasmic domains have been reported (Du and Williams, cited above). The IL-11 receptor α chain (IL-11Rα) shares many structural and functional similarities with the IL-6 receptor α chain (IL-6Rα). The extracellular domain exhibits 24% amino acid identity, including a characteristic conserved Trp-Ser-X-Trp-Ser (WSXWS) motif. The short cytoplasmic domain (34 amino acids) lacks the Box 1 and 2 regions required for activation of the JAK / STAT signaling pathway.

[0029] The receptor binding sites on mouse IL-11 have been mapped, and three sites (sites I, II, and III) have been identified. Binding to gp130 is reduced by substitutions in the site II and site III regions. Site III mutants do not exhibit detectable agonist activity but possess IL-11Rα antagonist activity (Cytokine Inhibitors Chapter 8; Gennaro Ciliberto and Rocco Savino (eds.), Marcel Dekker, Inc. 2001).

[0030] In this specification, the IL-11 receptor (IL-11R) refers to a polypeptide or polypeptide complex capable of binding to IL-11. In some embodiments, the IL-11 receptor can bind to IL-11 and induce signaling in cells expressing that receptor.

[0031] The IL-11 receptor may be derived from any species and may include isoforms, fragments, variants, or homologs of the IL-11 receptor derived from any species. In a preferred embodiment, the species is human (Homo sapiens).

[0032] In some embodiments, the IL-11 receptor may be IL-11Rα. In some embodiments, the IL-11 receptor may be a polypeptide complex containing IL-11Rα. In some embodiments, the IL-11 receptor may be a polypeptide complex containing IL-11Rα and gp130. In some embodiments, the IL-11 receptor may be a complex containing gp130 or gp130 to which IL-11 binds.

[0033] Isoforms, fragments, variants, or homologs of IL-11Rα may, if necessary, be characterized by having at least 70%, preferably 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with respect to the amino acid sequence of IL-11Rα derived from a given species, e.g., human. Isoforms, fragments, variants, or homologs of IL-11Rα may, if necessary, be characterized by the ability to bind to IL-11 (preferably derived from the same species) and stimulate signaling in cells expressing IL-11Rα and gp130 (as described, e.g., Curtis et al., Blood, 1997, 90(11); or Karpovich et al., Mol.Hum.Reprod.2003 9(2):75-80). The IL-11 receptor fragment may be of any length (in terms of the number of amino acids), but may, if necessary, be at least 25% of the length of mature IL-11Rα and may have one maximum length of 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of mature IL-11Rα. The IL-11 receptor fragment may have a minimum length of 10 amino acids and one maximum length of 15, 20, 25, 30, 40, 50, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 400, or 415 amino acids.

[0034] IL-11 signaling IL-11 binds to IL-11Rα with low affinity (Kd approximately 22 nM; see Metcalfe et al., JBC (2020) manuscript RA119.012351), and the interaction between these binding partners alone is insufficient for biological signal transduction. Co-expression of IL-11Rα and gp130 is necessary to generate a high-affinity receptor (Kd approximately 400-800 pmol / L) that enables signal transduction (Curtis et al., Blood 1997;90(11):4403-12; Hilton et al., EMBO J 13:4765, 1994; Nandurkar et al., Oncogene 12:585, 1996). The binding of IL-11 to cell surface IL-11Rα primarily induces heterodimerization, tyrosine phosphorylation, activation, and downstream signaling of gp130 via mitogen-activated protein kinase (MAPK) cascades and activators of the Janus kinase / signaling factor and transcription (Jak / STAT) pathway (Garbers and Scheller, cited above).

[0035] In principle, soluble IL-11Rα can also form a bioactive soluble complex with IL-11 (Pflanz et al., 1999, FEBS Lett, 450, pp. 117-122), and, similar to IL-6, increases the possibility that IL-11 can bind to soluble IL-11Rα before binding to cell surface gp130 in some cases (Garbers and Scheller, cited above). Curtis et al. (Blood 1997 Dec 1;90(11):4403-12) described the expression of soluble mouse IL-11 receptor alpha chain (sIL-11R) and examined signal transduction in gp130-expressing cells. In the presence of gp130, rather than transmembrane IL-11R, sIL-11R mediated early intracellular events, including IL-11-dependent differentiation and proliferation of M1 leukemia cells in Ba / F3 cells, as well as phosphorylation of gp130, STAT3, and SHP2, similar to signaling by transmembrane IL-11R. Activation of cell membrane-bound gp130-mediated signaling by IL-11 bound to soluble IL-11R alpha has recently been demonstrated (Lokau et al., 2016, Cell Reports 14, pp. 1761-1773). While this so-called IL-11 transsignaling may be important for disease pathogenesis, its role in human diseases remains unstudied.

[0036] As used herein, “trans-signaling of IL-11” refers to the signaling induced by the binding of IL-11 bound to IL-11Rα to gp130. IL-11 may bind to IL-11Rα as a non-covalent complex. gp130 is membrane-bound and expressed by cells in which signaling occurs after the binding of the IL-11:IL-11Rα complex to gp130. In some embodiments, IL-11Rα may be soluble IL-11Rα. In some embodiments, soluble IL-11Rα is a soluble (secreted) isoform of IL-11Rα (e.g., lacking a transmembrane domain). In some embodiments, soluble IL-11Rα is the free product of proteolytic cleavage of the extracellular domain of IL-11Rα bound to the cell membrane. In some embodiments, IL-11Rα may be in a cell membrane-bound form, and signaling via gp130 is induced by the binding of IL-11 to cell membrane-bound IL-11Rα, which is called "IL-11 cis signaling." In preferred embodiments, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated cis signaling.

[0037] IL-11-mediated signaling has been shown to stimulate hematopoiesis and plateletogenesis, stimulate osteoclast activity, stimulate neurogenesis, inhibit lipid synthesis, reduce pro-inflammatory cytokine expression, modulate extracellular matrix (ECM) metabolism, and mediate the normal proliferation control of gastrointestinal epithelial cells (Du and Williams, op. cit.).

[0038] The physiological role of interleukin-11 (IL-11) remains unclear. IL-11 is most strongly associated with hematopoietic cell activation and platelet production. IL-11 has also been shown to confer protection against graft-versus-host disease, inflammatory arthritis, and inflammatory bowel disease, leading to its consideration as an anti-inflammatory cytokine (Putoczki and Ernst, J Leukoc Biol 2010, 88(6):1109-1117). However, IL-11 is both pro-inflammatory, anti-inflammatory, and pro-angiogenic, suggesting its importance to neoplasms. Recent studies have shown that IL-11 is readily detectable during virus-induced inflammation in mouse arthritis models and cancer, suggesting that pathological stimuli can induce IL-11 expression. IL-11 has also been associated with Stat3-dependent activation of tumorigenic target genes in neoplastic gastrointestinal epithelium (Putoczki and Ernst, op. cit.).

[0039] As used herein, “IL-11 signaling” and “IL-11-mediated signaling” refer to signaling mediated by the binding of IL-11 or a functional fragment of the mature IL-11 molecule to its receptor. “IL-11 signaling” and “IL-11-mediated signaling” are understood to refer to signaling initiated by IL-11 / its functional fragment, for example, through the binding of IL-11 to its receptor. “Signaling” then refers to signaling and other cellular processes that govern cellular activity.

[0040] Drugs that can inhibit the action of IL-11 Aspects of this disclosure include the inhibition of IL-11-mediated signaling. In this specification, “inhibition” refers to a reduction, decrease, or attenuation compared to a control condition. For example, inhibition of the action of IL-11 by a drug capable of inhibiting IL-11-mediated signaling refers to a reduction, decrease, or attenuation of the range / degree of IL-11-mediated signaling in the absence of the drug and / or in the presence of a suitable control drug.

[0041] Inhibition may also be referred to as neutralization or antagonism in this specification. That is, an agent capable of inhibiting IL-11-mediated signaling (e.g., interactions, signaling, or other activities mediated by IL-11 or IL-11-containing complexes) can be said to be a “neutralizing” or “antagonizing” agent with respect to the relevant function or process. For example, an agent capable of inhibiting IL-11-mediated signaling may be called an agent capable of neutralizing IL-11-mediated signaling, or an antagonist of IL-11-mediated signaling.

[0042] The IL-11 signaling pathway provides multiple pathways for inhibiting IL-11 signaling. Drugs capable of inhibiting IL-11-mediated signaling can do so, for example, by inhibiting the action of one or more factors involved in or required for signaling through IL-11 receptors.

[0043] For example, inhibition of IL-11 signaling can be achieved by disrupting the interaction between IL-11 (or an IL-11-containing complex, e.g., a complex of IL-11 and IL-11Rα) and the IL-11 receptor (e.g., IL-11Rα, a receptor complex containing IL-11Rα, gp130, or a receptor complex containing IL-11Rα and gp130). In some embodiments, inhibition of IL-11-mediated signaling is achieved, for example, by inhibiting the expression of one or more genes or proteins among IL-11, IL-11Rα, and gp130.

[0044] Inhibition of IL-11-mediated signaling can also be achieved by disrupting the interaction between IL-11:11 receptor complexes (i.e., complexes containing IL-11 and IL-11Rα, or IL-11 and gp130, or IL-11, IL-11Rα, and gp130) to form multimers (e.g., hexamer complexes) required for the activation of downstream signaling by cells expressing the IL-11 receptor.

[0045] In some embodiments, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated cis signaling rather than disrupting IL-11-mediated trans signaling; for example, inhibition of IL-11-mediated signaling is achieved by inhibiting a gp130-mediated cis complex containing membrane-bound IL-11Rα. In some embodiments, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated trans signaling rather than disrupting IL-11-mediated cis signaling; that is, inhibition of IL-11-mediated signaling is achieved by inhibiting a gp130-mediated trans signaling complex such as IL-11 bound to soluble IL-11Rα or IL-6 bound to soluble IL-6R. In some embodiments, inhibition of IL-11-mediated signaling is achieved by disrupting both IL-11-mediated cis signaling and IL-11-mediated trans signaling. Any of the agents described herein can be used to inhibit IL-11-mediated cis and / or trans signaling.

[0046] In other examples, inhibition of IL-11 signaling can be achieved by disrupting the downstream signaling pathway of IL-11 / IL-11Rα / gp130. That is, in some embodiments, inhibition / antagonism of IL-11-mediated signaling involves inhibition of the downstream signaling pathway / process / factor of signaling through the IL-11 / IL-11 receptor complex.

[0047] In some embodiments, inhibition / antagonism of IL-11-mediated signaling includes inhibition of signaling through intracellular signaling pathways activated by the IL-11 / IL-11 receptor complex. In some embodiments, inhibition / antagonism of IL-11-mediated signaling includes inhibition of one or more factors whose expression / activity is upregulated as a result of signaling through the IL-11 / IL-11 receptor complex.

[0048] In some embodiments, the methods of the present disclosure utilize agents capable of inhibiting JAK / STAT signaling. In some embodiments, agents capable of inhibiting JAK / STAT signaling can inhibit the action of JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and / or STAT6. For example, the agents may inhibit the activation of JAK / STAT proteins, inhibit the interaction between JAK or STAT proteins and cell surface receptors, such as IL-11Rα or gp130, inhibit the interaction between JAK proteins and STAT proteins, inhibit the phosphorylation of STAT proteins, inhibit the dimerization of STAT proteins, inhibit the translocation of STAT proteins to the cell nucleus, inhibit the binding of STAT proteins to DNA, and / or promote the degradation of JAK and / or STAT proteins. In some embodiments, the JAK / STAT inhibitor is ruxolitinib (Jakafi / Jakavi; Incyte), tofacitinib (Xeljanz / Jakvinus; NIH / Pfizer), oclacitinib (Apoquel), baricitinib (Olumiant; Incyte / Eli Lilly), filgotinib (G-146034 / GLPG-0634; Galapagos NV), gandotinib (LY-2784544; Eli Lilly), restaurtinib (CEP-701; Teva), momerotinib (GS-0387 / CYT-387; Gilead The following are selected from Sciences, pacritinib (SB1518;CTI), PF-04965842 (Pfizer), upadacitinib (ABT-494;AbbVie), peficitinib (ASP015K / JNJ-54781532;Astellas), fedratinib (SAR302503;Celgene), cucurbitacin I (JSI-124), and CHZ868.

[0049] In some embodiments, the method of the present disclosure uses a drug capable of inhibiting MAPK / ERK signaling. In some embodiments, the drug capable of inhibiting MAPK / ERK signaling can inhibit the action of GRB2, the action of RAF kinase, the action of MEK protein, the activation of MAP3K / MAP2K / MAPK and / or Myc, and / or the phosphorylation of STAT protein. In some embodiments, the drug capable of inhibiting ERK signaling can inhibit ERK p42 / 44. In some embodiments, the ERK inhibitor is selected from SCH772984, SC1, VX-11e, DEL-22379, sorafenib (Nexavar; Bayer / Onyx), SB590885, PLX4720, XL281, RAF265 (Novartis), encorafenib (LGX818 / Braftovi; Array BioPharma), dabrafenib (Tafinlar; GSK), vemurafenib (Zelboraf; Roche), cobimetinib (Cotellic; Roche), CI-1040, PD0325901, binimetinib (MEK162 / MEKTOVI; Array BioPharma), selumetinib (AZD6244; Array / AstraZeneca), and trametinib (GSK1120212 / Mekinist; Novartis). In some embodiments, the methods of the present disclosure utilize agents capable of inhibiting c-Jun N-terminal kinase (JNK) signaling / activity. In some embodiments, the agents capable of inhibiting JNK signaling / activity are capable of inhibiting the action and / or phosphorylation of JNK (e.g., JNK1, JNK2). In some embodiments, the JNK inhibitor is selected from SP600125, CEP1347, TCS JNK 6o, c-Jun peptide, SU3327, AEG 3482, TCS JNK 5a, BI78D3, IQ3, SR3576, IQ1S, JIP-1 (153-163), and CC401 hydride dichloride.

[0050] In this example, the inventors demonstrate that NOX4 expression and activity are upregulated by signaling via IL-11 / IL-11Rα / gp130. NOX4 is an NADPH oxidase and a source of reactive oxygen species (ROS). NOX4 expression is upregulated in transgenic mice with hepatocyte-specific Il11 expression, and primary human hepatocytes stimulated with IL11 upregulate NOX4 expression.

[0051] In some embodiments, the disclosure uses agents capable of inhibiting NOX4 expression (gene or protein expression) or function. In some embodiments, the disclosure uses agents capable of inhibiting IL-11-mediated upregulation of NOX4 expression / function. Agents capable of inhibiting NOX4 expression or function may be referred to herein as NOX4 inhibitors. For example, NOX4 inhibitors can reduce NOX4 expression (e.g., gene and / or protein expression), reduce the level of NOX4-encoding RNA, reduce the level of NOX4 protein, and / or reduce the level of NOX4 activity (e.g., reduce NOX4-mediated NADPH oxidase activity and / or NOX4-mediated ROS production).

[0052] NOX4 inhibitors include NOX4-binding molecules and molecules capable of reducing NOX4 expression. NOX4-binding inhibitors include peptide / nucleic acid aptamers, antibodies (and antibody fragments), fragments of NOX4 interaction partners that act as antagonists to NOX4 function, and small molecule inhibitors of NOX4. Molecules capable of reducing NOX4 expression include antisense RNAs (e.g., siRNA, shRNA) to NOX4. In some embodiments, NOX4 inhibitors are selected from NOX4 inhibitors described in Altenhofer et al., Antioxid Redox Signal. (2015) 23(5): pp. 406-427 or Augsburder et al., Redox Biol. (2019) 26: pp. 101-272, e.g., GKT137831.

[0053] Binder In some embodiments, a drug capable of inhibiting IL-11-mediated signaling may bind to IL-11. In some embodiments, a drug capable of inhibiting IL-11-mediated signaling may bind to an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130). Such drug binding can inhibit IL-11-mediated signaling by inhibiting downstream signaling by reducing / preventing the ability of IL-11 to bind to its receptor. Such drug binding can inhibit IL-11-mediated cis and / or trans signaling by inhibiting downstream signaling by reducing / preventing the ability of IL-11 to bind to its receptor, e.g., IL-11Rα and / or gp130. A drug can bind to a trans signaling complex such as IL-11 and soluble IL-11Rα, thereby inhibiting gp130-mediated signaling.

[0054] The IL-11 / IL-11-containing complex or the agent capable of binding to the IL-11 receptor may be of any type, but in some embodiments, the agent may be an antibody, its antigen-binding fragment, polypeptide, peptide, nucleic acid, oligonucleotide, aptamer, or small molecule. The agent may be provided in isolated or purified form, or formulated as a pharmaceutical composition or pharmaceutical.

[0055] Antibody and antigen-binding fragments In some embodiments, the agent capable of binding to the IL-11 / IL-11-containing complex or the IL-11 receptor is an antibody or its antigen-binding fragment. In some embodiments, the agent capable of binding to the IL-11 / IL-11-containing complex or the IL-11 receptor is a polypeptide, such as a decoy receptor molecule. In some embodiments, the agent capable of binding to the IL-11 / IL-11-containing complex or the IL-11 receptor may be an aptamer.

[0056] In some embodiments, the agent capable of binding to an IL-11 / IL-11-containing complex or the IL-11 receptor is an antibody or its antigen-binding fragment. “Antibody” is used herein in its broadest sense and includes monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, insofar as they demonstrate binding to the relevant target molecule.

[0057] Considering monoclonal antibody technology and related technologies today, antibodies against many antigens can be prepared. The antigen-binding portion may be a part of the antibody (e.g., a Fab fragment) or a synthetic antibody fragment (e.g., a single-stranded Fv fragment [ScFv]). Monoclonal antibodies against selected antigens can be prepared by known techniques, e.g., disclosed in "Monoclonal Antibodies: A manual of techniques," H. Zola (CRC Press, 1988) and "Monoclonal Hybridoma Antibodies: Techniques and Applications," J.G. Hurrell (CRC Press, 1982). Chimeric antibodies have been discussed by Neuberger et al. (1988, 8th International Biotechnology Symposium Part 2, pp. 792-799). Monoclonal antibodies (mAbs) are particularly useful in the methods of this disclosure as a homogeneous population of antibodies that specifically target a single epitope on an antigen.

[0058] Polyclonal antibodies are also useful in the methods disclosed herein. Monospecific polyclonal antibodies are preferred. Suitable polyclonal antibodies can be prepared using methods well known in the art.

[0059] Because antibodies and antibody fragments can be genetically engineered, antigen-binding fragments of antibodies, such as Fab and Fab2 fragments, can also be used / provided. The variable heavy (VH) and variable light (VL) domains of antibodies are involved in antigen recognition, a fact first recognized by initial protease digestion experiments. Further confirmation can be found through the "humanization" of rodent antibodies. Variable domains of rodent origin can be fused to constant domains of human origin so that the resulting antibody retains the antigen specificity of the rodent parent antibody (Morrison et al. (1984) Proc. Natl. Acad. Sd. USA 81, pp. 6851-6855).

[0060] The antibodies and antigen-binding fragments of this disclosure include an antibody complementarity-determining region (CDR) that can bind to the relevant target molecule (i.e., IL-11 / IL-11-containing complex / IL-11 receptor).

[0061] In some embodiments, the drug is an IL-11-binding antibody or an IL-11-binding fragment thereof. Antibodies that bind to IL-11 include, for example, the monoclonal mouse anti-human IL-11 antibody clone #22626 used in Bockhorn et al., Nat.Commun. (2013) 4(0):1393; catalog numbers MAB218 (R&D Systems, MN, USA), clone 6D9A (Abbiotec), clone KT8 (Abbiotec), clone M3103F11 (BioLegend), clone 1F1 (Abnova Corporation), clone 3C6 (Abnova Corporation), clone GF1 (LifeSpan Biosciences), clone 13455 (Source BioScience), 11h3 / 19.6.1 (Hermann et al., Arthritis Rheum. (1998) 41(8):1388~97), AB-218-NA (R&D Systems), X203 (Ng et al., Sci Transl This includes anti-IL-11 antibodies disclosed in Med.(2019)11(511)pii:eaaw1237) and U.S. Patent Application Publication Nos. 2009 / 0202533, WO99 / 59608A2, WO2018 / 109174A2, and WO2019 / 238882A1.

[0062] In particular, the anti-IL-11 antibody clone 22626 (also known as MAB218) has been shown to be an antagonist of IL-11-mediated signaling, for example, in Schaefer et al., Nature (2017) 552(7683): ​​pp. 110-115. The monoclonal antibody 11h3 / 19.6.1 is disclosed as a neutralizing anti-IL-11 IgG1 in Hermann et al., Arthritis Rheum. (1998) 41(8): pp. 1388-97. Another example of a neutralizing anti-IL-11 antibody is AB-218-NA from R&D Systems, used, for example, in McCoy et al., BMC Cancer (2013) 13:16. WO2018 / 109174A2 and WO2019 / 238882A1 disclose further exemplary anti-IL-11 antibody antagonists of IL-11-mediated signaling. X203 (also known as Enx203), disclosed in Ng et al., "IL-11 is therapeutic target in idiopathic pulmonary fibrosis," bioRxiv 336537;doi:https: / / doi.org / 10.1101 / 336537 and WO2019 / 238882A1, is an anti-IL-11 antibody antagonist of IL-11 mediated signaling, comprising the VH region by SEQ ID NO: 92 of WO2019 / 238882A1 (SEQ ID NO: 22 in this disclosure) and the VL region by SEQ ID NO: 94 of WO2019 / 238882A1 (SEQ ID NO: 23 in this disclosure). A humanized version of X203 is described in WO2019 / 238882A1, which includes, for example, hEnx203, which includes a VH region by SEQ ID NO: 117 (SEQ ID NO: 30 in this disclosure) of WO2019 / 238882A1 and a VL region by SEQ ID NO: 122 (SEQ ID NO: 31 in this disclosure) of WO2019 / 238882A1. Enx108A is a further example of an anti-IL-11 antibody antagonist for IL-11 mediated signaling, which includes a VH region by SEQ ID NO: 8 (SEQ ID NO: 26 in this disclosure) of WO2019 / 238882A1 and a VL region by SEQ ID NO: 20 (SEQ ID NO: 27 in this disclosure) of WO2019 / 238882A1.

[0063] In some embodiments, the drug is an IL-11Rα-binding antibody or an IL-11Rα-binding fragment thereof. Antibodies that bind to IL-11Rα include, for example, the monoclonal antibody clone 025 (Sino Biological), clone EPR5446 (Abcam), clone 473143 (R&D Systems), clones 8E2, 8D10 and 8E4, and the affinity-matured variant of 8E2 described in U.S. Patent Application Publication No. 2014 / 0219919, the monoclonal antibody described by Blanc et al. (J. Immunol Methods. July 31, 2000; 241(1-2); pp. 43-59), and X209 (Widjaja et al., "IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH." bioRxiv). This includes antibodies disclosed in Widjaja et al., Gastroenterology (2019) 157(3):777-792, WO2014121325A1 and U.S. Patent Application Publication 2013 / 0302277, also published as 470062;doi:https: / / doi.org / 10.1101 / 470062, as well as anti-IL-11Rα antibodies disclosed in U.S. Patent Application Publication 2009 / 0202533, WO99 / 59608A2, WO2018 / 109170A2 and WO2019 / 238884A1.

[0064] In particular, the anti-IL-11Rα antibody clone 473143 (also known as MAB1977) has been shown to be an antagonist of IL-11-mediated signaling, for example, in Schaefer et al., Nature (2017) 552(7683): ​​pp. 110-115. U.S. Patent Application Publication 2014 / 0219919 provides sequences of anti-human IL-11Rα antibody clones 8E2, 8D10 and 8E4 and discloses their ability to antagonize IL-11-mediated signaling—see, for example, sections

[0489] -

[0490] of U.S. Patent Application Publication 2014 / 0219919. U.S. Patent Application Publication 2014 / 0219919 further provides sequence information for 62 additional affinity-mature variants of clone 8E2, 61 of which are disclosed to antagonize IL-11-mediated signaling—see Table 3 of U.S. Patent Application Publication 2014 / 0219919. WO2018 / 109170A2 and WO2019 / 238884A1 disclose further exemplary anti-IL-11Rα antibody antagonists for IL-11-mediated signaling. X209 (also known as Enx209), disclosed in Widjaja et al., "IL-11 neutralizing therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH," bioRxiv 470062;doi:https: / / doi.org / 10.1101 / 470062 and WO2019 / 238884A1, is an anti-IL-11Rα antibody antagonist of IL-11 mediated signaling, comprising the VH region by SEQ ID NO: 7 of WO2019 / 238884A1 (SEQ ID NO: 24 in this disclosure) and the VL region by SEQ ID NO: 14 of WO2019 / 238884A1 (SEQ ID NO: 25 in this disclosure). A humanized version of X209 is described in WO2019 / 238884A1, which includes, for example, hEnx209, which includes the VH region by Sequence ID No. 11 of WO2019 / 238884A1 (Sequence ID No. 32 in this disclosure) and the VL region by Sequence ID No. 17 of WO2019 / 238884A1 (Sequence ID No. 33 in this disclosure).

[0065] Those skilled in the art are well familiar with antibody production techniques suitable for therapeutic use in a given species / subject. For example, a procedure for antibody production suitable for therapeutic use in humans is described in Park and Smolen, Advances in Protein Chemistry (2001) 56:369–421 (which is fully incorporated here by reference).

[0066] Antibodies against a given target protein (e.g., IL-11 or IL-11Rα) can be produced in model species (e.g., rodents, rabbits) and then engineered to improve their suitability for therapeutic use in a given species / subject. For example, one or more amino acids in monoclonal antibodies produced by immunization of a model species can be substituted to achieve an antibody sequence more similar to a human germline immunoglobulin sequence (thereby reducing the likelihood of an anti-exogenous antibody immune response in human subjects treated with the antibody). Modifications in the antibody variable domain can focus on framework regions to preserve the antibody paratope. Antibody humanization is a matter of routine practice in the field of antibody technology, and has been reviewed, for example, by Almagro and Fransson, Frontiers in Bioscience (2008) 13: pp. 1619-1633, Safdari et al., Biotechnology and Genetic Engineering Reviews (2013) 29(2): pp. 175-186, and Lo et al., Microbiology Spectrum (2014) 2(1), all of which are fully incorporated here by reference. The requirement for humanization can be avoided by producing antibodies against a given target protein (e.g., IL-11 or IL-11Rα) in transgenic model species that express human immunoglobulin genes so that antibodies produced in such animals are fully human (for example, described by Bruggemann et al., Arch Immunol Ther Exp (Warsz) (2015) 63(2): pp. 101-108, which are fully incorporated here by reference).

[0067] Phage display techniques can also be used to identify antibodies against specific target proteins (e.g., IL-11 or IL-11Rα), and these are well known to those skilled in the art. For example, the use of phage display for identifying fully human antibodies against human target proteins has been reviewed, e.g., by Hoogenboom, Nat. Biotechnol. (2005) 23, pp. 1105-1116 and by Chan et al., International Immunology (2014) 26(12): pp. 649-657, which are fully incorporated here by reference.

[0068] The antibody / fragment may be an antagonist antibody / fragment that inhibits or reduces the biological activity of IL-11. The antibody / fragment may also be a neutralizing antibody that neutralizes the biological effect of IL-11, for example, its ability to stimulate production signaling by the IL-11 receptor. Neutralizing activity can be measured by its ability to neutralize IL-11-induced proliferation in the T11 mouse plasmacytoma cell line (Nordan, RP et al. (1987) J. Immunol. 139:813).

[0069] IL-11 or IL-11Rα-binding antibodies can be evaluated for their ability to antagonize IL-11-mediated signaling using assays such as those described in U.S. Patent Application Publication No. 2014 / 0219919 or by Blanc et al. (J. Immunol Methods. July 31, 2000; 241(1-2); pp. 43-59). In short, IL-11 and IL-11Rα-binding antibodies can be evaluated in vitro for their ability to inhibit the proliferation of Ba / F3 cells expressing IL-11Rα and gp130 from a suitable species in response to stimulation with IL-11 from a suitable species. Alternatively, IL-11 and IL-11Rα-binding antibodies can be evaluated in vitro for their ability to inhibit the transition from fibroblasts to myofibroblasts after fibroblast stimulation with TGFβ1 by evaluating αSMA expression. It can be analyzed in vitro (for example, as described in WO2018 / 109174A2 (Example 6) and WO2018 / 109170A2 (Example 6), Ng et al., Sci Transl Med. (2019) 11(511)pii:eaaw1237 and Widjaja et al., Gastroenterology (2019) 157(3):777~792).

[0070] Antibodies generally contain six CDRs; three in the light chain variable region (VL): LC-CDR1, LC-CDR2, and LC-CDR3, and three in the heavy chain variable region (VH): HC-CDR1, HC-CDR2, and HC-CDR3. Together, the six CDRs define the antibody paratope, which is the portion of the antibody that binds to the target molecule. The VH and VL regions contain a framework region (FR) on either side of each CDR, which provides a scaffold for the CDR. From the N-terminus to the C-terminus, the VH region contains the following structure: N-term - [HC-FR1] - [HC-CDR1] - [HC-FR2] - [HC-CDR2] - [HC-FR3] - [HC-CDR3] - [HC-FR4] - C-term; the VL region contains the following structure: N-term - [LC-FR1] - [LC-CDR1] - [LC-FR2] - [LC-CDR2] - [LC-FR3] - [LC-CDR3] - [LC-FR4] - C-term.

[0071] There are several different conventions for defining antibody CDR and FR, such as those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), Chothia et al., J.Mol.Biol.196:901-917 (1987), and VBASE2, as described in Retter et al., Nucl. Acids Res. (2005) 33(suppl 1):D671-D674. The CDR and FR of the VH and VL regions of antibodies described herein are defined by the Kabat system.

[0072] In some embodiments, the antibody or its antigen-binding fragment according to the Disclosure is derived from an antibody that specifically binds to IL-11 (e.g., Enx108A, Enx203, or hEnx203). In some embodiments, the antibody or its antigen-binding fragment according to the Disclosure is derived from an antibody that specifically binds to IL-11Rα (e.g., Enx209, or hEnx209).

[0073] The antibodies and antigen-binding fragments of this disclosure preferably inhibit IL-11-mediated signaling. Such antibody / antigen-binding fragments may be described as antagonists of IL-11-mediated signaling and / or as having the ability to neutralize IL-11-mediated signaling.

[0074] In some embodiments, the antibody / antigen-binding fragment comprises a CDR of an antibody that binds to IL-11. In some embodiments, the antibody / antigen-binding fragment comprises a CDR of an IL-11-binding antibody described herein (e.g., Enx108A, Enx203, or hEnx203) or a CDR derived from such a CDR.

[0075] In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating the following CDR: (1) HC-CDR1 having the amino acid sequence of SEQ ID NO: 34 HC-CDR2 having the amino acid sequence of SEQ ID NO: 35 HC-CDR3 having the amino acid sequence of SEQ ID NO: 36, Alternatively, a variant thereof in which one or more amino acids in HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with other amino acids.

[0076] In some embodiments, the antibody / antigen-binding fragment includes a VL region incorporating the following CDR: (2) LC-CDR1 having the amino acid sequence of SEQ ID NO: 37 LC-CDR2 having the amino acid sequence of SEQ ID NO: 38 LC-CDR3 having the amino acid sequence of SEQ ID NO: 39 Alternatively, a variant thereof in which one or more amino acids in LC-CDR1, LC-CDR2, or LC-CDR3 are substituted with other amino acids.

[0077] In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating the following CDR: (3) HC-CDR1 having the amino acid sequence of SEQ ID NO: 40 HC-CDR2 having the amino acid sequence of SEQ ID NO: 41 HC-CDR3 having the amino acid sequence of SEQ ID NO: 42 Alternatively, a variant thereof in which one or more amino acids in HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with other amino acids.

[0078] In some embodiments, the antibody / antigen-binding fragment includes a VL region incorporating the following CDR: (4) LC-CDR1 having the amino acid sequence of SEQ ID NO: 43 LC-CDR2 having the amino acid sequence of SEQ ID NO: 44 LC-CDR3 having the amino acid sequence of SEQ ID NO: 45 Alternatively, a variant thereof in which one or more amino acids in LC-CDR1, LC-CDR2, or LC-CDR3 are substituted with other amino acids.

[0079] In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating a CDR according to (1) and a VL region incorporating a CDR according to (2). In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating a CDR according to (3) and a VL region incorporating a CDR according to (4).

[0080] In some embodiments, the antibody / antigen-binding fragment includes the VH and VL regions of an antibody that binds to IL-11. In some embodiments, the antibody / antigen-binding fragment includes the VH and VL regions of an IL-11-binding antibody described herein (e.g., Enx108A, Enx203, or hEnx203), or VH and VL regions derived from such VH and VL regions.

[0081] In some embodiments, the antibody / antigen-binding fragment includes a VH region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 26, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VL region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 27, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VH region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 26, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, and a VL region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 27, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0082] In some embodiments, the antibody / antigen-binding fragment includes a VH region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 22, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VL region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 23, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VH region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 22, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, and a VL region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 23, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0083] In some embodiments, the antibody / antigen-binding fragment includes a VH region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 30, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VL region containing an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 31, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment includes a VH region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 30, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, and a VL region comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 31, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0084] In some embodiments, the antibody / antigen-binding fragment comprises a CDR of an antibody that binds to IL-11Rα. In some embodiments, the antibody / antigen-binding fragment comprises a CDR of an IL-11Rα-binding antibody described herein (e.g., Enx209 or hEnx209) or a CDR derived from this CDR.

[0085] In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating the following CDR: (5) HC-CDR1 having the amino acid sequence of SEQ ID NO: 46 HC-CDR2 having the amino acid sequence of SEQ ID NO: 47 HC-CDR3 having the amino acid sequence of SEQ ID NO: 48 Alternatively, a variant thereof in which one or more amino acids in HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with other amino acids.

[0086] In some embodiments, the antibody / antigen-binding fragment includes a VL region incorporating the following CDR: (6) LC-CDR1 having the amino acid sequence of SEQ ID NO: 49 LC-CDR2 having the amino acid sequence of SEQ ID NO: 50 LC-CDR3 having the amino acid sequence of SEQ ID NO: 51 Alternatively, a variant thereof in which one or more amino acids in LC-CDR1, LC-CDR2, or LC-CDR3 are substituted with other amino acids.

[0087] In some embodiments, the antibody / antigen-binding fragment includes a VH region incorporating the CDR according to (5) and a VL region incorporating the CDR according to (6). In some embodiments, the antibody / antigen-binding fragment includes the VH and VL regions of an antibody that binds to IL-11Rα. In some embodiments, the antibody / antigen-binding fragment includes the VH and VL regions of an IL-11Rα-binding antibody described herein (e.g., Enx209 or hEnx209), or VH and VL regions derived from this VH and VL region.

[0088] In embodiments of this disclosure in which one or more amino acids in a reference amino acid sequence (e.g., a CDR sequence, VH region sequence, or VL region sequence as described herein) are substituted with another amino acid, the substitution may be a conservative substitution, for example, as shown in the table below. In some embodiments, amino acids in the same block in the middle column are substituted. In some embodiments, amino acids in the same row in the rightmost column are substituted:

[0089] [Table 1]

[0090] In some embodiments, the substitution(s) may be functionally conserved. That is, in some embodiments, the substitution does not affect (or substantially does not affect) one or more functional properties (e.g., target binding) of the antibody / fragment containing the substitution compared to an equivalent non-substituted molecule.

[0091] In some embodiments, the substitution(s) compared to a reference VH region or VL region sequence can be concentrated in a specific region or a set of regions within the VH region or VL region sequence. For example, the changes from the reference VH region or VL region sequence can be concentrated in one or more framework regions (FR1, FR2, FR3, and / or FR4).

[0092] The antibodies and antigen-binding fragments described herein can be designed and prepared using sequences of monoclonal antibodies (mAbs) capable of binding to relevant target molecules. Antigen-binding regions of antibodies, such as single-strand variable fragments (scFv), Fab, and Fab2 fragments, can also be used / provided. An "antigen-binding region" or "antigen-binding fragment" is any fragment of an antibody capable of binding to a target to which a given antibody is specific.

[0093] In some embodiments, the antibody / fragment includes VL and VH regions of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. The VL and VH regions of the antibody's antigen-binding region together constitute an Fv region. In some embodiments, the antibody / fragment includes or consists of an Fv region of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. The Fv region can be expressed as a single chain, while the VH and VL regions are covalently linked, for example, by a flexible oligopeptide. Thus, the antibody / fragment may include or consist of an scFv containing the VL and VH regions of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor.

[0094] The VL and light chain constant (CL) regions of the antibody's antigen-binding region, as well as the VH region and heavy chain constant 1 (CH1) region, together constitute the Fab region. In some embodiments, the antibody / fragment comprises or consists of the Fab region of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor.

[0095] In some embodiments, the antibody / fragment comprises or consists of IL-11, an IL-11-containing complex, or a whole antibody capable of binding to the IL-11 receptor. “Whole antibody” refers to an antibody having a structure substantially similar to that of immunoglobulin (Ig). Various types of immunoglobulins and their structures are described, for example, in Schroeder and Cavacini J Allergy Clin Immunol. (2010) 125(202): pp. S41-S52, the entirety of which is incorporated herein by reference. G-type immunoglobulin (i.e., IgG) is a glycoprotein of approximately 150 kDa comprising two heavy chains and two light chains. From the N-terminus to the C-terminus, the heavy chain comprises VH, followed by a heavy chain constant region containing three constant domains (CH1, CH2, and CH3), and similarly the light chain comprises VL, followed by CL. Depending on the heavy chain, immunoglobulins can be classified as IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgA (e.g., IgA1, IgA2), IgD, IgE, or IgM. The light chain may be kappa (κ) or lambda (λ).

[0096] In some embodiments, the antibody / antigen-binding fragment of the Disclosure comprises an immunoglobulin heavy chain constant sequence. In some embodiments, the immunoglobulin heavy chain constant sequence may be a human immunoglobulin heavy chain constant sequence. In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the heavy chain constant sequences of IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgA (e.g., IgA1, IgA2), IgD, IgE, or IgM, for example, human IgG (e.g., hIgG1, hIgG2, hIgG3, hIgG4), hIgA (e.g., hIgA1, hIgA2), hIgD, hIgE, or hIgM. In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the heavy chain constant sequence of a human IgG1 allotype (e.g., G1m1, G1m2, G1m3, or G1m17).

[0097] In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the constant region sequence of human immunoglobulin G1 constant (IGHG1; UniProt: P01857-1, v1). In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the constant region sequence of human immunoglobulin G1 constant (IGHG1; UniProt: P01857-1, v1) containing substitutions K214R, D356E and L358M (i.e., G1m3 allotype). In some embodiments, the antibody / antigen-binding fragment contains an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 52, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0098] In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the constant region sequence of human immunoglobulin G4 constant (IGHG4; UniProt: P01861, v1). In some embodiments, the immunoglobulin heavy chain constant sequence is or is derived from the constant region sequence of human immunoglobulin G4 constant (IGHG4; UniProt: P01861, v1) containing substitutions S241P and / or L248E. The S241P mutation provides hinge stability, while the L248E mutation further reduces the already low ADCC effector function of IgG4 (Davies and Sutton, Immunol Rev. November 2015; 268(1): pp. 139-159; Angal et al., Mol Immunol. January 1993; 30(1): pp. 105-108). In some embodiments, the antibody / antigen-binding fragment includes an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 53, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0099] In some embodiments, the antibody / antigen-binding fragment of the Disclosure comprises an immunoglobulin light chain constant sequence. In some embodiments, the immunoglobulin light chain constant sequence may be a human immunoglobulin light chain constant sequence. In some embodiments, the immunoglobulin light chain constant sequence is or is derived from a kappa (κ) or lambda (λ) light chain, e.g., human immunoglobulin kappa constant (IGKC;Cκ;UniProt:P01834-1, v2), or human immunoglobulin lambda constant (IGLC;Cλ), e.g., IGLC1 (UniProt:P0CG04-1, v1), IGLC2 (UniProt:P0DOY2-1, v1), IGLC3 (UniProt:P0DOY3-1, v1), IGLC6 (UniProt:P0CF74-1, v1), or IGLC7 (UniProt:A0M8Q6-1, v3).

[0100] In some embodiments, the antibody / antigen-binding fragment includes an immunoglobulin light chain constant sequence. In some embodiments, the immunoglobulin light chain constant sequence is or is derived from human immunoglobulin kappa constant (IGKC; Cκ; UniProt: P01834-1, v2; SEQ ID NO: 90). In some embodiments, the immunoglobulin light chain constant sequence is human immunoglobulin lambda constant (IGLC; Cλ), e.g., IGLC1, IGLC2, IGLC3, IGLC6, or IGLC7. In some embodiments, the antibody / antigen-binding fragment includes an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 54, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. In some embodiments, the antibody / antigen-binding fragment comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 55, more preferably at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

[0101] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 28; and (ii) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 29.

[0102] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 56; and (ii) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 57.

[0103] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 58; and (ii) a polypeptide comprising or comprising an amino acid sequence having at least 70%, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 59.

[0104] The Fab, Fv, ScFv, and dAb antibody fragments can all be expressed in Escherichia coli (E. coli) and then secreted, thus enabling the easy production of large quantities of these fragments.

[0105] All antibodies and the F(ab')2 fragment are "bivalent." "Bivalent" means that the antibodies and F(ab')2 fragment have two antigen-binding sites. In contrast, the Fab, Fv, ScFv, and dAb fragments are monovalent, having only one antigen-binding site. Synthetic antibodies capable of binding to IL-11, IL-11-containing complexes, or IL-11 receptors can also be prepared using phage display techniques well known in the industry.

[0106] Antibodies can be produced by affinity maturation, a process that generates modified antibodies in which the antibody's affinity for the antigen is improved compared to an unmodified parent antibody. Affinity-matured antibodies can be produced by procedures known in the industry, such as those described in Marks et al., Rio / Technology 10:779-783 (1992); Barbas et al., Proc Nat.Acad.Sci.USA 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J.Immunol.155:1994-2004 (1995); Jackson et al., J.Immunol.154(7):331 0-15 9 (1995); and Hawkins et al., J.Mol.Biol.226:889-896 (1992).

[0107] The antibody / fragment includes a bispecific antibody composed of two different fragments of two different antibodies, for example, to bind to two different antigens. The bispecific antibody includes the antibodies / fragments described herein, which are capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. The antibody may contain different fragments having affinity for a second antigen, which may be any desired antigen. Techniques for preparing bispecific antibodies are well known in the art; see, for example, Mueller, D. et al. (2010 Biodrugs 24(2): pp. 89-98), Wozniak-Knopp G. et al. (2010 Protein Eng Des 23(4): pp. 289-297), and Baeuerle, PA. et al. (2009 Cancer Res 69(12): pp. 4941-4944). Bispecific antibodies and bispecific antigen-binding fragments can be provided in any preferred form, such as the form described in Kontermann MAbs 2012, 4(2):182-197, which is incorporated herein by reference in whole. For example, bispecific antibodies or bispecific antigen-binding fragments can be bispecific antibody conjugates (e.g., IgG2, F(ab')2, or CovX-Body), bispecific IgG, or IgG-like molecules (e.g., IgG, scFv4-Ig, IgG-scFv, scFv-IgG, DVD-Ig, IgG-sVD, sVD-IgG, 2 in 1-IgG, mAb 2 , or Tandemab common LC), asymmetric bispecific IgG or IgG-like molecules (e.g., kih IgG, kih IgG common LC, CrossMab, kih IgG-scFab, mAb-Fv, charge pair or SEED-body), small bispecific antibodies (e.g., diabody (Db), dsDb, DART, scDb, tandAb, tandem scFv (taFv), tandem dAb / VHH, triplebody, triple head, Fab-scFv, or F(ab')2-scFv2), bispecific Fc and C H 3 Fusion proteins (e.g., taFv-Fc, di-diabody, scDb-C) H3. scFv-Fc-scFv, HCAb-VHH, scFv-kih-Fc, or scFv-kih-C H 3) or bispecific fusion proteins (e.g., scFv2-albumin, scDb-albumin, taFv-toxin, DNL-Fab3, DNL-Fab4-IgG, DNL-Fab4-IgG-cytokine2). See Figure 2 in particular, Kontermann MAbs 2012, 4(2):182-19.

[0108] Methods for producing bispecific antibodies include, for example, the step of chemically crosslinking an antibody or antibody fragment with, for example, a reducing disulfide or a non-reducing thioether bond, as described in Segal and Bast, 2001. Production of Bispecific Antibodies. Current Protocols in Immunology. 14:IV:2.13:2.13.1~2.13.16 (the entirety of which is incorporated herein by reference). For example, N-succinimidyl-3-(-2-pyridyldithio)-propionic acid (SPDP) can be used to chemically crosslink a Fab fragment, for example, via a hinge region SH- group, to create a disulfide-bonded bispecific F(ab)2 heterodimer.

[0109] Other methods for producing bispecific antibodies include, for example, the step of fusing antibody-producing hybridomas with polyethylene glycol to produce quadroma cells capable of secreting bispecific antibodies, as described in DM and Bast, BJ2001. Production of Bispecific Antibodies. Current Protocols in Immunology. 14:IV:2.13:2.13.1~2.13.16.

[0110] Bispecific antibodies and bispecific antigen-binding fragments can also be recombinantly produced, for example, by expression from nucleic acid constructs encoding polypeptides for antigen-binding molecules, as described in Antibody Engineering: Methods and Protocols, 2nd edition (Humana Press, 2012), Chapter 40: Production of Bispecific Antibodies: Diabodies and Tandem scFv (Horning and Farber-Schwarz), or French, How to make bispecific antibodies, Methods Mol. Med. 2000; 40: pp. 333-339.

[0111] For example, a DNA construct can be prepared by molecular cloning techniques that encodes light and heavy chain variable domains for two antigen-binding domains (i.e., light and heavy chain variable domains for an antigen-binding domain that can bind to IL-11, an IL-11-containing complex, or an IL-11 receptor, and light and heavy chain variable domains for an antigen-binding domain that can bind to another target protein), and contains sequences encoding a suitable linker or dimerization domain between the antigen-binding domains. Recombinant bispecific antibodies can then be produced by expressing the construct (e.g., in vitro) in a suitable host cell (e.g., a mammalian host cell), and the expressed recombinant bispecific antibodies can be purified as needed.

[0112] The antibodies intended for use in this disclosure include antibodies that have long-lasting effects after administration to a subject. The antibodies may have pharmacokinetic properties that allow them to be administered occasionally, for example, once every six months. For example, the antibodies in this disclosure may be engineered using serial monoclonal antibody reuse technology (SMART-Ig), as described, for example, Fukuzawa et al., SciRep. (2017) 7(1): 1080, which is fully incorporated herein by reference. The antibodies may be SMART reuse antibodies or SMART clearing antibodies engineered, for example, as described, for example, Igawa et al., Nature Biotechnology (2010) 28: 1203-1207 or Sampei et al., PLoS One (2018) 13(12): e0209509 (both fully incorporated herein by reference).

[0113] Decoy receptor Peptide or polypeptide-based agents capable of binding to IL-11 or IL-11-containing complexes may be based on the IL-11 receptor, for example, an IL-11-binding fragment of the IL-11 receptor.

[0114] In some embodiments, the binder may comprise an IL-11 binding fragment of the IL-11Rα chain, preferably in a soluble form, and / or may not comprise one or more transmembrane domains, or all of them. In some embodiments, the binder may comprise an IL-11 binding fragment of gp130, preferably in a soluble form, and / or may not comprise one or more transmembrane domains, or all of them. Such molecules can be described as decoy receptors. Binding of such a drug can inhibit IL-11-mediated cis and / or trans signaling by inhibiting downstream signaling, thereby reducing / preventing the ability of IL-11 to bind to its receptor, e.g., IL-11Rα or gp130.

[0115] Curtis et al. (Blood 1997 Dec 1;90(11):4403-12) reported that soluble mouse IL-11 receptor alpha chain (sIL-11R) could antagonize IL-11 activity when tested on cells expressing transmembrane IL-11R and gp130. They proposed that the observed IL-11 antagonism by sIL-11R depends on the limited number of gp130 molecules on cells already expressing transmembrane IL-11R.

[0116] The use of soluble decoy receptors as a basis for signaling inhibition and therapeutic intervention has also been reported for other signaling molecule:receptor pairs, such as VEGF and the VEGF receptor (De-Chao Yu et al., Molecular Therapy (2012); 20 5, pp. 938-947; Konner and Dupont Clin Colorectal Cancer 2004 Oct; 4 Suppl 2: pp. S81-5).

[0117] Therefore, in some embodiments, the binder may be a decoy receptor, for example, a soluble receptor for IL-11 and / or an IL-11-containing complex. Competition for IL-11 and / or an IL-11-containing complex provided by the decoy receptor has been reported to result in IL-11 antagonist activity (Curtis et al., cited above). Decoy IL-11 receptors are also described in WO2017 / 103108A1 and WO2018 / 109168A1, which are incorporated herein by reference in their entirety.

[0118] Decoy IL-11 receptors preferably bind to IL-11 and / or IL-11-containing complexes, thereby preventing these species from binding to gp130, IL-11Rα, and / or gp130:IL-11Rα receptors. Thus, they act as “decoy” receptors for IL-11 and IL-11-containing complexes in much the same way that etanercept acts as a decoy receptor for TNFα. IL-11-mediated signaling is reduced compared to the level of signaling in the absence of the decoy receptors.

[0119] The decoy IL-11 receptor preferably binds to IL-11 via one or more cytokine-binding modules (CBMs). The CBMs are CBMs of naturally occurring IL-11 receptor molecules, derived therefrom, or homologous thereto. For example, the decoy IL-11 receptor may comprise, or consist of, one or more CBMs derived from, derived therefrom, or homologous thereto of gp130 and / or IL-11Rα CBMs.

[0120] In some embodiments, the decoy IL-11 receptor may include, or consist of, an amino acid sequence corresponding to the cytokine binding module of gp130. In some embodiments, the decoy IL-11 receptor may include an amino acid sequence corresponding to the cytokine binding module of IL-11Rα. Here, the amino acid sequence "corresponding" to a given reference region or sequence of peptide / polypeptide has at least 60% sequence identity with respect to the amino acid sequence of the reference region / sequence, for example, at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0121] In some embodiments, the decoy receptor may bind to IL-11 with a binding affinity of, for example, at least 100 μM or less, optionally 10 μM or less, 1 μM or less, 100 nM or less, or about 1 to 100 nM. In some embodiments, the decoy receptor may include all or part of the IL-11 binding domain, and optionally lack all or part of the transmembrane domain. The decoy receptor may optionally be fused to an immunoglobulin constant region, for example, an IgG Fc region.

[0122] inhibitors This disclosure intends to use inhibitory molecules capable of binding to IL-11 or IL-11-containing complexes to inhibit IL-11-mediated signaling. This disclosure also intends to use inhibitory molecules capable of binding to IL-11Rα, gp130, or IL-11Rα and / or gp130-containing complexes to inhibit IL-11-mediated signaling.

[0123] In some embodiments, the drug is a competitive inhibitor of IL-11. That is, in some embodiments, the drug is a drug that competes with IL-11 to inhibit the action of IL-11. Competitive inhibitors of IL-11 include drugs that compete with IL-11 for binding to the IL-11 receptor (i.e., receptors comprising IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130).

[0124] Competitive inhibitors of IL-11 may be binding agents based on IL-11 peptides or polypeptides, such as mutants, variants, or binding fragments of IL-11. Such agents may contain amino acid sequences having high sequence identity (e.g., 70%, 75%, 80%, 85%, or more) with the amino acid sequence of IL-11 or its fragments. Suitable peptide or polypeptide-based agents can bind to the IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) in a manner that does not lead to the initiation of signaling or results in suboptimal signaling (i.e., a reduced signaling level compared to the level of signaling initiated by binding of wild-type IL-11). IL-11 variants and fragments of this kind can act as competitive inhibitors of endogenous IL-11.

[0125] For example, W147A is an IL-11 antagonist in which amino acid 147 is mutated from tryptophan to alanine, disrupting the so-called "site III" of IL-11. This mutant can bind to IL-11Rα, but fails to occlude with the gp130 homodimer, resulting in efficient blockade of IL-11 signaling (Underhill-Day et al., 2003; Endocrinology 2003 Aug; 144(8): pp. 3406-14). Lee et al. (Am J respire Cell Mol Biol. 2008 Dec; pp. 39(6): pp. 739-746) also reported the generation of an IL-11 antagonist mutant ("mutant protein") that can specifically inhibit the binding of IL-11 to IL-11Rα. The IL-11 mutant protein is also described in WO2009 / 052588A1.

[0126] Menkhorst et al. (Biology of Reproduction, May 1, 2009, vol. 80, no. 5, pp. 920-927) described PEGIL11A (CSL Limited, Parkvill, Victoria, Australia), a PEGylated IL-11 antagonist that is effective in inhibiting IL-11 activity in female mice.

[0127] Pasqualini et al., Cancer (2015) 121(14): pp. 2411-2421, describe a ligand-directed peptide mimetic, bone metastasis-targeting peptide mimetic-11 (BMTP-11), that can bind to IL-11Rα.

[0128] In some embodiments, a conjugate capable of binding to the IL-11 receptor can be provided in the form of a small molecule inhibitor of one of IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130. In some embodiments, the conjugate can be provided in the form of a small molecule inhibitor of IL-11 or an IL-11-containing complex, for example, an IL-11 inhibitor described by Lay et al., Int. J. Oncol. (2012); 41(2): pp. 759-764 (the entire work of which is incorporated herein by reference).

[0129] Aptamer In some embodiments, a drug that can bind to an IL-11 / IL-11-containing complex or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) is an aptamer. Also called nucleic acid / peptide ligands, aptamers are nucleic acid or peptide molecules characterized by their ability to bind to a target molecule with high specificity and high affinity. Almost all aptamers identified to date are molecules that do not exist in nature.

[0130] Aptamers for a given target (e.g., IL-11, IL-11-containing complexes, or IL-11 receptors) can be identified and / or produced by the Systematic Evolution of Ligands by Exponential Enrichment (SELEX™) method or by developing SOMAmers (slow dissociation rate modified aptamers) (Gold L et al. (2010) PLoS ONE 5(12):e15004). Aptamers and SELEX are described in Turek and Gold, Science (1990) 249(4968): pp. 505-510, and WO91 / 19813. The application of SELEX and SOMAmer techniques includes, for example, the addition of functional groups that mimic amino acid side chains to expand the chemical diversity of aptamers. As a result, high-affinity aptamers for targets can be enriched and identified.

[0131] The aptamer may be a DNA or RNA molecule, and may be single-stranded or double-stranded. The aptamer may include chemically modified nucleic acids, for example, those chemically modified with sugars and / or phosphates and / or bases. Such modifications may improve the stability of the aptamer or make it more resistant to degradation, and may include modifications at the 2' position of ribose.

[0132] Aptamers can be synthesized by methods well known to those skilled in the art. For example, aptamers can be synthesized chemically, for example, on a solid-phase support. Solid-phase synthesis may use phosphoramidite chemistry. Briefly, a solid-phase supported nucleotide is detritylated and then coupled with a suitably activated nucleoside phosphoramidite to form a phosphite triester bond. After capping, the phosphite triester can be oxidized with an oxidizing agent, typically iodine. The cycle can then be repeated to assemble the aptamers (see, for example, Sinha, ND; Biernat, J.; McManus, J.; Koster, H. Nucleic Acids Res. 1984, 12, pp. 4539; and Beaucage, SL; Lyer, RP (1992). Tetrahedron 48(12): pp. 2223).

[0133] A suitable nucleic acid aptamer may, as needed, have one minimum length among 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. A preferred nucleic acid aptamer may, as needed, have the longest length of one of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides. Preferred nucleic acid aptamers may, as needed, have a length of one of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides.

[0134] Aptamers may be peptides selected and manipulated to bind to specific target molecules. Methods for peptide aptamers and their generation and identification are outlined in Reverdatto et al., Curr Top Med Chem. (2015) 15(12): pp. 1082-101, which is incorporated herein by reference in its entirety. Peptide aptamers may, as necessary, have a minimum length of one of 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. Peptide aptamers may, as necessary, have a maximum length of one of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids. A suitable peptide aptamer may, as needed, have one of the following lengths: 2-30, 2-25, 2-20, 5-30, 5-25, or 5-20 amino acids.

[0135] Aptamers are nM or pM ranges, e.g., one of the following K values: 500nM, 100nM, 50nM, 10nM, 1nM, 500pM, less than 100pM. D It may have. Characteristics of IL-11 binders The IL-11 / IL-11-containing complexes or agents capable of binding to IL-11 receptors according to this disclosure may exhibit one or more of the following characteristics: • Specific binding of IL-11 / IL-11-containing complexes or IL-11 to receptors; • Binding of the IL-11 / IL-11-containing complex or the IL-11 receptor by one KD of 10 μM or less, preferably ≤5 μM, ≤1 μM, ≤500 nM, ≤100 nM, ≤10 nM, ≤1 nM, or ≤100 pM; • Inhibition of the interaction between IL-11 and IL-11Rα; • Inhibition of the interaction between IL-11 and gp130; • Inhibition of the interaction between IL-11 and the IL-11Rα:gp130 receptor complex; • Inhibition of the interaction between the IL-11:IL-11Rα complex and gp130; and • Inhibition of the interaction between the IL-11:IL-11Rα:gp130 complex (i.e., multimerization of such a complex).

[0136] These characteristics can be determined by analyzing the drug in a suitable assay, which may include a comparison of the performance of the drug with a suitable control drug. Those skilled in the art can identify appropriate control conditions for a given assay.

[0137] For example, a suitable negative control for analyzing the ability of a test antibody / antigen-binding fragment to bind to IL-11 / IL-11-containing complex / IL-11 receptors may be an antibody / antigen-binding fragment against a non-target protein (i.e., an antibody / antigen-binding fragment that is not specific to IL-11 / IL-11-containing complex / IL-11 receptors). A suitable positive control may be a known, validated (e.g., commercially available) antibody that binds to IL-11 or the IL-11 receptor. The control may be of the same isotype as the putative IL-11 / IL-11-containing complex / IL-11 receptor-binding antibody / antigen-binding fragment being analyzed, and may, for example, have the same constant region.

[0138] In some embodiments, the drug may be able to specifically bind to IL-11 or an IL-11-containing complex, or to an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130). A drug that specifically binds to a given target molecule preferably binds to the target with higher affinity and / or a longer duration than it would to bind to other non-target molecules.

[0139] In some embodiments, the agent can bind to IL-11 or an IL-11-containing complex with an affinity greater than its affinity for binding to one or more other members of the IL-6 cytokine family (e.g., IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), and cardiotrophin-like cytokine (CLC)). In some embodiments, the agent may bind to the receptor for IL-11 (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) with an affinity higher than its affinity for binding to one or more other members of the IL-6 receptor family. In some embodiments, the agent can bind to IL-11Rα with an affinity greater than its affinity for binding to one or more of IL-6Rα, leukemia inhibitory factor receptor (LIFR), oncostatin M receptor (OSMR), ciliary neurotrophic factor receptor alpha (CNTFRα), and cytokine receptor-like factor 1 (CRLF1).

[0140] In some embodiments, the degree of binding of the binder to a non-target is, for example, less than about 10% of the binding of the agent to its target when measured by ELISA, SPR, biolayer interferometry (BLI), microscale thermophoresis (MST), or radioimmunoassay (RIA). Alternatively, the binding specificity is such that the binder has a K D at least 0.1 orders of magnitude higher than that for (i.e., 0.1x10 n (where n is an integer representing the order of magnitude)) K D and may be reflected in units of binding affinity when binding to IL-11, an IL-11-containing complex, or the receptor for IL-11. This may be, optionally, one of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, or 2.0.

[0141] The binding affinity of a given binder for its target is its dissociation constant (K D) is often expressed in units of . Binding affinity can be measured by methods known in the industry, such as ELISA, surface plasmon resonance (SPR; see, e.g., Hearty et al., Methods Mol Biol (2012) 907: pp. 411-442; or Rich et al., Anal Biochem. 2008 Feb 1; 373(1): pp. 112-20), biolayer interferometry (see, e.g., Lad et al. (2015) J Biomol Screen 20(4): pp. 498-507; or Concepcion et al., Comb Chem High Throughput Screen. 2009 Sep; 12(8): pp. 791-800), microscale thermophoresis (MST) analysis (see, e.g., Jerabek-Willemsen et al., Assay Drug Dev Technol. 2011 Aug; 9(4): pp. 342-353), or radiolabeled antigen binding assay (RIA).

[0142] In some embodiments, the drug contains one K molecule with a concentration of 50 μM or less, preferably 10 μM or less, 5 μM or less, 4 μM or less, 3 μM or less, 2 μM or less, 1 μM, 500 nM or less, 100 nM or less, 75 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, 12.5 nM or less, 10 nM or less, 9 nM or less, 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 500 pM or less, 400 pM or less, 300 pM or less, 200 pM or less, or 100 pM or less. D It can bind to IL-11 or an IL-11-containing complex, or to the IL-11 receptor.

[0143] In some embodiments, the drug has an EC50 of 10,000 ng / ml or less, preferably 5,000 ng / ml or less, 1,000 ng / ml or less, 900 ng / ml or less, 800 ng / ml or less, 700 ng / ml or less, 600 ng / ml or less, 500 ng / ml or less, 400 ng / ml or less, 300 ng / ml or less, 200 ng / ml or less, 100 ng / ml or less, 90 ng / ml or less, 80 ng / ml or less, and 70 ng / The IL-11 binds to IL-11, IL-11-containing complexes, or IL-11 receptors with an affinity (e.g., determined by ELISA) of one of the following: ≤ ml, ≤ 60 ng / ml, ≤ 50 ng / ml, ≤ 40 ng / ml, ≤ 30 ng / ml, ≤ 20 ng / ml, ≤ 15 ng / ml, ≤ 10 ng / ml, ≤ 7.5 ng / ml, ≤ 5 ng / ml, ≤ 2.5 ng / ml, or ≤ 1 ng / ml. Such an ELISA can be performed, for example, as described in Antibody Engineering, vol. 1 (2nd edition), Springer Protocols, Springer (2010), Part V, pp. 657-665.

[0144] In some embodiments, the drug inhibits the interaction between IL-11 or the IL-11-containing complex and the IL-11 receptor, and / or signaling through the receptor, by binding to IL-11 or the IL-11-containing complex in a region important for binding to the receptor of the IL-11 or the IL-11-containing complex, such as gp130 or IL-11Rα. In some embodiments, the drug inhibits the interaction between IL-11 or the IL-11-containing complex and the IL-11 receptor, and / or signaling through the receptor, by binding to the IL-11 receptor in a region important for binding to IL-11 or the IL-11-containing complex.

[0145] The ability of a given binder (e.g., an IL-11 / IL-11-containing complex or a drug capable of binding to the IL-11 receptor) to inhibit the interaction between two proteins can be determined, for example, by analyzing the interaction with the binder, either in the presence of the binder or after incubation of one or both of the interaction partners. A suitable assay for determining whether a given binder can inhibit the interaction between two interaction partners is competitive ELISA.

[0146] Binding agents capable of inhibiting a given interaction (e.g., between IL-11 and IL-11Rα, or between IL-11 and gp130, or between IL-11 and IL-11Rα:gp130, or between IL-11:IL-11Rα and gp130, or between the IL-11:IL-11Rα:gp130 complex) are identified by observing a reduction / decrease in the level of interaction between the interaction partners in the presence of the binding agent—or after incubation of one or both of the interaction partners—compared to the level of interaction in the absence of the binding agent (or in the presence of a suitable control binding agent). A suitable analysis can be performed in vitro, for example, using recombinant interaction partners or using cells expressing the interaction partners. Cells expressing the interaction partners may be endogenous or from nucleic acids introduced into the cells. For such assays, one or both of the interaction partner and / or the conjugate can be labeled with a detectable entity or used in conjunction with it to detect and / or measure the level of interaction. For example, a drug can be labeled with a radioactive atom or a colored or fluorescent molecule or any other molecule that can be readily detected by any other means. Suitable detectable molecules include fluorescent proteins, luciferases, enzyme substrates, and radiolabels. The conjugate can be labeled directly or indirectly with a detectable label. For example, the conjugate may be unlabeled and can be detected by another labeled conjugate. Alternatively, the second conjugate may have biotin conjugated to it, and the first conjugate can be indirectly labeled using the binding of labeled streptavidin to biotin.

[0147] The ability of a binder to inhibit the interaction between two binding partners can also be determined by analyzing the downstream functional consequences of such interactions, such as IL-11-mediated signaling. For example, downstream functional consequences of interactions between IL-11 and IL-11Rα:gp130, or between IL-11:IL-11Rα and gp130, or between the IL-11:IL-11Rα:gp130 complex may include processes mediated by, for example, IL-11, or the gene / protein expression of IL-11.

[0148] Inhibition of the interaction between IL-11 or an IL-11-containing complex and the IL-11 receptor can be analyzed using a 3H thymidine incorporation and / or Ba / F3 cell proliferation assay, e.g., Curtis et al., Blood, 1997, 90(11) and Karpovich et al., Mol. Hum. Reprod. 2003, 9(2):75-80. Ba / F3 cells co-express IL-11Rα and gp130.

[0149] In some embodiments, the binding agent may inhibit the interaction between IL-11 and IL-11Rα to less than 100% of the level of interaction between IL-11 and IL-11Rα in the absence of the binding agent (or in the presence of a suitable control binding agent), for example, 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less. In some embodiments, the binder may inhibit the interaction between IL-11 and IL-11Rα to less than 1 times the interaction level between IL-11 and IL-11Rα in the absence of the binder (or in the presence of a suitable control binder), for example, 0.99 times or less, 0.95 times or less, 0.9 times or less, 0.85 times or less, 0.8 times or less, 0.75 times or less, 0.7 times or less, 0.65 times or less, 0.6 times or less, 0.55 times or less, 0.5 times or less, 0.45 times or less, 0.4 times or less, 0.35 times or less, 0.3 times or less, 0.25 times or less, 0.2 times or less, 0.15 times or less, or 0.1 times or less.

[0150] In some embodiments, the binder may inhibit the interaction between IL-11 and gp130 to less than 100% of the interaction level between IL-11 and gp130 in the absence of the binder (or in the presence of a suitable control binder), for example, 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less. In some embodiments, the binder may inhibit the interaction between IL-11 and gp130 to less than 1 times the level of interaction between IL-11 and gp130 in the absence of the binder (or in the presence of a suitable control binder), for example, 0.99 times or less, 0.95 times or less, 0.9 times or less, 0.85 times or less, 0.8 times or less, 0.75 times or less, 0.7 times or less, 0.65 times or less, 0.6 times or less, 0.55 times or less, 0.5 times or less, 0.45 times or less, 0.4 times or less, 0.35 times or less, 0.3 times or less, 0.25 times or less, 0.2 times or less, 0.15 times or less, or 0.1 times or less.

[0151] In some embodiments, the binder may inhibit the interaction between IL-11 and IL-11Rα:gp130 to less than 100% of the interaction level between IL-11 and IL-11Rα:gp130 in the absence of the binder (or in the presence of a suitable control binder), for example, 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less. In some embodiments, the binder may inhibit the interaction between IL-11 and IL-11Rα:gp130 to less than 1 times the interaction level between IL-11 and IL-11Rα:gp130 in the absence of the binder (or in the presence of a suitable control binder), for example, 0.99 times or less, 0.95 times or less, 0.9 times or less, 0.85 times or less, 0.8 times or less, 0.75 times or less, 0.7 times or less, 0.65 times or less, 0.6 times or less, 0.55 times or less, 0.5 times or less, 0.45 times or less, 0.4 times or less, 0.35 times or less, 0.3 times or less, 0.25 times or less, 0.2 times or less, 0.15 times or less, or 0.1 times or less.

[0152] In some embodiments, the binder may inhibit the interaction between the IL-11:IL-11Rα complex and gp130 to less than 100% of the interaction level between the IL-11:IL-11Rα complex and gp130 in the absence of the binder (or in the presence of a suitable control binder), for example, ≤99%, ≤95%, ≤90%, ≤85%, ≤75%, ≤70%, ≤65%, ≤60%, ≤55%, ≤50%, ≤45%, ≤40%, ≤35%, ≤30%, ≤25%, ≤20%, ≤15%, ≤10%, ≤5%, or ≤1%. In some embodiments, the binder may inhibit the interaction between the IL-11:IL-11Rα complex and gp130 to less than 1 times the interaction level between the IL-11:IL-11Rα complex and gp130 in the absence of the binder, for example, 0.99 times or less, 0.95 times or less, 0.9 times or less, 0.85 times or less, 0.8 times or less, 0.75 times or less, 0.7 times or less, 0.65 times or less, 0.6 times or less, 0.55 times or less, 0.5 times or less, 0.45 times or less, 0.4 times or less, 0.35 times or less, 0.3 times or less, 0.25 times or less, 0.2 times or less, 0.15 times or less, or 0.1 times or less.

[0153] In some embodiments, the binding agent may inhibit the interaction between the IL-11:IL-11Rα:gp130 complex (i.e., the multimerization of such complex) to less than 100% of the level of interaction between the IL-11:IL-11Rα:gp130 complex in the absence of the binding agent (or in the presence of a suitable control binding agent), for example, ≤99%, ≤95%, ≤90%, ≤85%, ≤75%, ≤70%, ≤65%, ≤60%, ≤55%, ≤50%, ≤45%, ≤40%, ≤35%, ≤30%, ≤25%, ≤20%, ≤15%, ≤10%, ≤5%, or ≤1%. In some embodiments, the binding agent can inhibit the interaction between the IL-11:IL-11Rα:gp130 complex to less than 1x the level of interaction between the IL-11:IL-11Rα:gp130 complex in the absence of the binding agent, for example, ≤0.99x, ≤0.95x, ≤0.9x, ≤0.85x, ≤0.8x, ≤0.75x, ≤0.7x, ≤0.65x, ≤0.6x, ≤0.55x, ≤0.5x, ≤0.45x, ≤0.4x, ≤0.35x, ≤0.3x, ≤0.25x, ≤0.2x, ≤0.15x, or ≤0.1x.

[0154] Drugs capable of reducing the expression of IL-11 or the IL-11 receptor. In aspects of this disclosure, agents capable of inhibiting IL-11-mediated signaling may be capable of blocking or reducing the expression of one or more of IL-11, IL-11Rα, or gp130.

[0155] Expression may be the expression of a gene or a protein, and may be determined as described herein or by methods of the art that are well known to those skilled in the art. Expression may also be by the cells / tissues / organs / organ systems of interest.

[0156] The preferred agent may be of any type, but in some embodiments, the agent that can prevent or reduce the expression of one or more of IL-11, IL-11Rα, or gp130 may be a small molecule or an oligonucleotide.

[0157] Agents that can prevent or reduce the expression of one or more of IL-11, IL-11Rα, or gp130 may do so, for example, by inhibiting the transcription of a gene encoding IL-11, IL-11Rα, or gp130; inhibiting post-transcriptional processing of RNA encoding IL-11, IL-11Rα, or gp130; reducing the stability of RNA encoding IL-11, IL-11Rα, or gp130; accelerating the degradation of RNA encoding IL-11, IL-11Rα, or gp130; inhibiting post-translational processing of IL-11, IL-11Rα, or gp130 polypeptides; reducing the stability of IL-11, IL-11Rα, or gp130 polypeptides; or accelerating the degradation of IL-11, IL-11Rα, or gp130 polypeptides.

[0158] Taki et al., Clin Exp Immunol (1998) Apr;112(1):133-138, reported a reduction in IL-11 expression in rheumatoid synovial cells following treatment with indomethacin, dexamethasone, or interferon-gamma (IFNγ).

[0159] This disclosure envisions the use of antisense nucleic acids to block / reduce the expression of IL-11, IL-11Rα, or gp130. In some embodiments, agents capable of blocking or reducing the expression of IL-11, IL-11Rα, or gp130 can induce reduction in expression through RNA interference (RNAi).

[0160] In some embodiments, the agent may be an inhibitory nucleic acid, such as an antisense or small interfering RNA, including but not limited to shRNA or siRNA. In some embodiments, the inhibitory nucleic acid is provided in a vector. For example, in some embodiments, the drug may be a lentiviral vector encoding shRNA for one or more of IL-11, IL-11Rα, or gp130.

[0161] Oligonucleotide molecules, particularly RNA, can be used to regulate gene expression. These include targeted degradation of mRNA by oligonucleotides and small interfering RNAs (siRNAs), post-transcriptional gene silencing (PTG), developmentally regulated sequence-specific translational repression of mRNA by microRNAs (miRNAs), and targeted transcriptional gene silencing.

[0162] Antisense oligonucleotides are preferably single-stranded oligonucleotides that target and bind to a target oligonucleotide, such as mRNA, by complementary sequence binding. When the target oligonucleotide is mRNA, the binding of the antisense to the mRNA blocks the translation and expression of the mRNA's gene product. Antisense oligonucleotides can be designed to bind to sense genomic nucleic acids and inhibit the transcription of a target nucleotide sequence.

[0163] Known nucleic acid sequences for IL-11, IL-11Rα, and gp130 (e.g., accession number BC012506.1 GI:15341754 (human IL-11), BC134354.1 GI:126632002 (mouse IL-11), AF347935.1 GI:13549072 (rat IL-11), NM_001142784.2 GI:391353394 (human IL-11Rα), NM_001163401.1 GI:254281268 (mouse IL-11Rα), NM_139116.1 GI:20806172 (rat IL-11Rα), NM_001190981.1) Oligonucleotides can be designed to repress or silence the expression of IL-11, IL-11Rα, or gp130, taking into account known mRNA sequences available from GenBank under GI:300244534 (human gp130), NM_010560.3, GI:225007624 (mouse gp130), NM_001008725.3, and GI:300244570 (rat gp130).

[0164] Such oligonucleotides can have any length, but are preferably short, for example, less than 100 nucleotides, for example, 10-40 nucleotides or 20-50 nucleotides, and may include nucleotide sequences that have complete or near-complete complementarity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) with the corresponding length nucleotide sequence in the mRNA of the target oligonucleotide, for example, IL-11, IL-11Rα, or gp130. The complementary region of the nucleotide sequence may have any length, but preferably it has a nucleotide length of at least 5, and optionally 50 or less, for example, one of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.

[0165] Suppression of IL-11, IL-11Rα, or gp130 expression is preferably expected to result in a decrease in the amount of IL-11, IL-11Rα, or gp130 expressed by cells / tissues / organs / organ systems / targets. For example, suppression of IL-11, IL-11Rα, or gp130 in a given cell by administration of a suitable nucleic acid is expected to result in a decrease in the amount of IL-11, IL-11Rα, or gp130 expressed by that cell compared to untreated cells. The suppression may be partial. A preferred degree of suppression is at least 50%, more preferably one of at least 60%, 70%, 80%, 85%, or 90%. Levels of suppression between 90% and 100% are considered "silencing" of expression or function.

[0166] The role of RNAi mechanisms and small RNAs in the targeting of heterochromatin complexes and epigenetic gene silencing at specific chromosomal loci has been demonstrated. Double-stranded RNA (dsRNA)-dependent post-transcriptional silencing, also known as RNA interference (RNAi), is a phenomenon in which dsRNA complexes can target specific homologous genes for silencing in a short period of time. It acts as a signal to promote the degradation of mRNA with sequence identity. 20nt siRNAs are generally long enough to induce gene-specific silencing but short enough to evade the host response. The reduction in the expression of the target gene product can be widespread, with 90% of silencing induced by small siRNA molecules. RNAi-based therapies are progressing to phase I, II, and III clinical trials for several indications (Nature 2009 Jan 22;457(7228):426-433).

[0167] In this field, these RNA sequences are called "short, or small, interfering RNAs" (siRNA) or "microRNAs" (miRNA), depending on their origin. Both types of sequences can be used to downregulate gene expression by binding to complementary RNA and inducing mRNA cleavage (RNAi) or halting mRNA translation into protein. siRNAs are induced by the processing of long, double-stranded RNA and, when found in nature, are typically of exogenous origin. Microinterfering RNAs (miRNAs) are endogenously encoded, small, non-coding RNAs induced by the processing of short, hairpin-like sequences. Both siRNAs and miRNAs can inhibit the translation of mRNA carrying partially complementary target sequences and degrade mRNA carrying fully complementary sequences without cleaving the RNA.

[0168] siRNA ligands are typically double-stranded, and to optimize the effectiveness of RNA-mediated downregulation of target gene function, the length of the siRNA molecule is selected to ensure accurate recognition of the siRNA by the RISC complex that mediates the recognition of mRNA targets by the siRNA; therefore, it is preferable that the siRNA be short enough to reduce the host response.

[0169] miRNA ligands are typically single-stranded, partially complementary, and possess regions that allow the ligand to form a hairpin. miRNAs are RNA genes that are transcribed from DNA but not translated into proteins. The DNA sequence encoding a miRNA gene is longer than the miRNA itself. This DNA sequence contains the miRNA sequence and its approximate reverse complement. When this DNA sequence is transcribed into a single-stranded RNA molecule, the miRNA sequence and its reverse complement form base pairs to create a partially double-stranded RNA segment. MicroRNA sequence design is discussed in John et al., PLoS Biology, 11(2), pp. 1862-1879, 2004.

[0170] Typically, RNA ligands intended to mimic the effects of siRNA or miRNA have 10 to 40 ribonucleotides (or their synthetic analogues), more preferably 17 to 30 ribonucleotides, more preferably 19 to 25 ribonucleotides, and most preferably 21 to 23 ribonucleotides. In some embodiments using double-stranded siRNA, the molecule may have, for example, one or two (ribo)nucleotides, typically a symmetric 3' protrusion of dTdT3' protrusion UU. Based on the disclosures provided herein, those skilled in the art can easily design suitable siRNA and miRNA sequences using resources such as the Ambion siRNA finder. siRNA and miRNA sequences can be produced synthetically and exogenously to induce gene downregulation, or produced using an expression system (e.g., a vector). In preferred embodiments, the siRNA is synthesized.

[0171] Longer double-stranded RNA may be processed in cells to produce siRNA (see, for example, Myers (2003) Nature Biotechnology 21: pp. 324-328). Longer dsRNA molecules may have, for example, one or two symmetrical 3' or 5' overhangs of (ribo)nucleotides, or they may have blunt ends. Longer dsRNA molecules may be 25 nucleotides or longer. Preferably, longer dsRNA molecules are 25-30 nucleotides long. More preferably, longer dsRNA molecules are 25-27 nucleotides long. Most preferably, longer dsRNA molecules are 27 nucleotides long. dsRNA molecules longer than 30 nucleotides can be expressed using the vector pDECAP (Shinagawa et al., Genes and Dev., 17, pp. 1340-1345, 2003).

[0172] Another option is the expression of short hairpin RNA molecules (shRNAs) in cells. shRNAs are more stable than synthetic siRNAs. shRNAs consist of short reverse repeats separated by small loop sequences. One reverse repeat is complementary to the gene target. In cells, shRNAs are processed by DICER into siRNAs that degrade the mRNA of the target gene and suppress its expression. In preferred embodiments, shRNAs are produced endogenously (intracellularly) by transcription from a vector. Intracellular production of shRNAs can be induced by transfecting cells with a vector encoding an shRNA sequence under the control of an RNA polymerase III or RNA polymerase II promoter, such as a human H1 or 7SK promoter. Alternatively, shRNAs can be synthesized exogenously (in vitro) by transcription from a vector. The shRNAs can then be directly introduced into cells. Preferably, the shRNA molecule contains a partial sequence of IL-11, IL-11Rα, or gp130. Preferably, the shRNA sequence is 40 to 100 base pairs long, more preferably 40 to 70 base pairs long. The hairpin stem is preferably 19 to 30 base pairs long. The stem may contain GU pairs to stabilize the hairpin structure.

[0173] siRNA molecules, longer dsRNA molecules, or miRNA molecules can be recombinantly produced, preferably by transcription of nucleic acid sequences contained within a vector. Preferably, the siRNA molecule, longer dsRNA molecule, or miRNA molecule contains a partial sequence of IL-11, IL-11Rα, or gp130.

[0174] In one embodiment, the siRNA, longer dsRNA, or miRNA is produced endogenously (intracellularly) by transcription from the vector. The vector may be introduced into the cell by any method known in the art. If necessary, the expression of the RNA sequence can be regulated using tissue-specific (e.g., heart, liver, or kidney-specific) promoters. In a further embodiment, the siRNA, longer dsRNA, or miRNA is produced exogenously (in vitro) by transcription from the vector.

[0175] A suitable vector may be an oligonucleotide vector configured to express an oligonucleotide agent capable of suppressing IL-11, IL-11Rα, or gp130. Such a vector may be a viral vector or a plasmid vector. The therapeutic oligonucleotide can be incorporated into the genome of a viral vector and operably ligated to a regulatory sequence, such as a promoter that drives its expression. The term “operably ligated” may include situations in which a selected nucleotide sequence and a regulatory nucleotide sequence are covalently ligated in such a way that the expression of the nucleotide sequence is under the influence or control of the regulatory sequence. Thus, if the regulatory sequence can transcribe a nucleotide sequence that forms part or all of the selected nucleotide sequence, then the regulatory sequence is operably ligated to the selected nucleotide sequence.

[0176] Viral vectors encoding promoter-expressed siRNA sequences are well-known in the industry and offer the benefit of long-term expression of therapeutic oligonucleotides. Examples include lentiviruses (Nature 2009 Jan 22;457(7228):426-433), adenoviruses (Shen et al., FEBS Lett 2003 Mar 27;539(1-3)111-4), and retroviruses (Barton and Medzhitov, PNAS November 12, 2002, vol.99, no.23, pp. 14943-14945).

[0177] In other embodiments, the vector may be configured to assist in the delivery of therapeutic oligonucleotides to sites where suppression of IL-11, IL-11Rα, or gp130 expression is required. Such vectors typically involve conjugating oligonucleotides with positively charged vectors (e.g., cationic cell-permeable peptides, cationic polymers and dendrimers, and cationic lipids); conjugating oligonucleotides with small molecules (e.g., cholesterol, bile acids, and lipids), polymers, antibodies, and RNA; or encapsulating oligonucleotides in nanoparticle formulations (Wang et al., AAPS J.2010 Dec;12(4):492-503).

[0178] In one embodiment, the vector may contain both sense-oriented and antisense-oriented nucleic acid sequences so that, when expressed as RNA, the sense and antisense sections associate to form double-stranded RNA.

[0179] Alternatively, siRNA molecules can be synthesized using standard solid-phase or liquid-phase synthesis techniques known in the industry. The linkage between nucleotides may be phosphodiester bonds, or, for example, a linking group of the formula P(O)S,(thioate);P(S)S,(dithioate);P(O)NR'2;P(O)R';P(O)OR6;CO;or CONR'2 (wherein R is H (or a salt) or alkyl (1-12C), and R6 is alkyl (1-9C)) may be linked to an adjacent nucleotide via -O- or -S-.

[0180] Modified nucleotide bases may be used in addition to naturally occurring bases, and they may confer advantageous properties to siRNA molecules containing them. For example, modified bases can reduce the amount required for silencing by increasing the stability of the siRNA molecule. Providing modified bases can also provide siRNA molecules that are more or less more stable than unmodified siRNA.

[0181] The term “modified nucleotide base” encompasses nucleotides having covalently modified bases and / or sugars. For example, modified nucleotides include nucleotides having sugars covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus, modified nucleotides may also include 2'-substituted sugars such as 2'-O-methyl-; 2'-O-alkyl; 2'-O-allyl; 2'-S-alkyl; 2'-S-allyl; 2'-fluoro-; 2'-halo or azidolibose, carbocyclic sugar analogs, α-anomeric sugars; epimeric sugars such as arabinose, xylose or lyxose, pyranose sugars, furanose sugars, and sedoheptulose.

[0182] Modified nucleotides are known in the art and include alkylated purines and pyrimidines, acylated purines and pyrimidines, and other heterocyclic nucleotides. Pyrimidines and purines of these classes are known in the art and include pseudoisocytosine, N4,N4-ethanocytosine, 8-hydroxy-N6-methyladenine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentyl-adenine, 1-methyladenine, 1-methylpseuduracil, 1-methylguanine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, and 5-methoxy Examples include aminomethyl-2-thiouracil, D-mannosylkeosin, 5-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetate methyl ester, pseudouracil, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetate methyl ester, uracil-5-oxyacetate, keosin, 2-thiocytosine, 5-propyluracil, 5-propylcytosine, 5-ethyluracil, 5-ethylcytosine, 5-butyluracil, 5-pentyluracil, 5-pentylcytosine, and 2,6-diaminopurine, methylpseudracil, 1-methylguanine, and 1-methylcytosine.

[0183] Methods for using RNAi to silence genes in C. elegans, Drosophila, plants, and mammals are publicly known in the industry (Fire A. et al., 1998 Nature 391: pp. 806-811; Fire, A. Trends Genet. 15, pp. 358-363 (1999); Sharp, PARNA interference 2001, Genes Dev. 15, pp. 485-490 (2001); Hammond, SM et al., Nature Rev. Genet. 2, pp. 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, pp. 239-245 (2001); Hamilton, A. et al., Science 286, pp. 950-952 (1999); Hammond, SM et al., Nature 404, pp. 293-296 (2000); Zamore, PD et al., Cell 101, pp. 25-33 (2000); Bernstein, E. et al., Nature 409, pp. 363-366 (2001); Elbashir, S. M. et al., Genes Dev. 15, pp. 188-200 (2001); WO0129058; WO9932619, and Elbashir S. M. et al., 2001, Nature 411: pp. 494-498).

[0184] Accordingly, this disclosure provides nucleic acids that can suppress the expression of IL-11, IL-11Rα, or gp130 by RNAi when they are appropriately introduced into or expressed in mammalian cells, such as human cells, that otherwise express IL-11, IL-11Rα, or gp130.

[0185] Nucleic acid sequences for IL-11, IL-11Rα, and gp130 (e.g., accession number BC012506.1 GI:15341754 (human IL-11), BC134354.1 GI:126632002 (mouse IL-11), AF347935.1 GI:13549072 (rat IL-11), NM_001142784.2 GI:391353394 (human IL-11Rα), NM_001163401.1 GI:254281268 (mouse IL-11Rα), NM_139116.1 GI:20806172 (rat IL-11Rα), NM_001190981.1) Oligonucleotides of known mRNA sequences available from GenBank under GI:300244534 (human gp130), NM_010560.3, GI:225007624 (mouse gp130), NM_001008725.3, and GI:300244570 (rat gp130) can be designed to suppress or silence the expression of IL-11, IL-11Rα, or gp130.

[0186] The nucleic acid may have substantial sequence identity with respect to a portion of IL-11, IL-11Rα, or gp130 mRNA or a complementary sequence to said mRNA, as defined in, for example, GenBank accession numbers NM_000641.3 GI:391353405 (IL-11), NM_001142784.2 GI:391353394 (IL-11Rα), and NM_0011909891.1 GI:300244534 (gp130).

[0187] The nucleic acid may be a double-stranded siRNA (as will be understood by those skilled in the art, and as will be further explained below, the siRNA molecule may also contain a short 3' DNA sequence).

[0188] Alternatively, the nucleic acid may be DNA (usually double-stranded DNA) that, when transcribed in mammalian cells, yields RNA having two complementary regions linked via a spacer, such that the RNA takes the form of a hairpin when the complementary regions hybridize with each other. In mammalian cells, the hairpin structure may be cleaved from the molecule by the DICER enzyme, yielding two different but hybridized RNA molecules.

[0189] In some preferred embodiments, the nucleic acid is targeted as a whole to one of the sequences of sequence numbers 4-7 (IL-11) or one of the sequences of sequence numbers 8-11 (IL-11Rα). Only single-stranded (i.e., non-self-hybridized) regions of mRNA transcripts are expected to be suitable targets for RNAi. Therefore, it is proposed that other very close sequences in IL-11 or IL-11Rα mRNA transcripts to the sequence represented by one of sequence numbers 4-7 or 8-11 may also be suitable targets for RNAi. Such target sequences are preferably 17-23 nucleotides in length, and preferably one of sequence numbers 4-7 or 8-11 overlaps with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all 19 nucleotides (at either end of one of sequence numbers 4-7 or 8-11).

[0190] Accordingly, the present disclosure provides nucleic acids that can suppress the expression of IL-11 or IL-11Rα by RNAi when appropriately introduced into or expressed in mammalian cells otherwise expressing IL-11 or IL-11Rα, wherein the nucleic acids generally target one of the sequences of SEQ ID NOs: 4-7 or 8-11.

[0191] A nucleic acid that is "targeted as a whole" may target sequences that overlap with sequence numbers 4-7 or 8-11. In particular, the nucleic acid may target a sequence (preferably 17-23 nucleotides long) in human IL-11 or IL-11Rα mRNA that is slightly longer or shorter than one of sequence numbers 4-7 or 8-11, but otherwise identical to one of sequence numbers 4-7 or 8-11.

[0192] While complete identity / complementarity between the nucleic acids and target sequences of this disclosure is desirable, it is not expected to be essential. Therefore, the nucleic acids of this disclosure may contain a single mismatch compared to the mRNA of IL-11 or IL-11Rα. However, the absence of mismatches is preferred, as even the presence of a single mismatch may lead to reduced efficiency. If present, the 3' overhang may be excluded from the calculation of the number of mismatches.

[0193] The term “complementarity” is not limited to conventional base pairing between naturally occurring nucleic acids consisting of ribo and / or deoxyribonucleotides, but also includes base pairing between mRNA and nucleic acids of this disclosure that include non-natural nucleotides.

[0194] In one embodiment, the nucleic acid (referred to herein as double-stranded siRNA) comprises the double-stranded RNA sequences shown in SEQ ID NOs. 12-15. In another embodiment, the nucleic acid (referred to herein as double-stranded siRNA) comprises the double-stranded RNA sequences shown in SEQ ID NOs. 16-19.

[0195] However, it is also expected that slightly shorter or longer sequences pointing to the same region of IL-11 or IL-11Rα mRNA may be effective. In particular, double-stranded sequences of 17–23 bp in length are also expected to be effective.

[0196] The strands forming the double-stranded RNA may be DNA or RNA, and may have short 3' dinucleotide overhangs. While the use of 3' DNA overhangs has no effect on siRNA activity compared to 3' RNA overhangs, it reduces the cost of chemosynthesis of nucleic acid strands (Elbashir et al., 2001c). For this reason, DNA dinucleotides may be preferred.

[0197] If present, the dinucleotide overhangs may be symmetrical to each other, but this is not essential. In fact, the 3' overhang of the sense (upper) strand is irrelevant to RNAi activity as it does not participate in mRNA recognition and degradation (Elbashir et al., 2001a, 2001b, 2001c).

[0198] RNAi experiments in Drosophila suggest that the antisense 3' overhang may participate in mRNA recognition and targeting (Elbashir et al., 2001c), but the 3' overhang is not considered necessary for siRNA RNAi activity in mammalian cells. Inaccurate annealing of the 3' overhang is therefore thought to have little effect in mammalian cells (Elbashir et al., 2001c; Czauderna et al., 2003).

[0199] Therefore, any dinucleotide overhang can be used in the antisense strand of siRNA. Nevertheless, the dinucleotide is preferably -UU or -UG (or -TT or TG if the overhang is DNA), more preferably -UU (or -TT). The -UU (or -TT) dinucleotide overhang is the most effective and coincides with (i.e., can form part of) the RNA polymerase III terminus of the transcription signal (the termination signal is TTTTT). Therefore, this dinucleotide is the most preferred. Dinucleotides AA, CC, and GG may be used, but they are less effective and, as a result, less preferred.

[0200] Furthermore, the 3' protrusion may be completely omitted from the siRNA. The disclosure also provides single-stranded nucleic acids (hereinafter referred to as single-stranded siRNAs) each comprising one component strand of the double-stranded nucleic acid, preferably having a 3' protrusion, but optionally not having one. The disclosure also provides a kit containing such a pair of single-stranded nucleic acids that can be hybridized in vitro to form the double-stranded siRNAs and then introduced into cells.

[0201] The disclosure also provides DNA that, when transcribed in mammalian cells, gives RNA (also referred to herein as shRNA) having two complementary regions capable of self-hybridizing to generate a double-stranded motif, which may include, for example, a sequence selected from the group consisting of SEQ ID NOs. 12-15 or 16-19, or a sequence different from any one of the aforementioned sequences by a single base pair substitution.

[0202] Complementary regions are generally expected to be linked by a spacer having a suitable length and sequence for hybridizing the two complementary regions. The two complementary (i.e., sense and antisense) regions can be linked 5'-3' in either order. The spacer is typically expected to be a short sequence of about 4-12 nucleotides, preferably 4-9 nucleotides, and more preferably 6-9 nucleotides.

[0203] Preferably, the 5' end of the spacer (immediately 3' from the upstream complementary portion) consists of a nucleotide -UU- or -UG-, again preferably -UU- (but again, the use of these specific dinucleotides is not mandatory). A preferred spacer recommended for use in the pSuper system of OligoEngine (Seattle, Washington, USA) is UUCAAGAGA. In this and other cases, the ends of the spacers hybridize with each other, allowing the double-stranded motif to be extended by a few (e.g., one or two) base pairs beyond the exact sequences of, for example, SEQ ID NOs. 12-15 or 16-19.

[0204] Similarly, the transcribed RNA preferably includes a 3' overhang derived from the downstream complementary region. Again, this is preferably -UU or -UG, more preferably -UU. Next, such shRNA molecules can be cleaved in mammalian cells using the DICER enzyme to obtain the double-stranded siRNA described above, in which one or each of the hybridized dsRNA strands contains a 3' overhang.

[0205] The techniques for nucleic acid synthesis described herein are, of course, well known in the industry. Those skilled in the art can construct suitable transcription vectors for the DNA of this disclosure using well-known techniques and commercially available materials. In particular, the DNA is conjugated to a regulatory sequence including a promoter and a transcription termination sequence.

[0206] Particularly suitable are the commercially available pSuper and pSuperior systems from OligoEngine (Seattle, Washington, USA). These utilize a polymerase-III promoter (H1) and a T5 transcription termination sequence that contributes two U residues at the 3' end of the transcript (providing a 3'UU overhang on one strand of the siRNA after DICER processing).

[0207] Another preferred system using a different polymerase-III promoter (U6) is described by Shin et al. (RNA, 2009 May;15(5):898-910). The double-stranded siRNAs of this disclosure can be introduced into mammalian cells in vitro or in vivo using known techniques as described below to suppress the expression of IL-11 or the IL-11 receptor.

[0208] Similarly, transcription vectors containing the DNA of this disclosure can be introduced into tumor cells in vitro or in vivo using known techniques, as described below, for transient or stable expression of RNA, also to suppress the expression of IL-11 or the IL-11 receptor.

[0209] Accordingly, the present disclosure also provides a method for suppressing the expression of IL-11 or the IL-11 receptor in mammalian cells, such as human cells, which comprises administering the cells with the double-stranded siRNA or the transcription vector of the present disclosure.

[0210] Similarly, the present disclosure further provides methods for treating the diseases / conditions described herein, which include administering to a subject the double-stranded siRNA or transcription vector of the present disclosure.

[0211] This disclosure further provides the double-stranded siRNA and transcription vector of this disclosure for use in methods of treating / preventing the diseases / conditions described herein. This disclosure further provides the use of the double-stranded siRNA and transcription vectors of this disclosure in the preparation of pharmaceuticals for the treatment / prevention of the diseases / conditions described herein.

[0212] This disclosure further provides compositions comprising the double-stranded siRNA of this disclosure or the transcription vector of this disclosure in mixtures with one or more pharmaceutically acceptable carriers. Suitable carriers include lipophilic carriers or vesicles that can assist in translocation across cell membranes.

[0213] Suitable materials and methods for administering the siRNA double-stranded and DNA vectors of this disclosure are well known in the industry, and improved methods are under development that take into account the potential of RNAi technology.

[0214] In general, many techniques are available for introducing nucleic acids into mammalian cells. The choice of technique is expected to depend on whether the nucleic acid is to be transferred into cultured cells in vitro or into patient cells in vivo. Suitable techniques for the in vitro transfer of nucleic acids into mammalian cells include the use of liposomes, electroporation, microinjection, cell fusion, DEAE, dextran, and calcium phosphate precipitation. In vivo gene transfer techniques include viral (typically retroviral) vectors and viral coat protein-liposome-mediated transfection (Dzau et al. (2003) Trends in Biotechnology 11, pp. 205-210).

[0215] In particular, preferred techniques for the cellular administration of the nucleic acids of this disclosure both in vitro and in vivo are disclosed in the following paper: General overview: Borkhardt, A. 2002. Blocking oncogenes in malignant cells by RNA interference - new hope for a highly specific cancer treatment? Cancer Cell. 2: pp. 167-168. Hannon, GJ 2002. RNA interference. Nature. 418: pp. 244-2451. McManus, MT and PASharp. 2002. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 3: pp. 737-747. Scherr, M., MAMorgan, and M. Eder. 2003b. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem. 10: pp. 245-2456. Shuey, DJ, DEMcCallus, and T. Giordano. 2002. RNAi: gene-silencing in therapeutic intervention. Drug Discov Today. 7: pp. 1040-1046.

[0216] Systemic delivery using liposomes: Lewis, DL, JE Hagstrom, AG Loomis, JA Wolff, and H. Herweijer. 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet. 32: pp. 107-108. Paul, CP, PD Good, I. Winer, and D. Engelke. 2002. Effective expression of small interfering RNA in human cells. Nat Biotechnol. 20: pp. 505-508. Song, E., SK Lee, J. Wang, N. Ince, N. Ouyang, J. Min, J. Chen, P. Shankar, and J. Lieberman. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 9: pp. 347-351. Sorensen, DR, M. Leirdal, and M. Sioud. 2003. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 327:761–6.

[0217] Virus-mediated transfer: Abbas-Terki, T., W. Blanco-Bose, N. Deglon, W. Pralong, and P. Aebischer. 2002. Lentiviral-mediated RNA interference. Hum Gene Ther. 13:2197-201. Barton, GM, and R. Medzhitov. 2002. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA. 99:14943~5. Devroe, E., and PASilver. 2002. Retrovirus-delivered siRNA. BMC Biotechnol. 2:15 pages. Lori, F., P. Guallini, L. Galluzzi, and J. Lisziewicz. 2002. Gene therapy approaches to HIV infection. Am J Pharmacogenomics. 2:245-52. Matta, H., B. Hozayev, R. Tomar, P. Chugh, and P. Chaudhary. 2003. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther. 2: pp. 206-2010. Qin, XF, DS An, ISchen, and D. Baltimore. 2003. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA. 100: pp. 183-188. Scherr, M., K. Battmer, A. Ganser, and M. Eder. 2003a. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle. 2: pp. 251-257.Shen, C., AKBuck, X. Liu, M. Winkler, and SNReske. 2003. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539: pp. 111-114.

[0218] Peptide delivery: Morris, MC, L. Chaloin, F. Heitz, and G. Divita. 2000. Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol. 11: pp. 461-466. Simeoni, F., M. Morris, F. Heitz, and G. Divita. 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31: pp. 2717-24. Other techniques that may be suitable for the delivery of siRNA to target cells are based on nanoparticles or nanocapsules, such as those described in U.S. Patent Nos. 6,649,192B and 5,843,509B.

[0219] Inhibition of IL-11-mediated signaling In embodiments of this disclosure, agents capable of inhibiting the action of IL-11 may have one or more of the following functional properties: • Inhibition of IL-11-mediated signaling; • Inhibition of signal transduction mediated by the binding of IL-11 to the IL-11Rα:gp130 receptor complex; • Inhibition of signaling mediated by the binding of the IL-11:IL-11Rα complex to gp130 (i.e., IL-11 transsignaling); • Inhibition of signal transduction mediated by the multimerization of the IL-11:IL-11Rα:gp130 complex; ·Inhibition of processes mediated by IL-11; ·Inhibition of the expression of the gene / protein of IL-11 and / or IL-11Rα.

[0220] These properties can be determined by analysis of the agent in a suitable assay, which may include comparison of the performance of the relevant agent with a suitable control agent. One skilled in the art can identify appropriate control conditions for a given assay.

[0221] IL-11-mediated signaling and / or processes mediated by IL-11 include signaling mediated by fragments of IL-11 and polypeptide complexes containing IL-11 or fragments thereof. IL-11-mediated signaling may be signaling mediated by human IL-11 and / or mouse IL-11. Signaling mediated by IL-11 may occur after binding of IL-11 or an IL-11-containing complex to the receptor to which IL-11 or the complex binds.

[0222] In some embodiments, the agent may be able to inhibit the biological activity of IL-11 or an IL-11-containing complex. In some embodiments, the agent is an antagonist of one or more signaling pathways activated by signaling through a receptor comprising IL-11Rα and / or gp130, such as IL-11Rα:gp130. In some embodiments, the agent can inhibit signaling through one or more immune receptor complexes comprising IL-11Rα and / or gp130, such as IL-11Rα:gp130. In various aspects of the present disclosure, the agents provided herein are capable of inhibiting IL-11-mediated cis and / or trans signaling. In some embodiments according to various aspects of the present disclosure, the agents provided herein are capable of inhibiting IL-11-mediated cis signaling.

[0223] In some embodiments, the drug may inhibit IL-11-mediated signaling at a level less than 100% of the signaling level in the absence of the drug (or in the presence of a suitable control drug), for example, ≤99%, ≤95%, ≤90%, ≤85%, ≤80%, ≤75%, ≤70%, ≤65%, ≤60%, ≤55%, ≤50%, ≤45%, ≤40%, ≤35%, ≤30%, ≤25%, ≤20%, ≤15%, ≤10%, ≤5%, or ≤1%. In some embodiments, the drug can reduce IL-11-mediated signaling to less than 1x the level of signaling in the absence of the drug (or in the presence of a suitable control drug), for example, 0.99x or less, 0.95x or less, 0.9x or less, 0.85x or less, 0.8x or less, 0.75x or less, 0.7x or less, 0.65x or less, 0.6x or less, 0.55x or less, 0.5x or less, 0.45x or less, 0.4x or less, 0.35x or less, 0.3x or less, 0.25x or less, 0.2x or less, 0.15x or less, or 0.1x or less.

[0224] In some embodiments, IL-11-mediated signaling may be signaling mediated by the binding of IL-11 to the IL-11Rα:gp130 receptor. Such signaling can be analyzed, for example, by treating cells expressing IL-11Rα and gp130 with IL-11, or by stimulating IL-11 production in cells expressing IL-11Rα and gp130.

[0225] IC for drugs to inhibit IL-11-mediated signaling 50 For example, culturing Ba / F3 cells expressing IL-11Rα and gp130 in the presence of human IL-11 and drugs, and adding to DNA 3The IC of 10 μg / ml or less, preferably one of the following ICs in such assay: 10 μg / ml or less, 5 μg / ml or less, 4 μg / ml or less, 3.5 μg / ml or less, 3 μg / ml or less, 2 μg / ml or less, 1 μg / ml or less, 0.9 μg / ml or less, 0.8 μg / ml or less, 0.7 μg / ml or less, 0.6 μg / ml or less, or 0.5 μg / ml or less. 50 You may also indicate this.

[0226] In some embodiments, IL-11-mediated signaling may be signaling mediated by the binding of the IL-11:IL-11Rα complex to gp130. In some embodiments, the IL-11:IL-11Rα complex may be a soluble complex, for example, of IL-11Rα and the extracellular domain of IL-11, or a complex of a soluble IL-11Rα isoform / fragment with IL-11. In some embodiments, soluble IL-11Rα may be a soluble (secreted) isoform of IL-11Rα, or a free product of proteolytic cleavage of the extracellular domain of IL-11Rα bound to the cell membrane.

[0227] In some embodiments, the IL-11:IL-11Rα complex may be a cell-bound, for example, cell membrane-bound, complex of IL-11 and IL-11. Signaling mediated by the binding of the IL-11:IL-11Rα complex to gp130 can be analyzed by treating cells expressing gp130 with a recombinant fusion protein containing the IL-11:IL-11Rα complex, for example, IL-11 linked to the extracellular domain of IL-11Rα, for example, hyperIL-11, via a peptide linker. HyperIL-11 was constructed using fragments of IL-11Rα (amino acid residues 1-317, consisting of domains 1-3; UniProtKB:Q14626) and IL-11 (amino acid residues 22-199, UniProtKB:P20809) with a 20-amino acid linker (SEQ ID NO: 20). The amino acid sequence of hyperIL-11 is shown in SEQ ID NO: 21.

[0228] In some embodiments, the drug may be able to inhibit signaling mediated by the binding of the IL-11:IL-11Rα complex to gp130, or it may be able to inhibit signaling mediated by the binding of IL-11 to the IL-11Rα:gp130 receptor.

[0229] In some embodiments, the drug may be capable of inhibiting the process mediated by IL-11. In some embodiments, the agent may be capable of inhibiting the expression of the IL-11 and / or IL-11Rα gene / protein. The expression of the gene and / or protein can be measured as described herein or by methods of the art that are well known to those skilled in the art.

[0230] In some embodiments, the drug may inhibit the gene / protein expression of IL-11 and / or IL-11Rα to less than 100% of the level of expression in the absence of the drug (or in the presence of a suitable control drug), for example, 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less. In some embodiments, the drug can inhibit the expression of the IL-11 and / or IL-11Rα gene / protein to less than 1x the level of expression in the absence of the drug (or in the presence of a suitable control drug), for example, ≤0.99x, ≤0.95x, ≤0.9x, ≤0.85x, ≤0.8x, ≤0.75x, ≤0.7x, ≤0.65x, ≤0.6x, ≤0.55x, ≤0.5x, ≤0.45x, ≤0.4x, ≤0.35x, ≤0.3x, ≤0.25x, ≤0.2x, ≤0.15x, or ≤0.1x.

[0231] Indications for treatment and prevention This disclosure broadly relates to the treatment and prevention of age-related diseases / conditions. Age-related diseases / conditions as referred herein are diseases / conditions that have an increasing incidence with age. Age-related diseases and conditions are described, for example, Franceschi et al., Front Med (Lausanne) (2018) 5:61 and Jaul and Barron, Front Public Health (2017) 5:335, both of which are fully incorporated herein by reference.

[0232] Age-related diseases / conditions are generally characterized by the progressive degeneration of tissue structures and / or the progressive decline of physiological tissue functions. The molecular and cellular mechanisms underlying such diseases / conditions include one or more of the following: disregulated autophagy, mitochondrial dysfunction, telomere shortening, oxidative stress, inflammation, metabolic dysfunction, and cellular senescence in general.

[0233] Aging is a major risk factor for many chronic diseases. In the liver, aging increases susceptibility to acute liver injury and hepatic fibrosis responses (Kim et al., Curr Opin Gastroenterol (2015) 31(3): pp. 184-191; Hunt et al., Comput Struct Biotechnol J (2019) 17: pp. 1151-1161; Ferrucci et al., Aging Cell (2020) 19(2): e13080). Furthermore, aging is positively associated with an increased risk and worsening prognosis of various liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and hepatitis C, and negatively associated with liver regenerative capacity (Kim et al., Curr Opin Gastroenterol (2015) 31(3): pp. 184-191; Papatheodoridi et al., Hepatology (2020) 71(1): pp. 363-374).

[0234] As used herein, “age-related” disease / condition or phenotype may also be referred to as “age-associated” or “age / age-related.” In aspects and embodiments of this disclosure, a disease / condition or phenotype described as “age-related” may occur as a result of the age of the subject having a disease / condition or phenotype that is more relevant than any other etiology. In some aspects and embodiments, an “age-related” disease / condition or phenotype may occur as a result of cellular senescence. For example, “age-related” changes in body composition may refer to changes in body composition that occur as a result of aging and / or cellular senescence of the subject rather than the diet of the subject.

[0235] The accumulation of senescent cells is one of the characteristics of aging (Hunt et al., Comput Struct Biotechnol J (2019) 17: pp. 1151-1161). Cellular senescence is characterized by reduced replication capacity, the production of senescence-associated secretory phenotype (SASP) proteins, and a chronically poor-quality inflammatory environment for neighboring cells (Hunt et al., Comput Struct Biotechnol J (2019) 17: pp. 1151-1161; Borghesan et al., Trends Cell Biol. (2020) 30(10): pp. 777-791). Under pathological stress conditions, the excessive accumulation of senescent cells in affected tissues can negatively impact the regenerative capacity and chronic inflammation of tissues, which can resemble various age-related disorders such as Alzheimer's disease, cancer, arthritis, cataracts, osteoporosis, atherosclerosis, hypertension, cardiovascular disease, type 2 diabetes, and chronic liver disease (Baker and Haynes, Trends Biochem Sci (2011) 36(5): pp. 254-261; Kim et al., Curr Opin Gastroenterol (2015) 31(3): pp. 184-191; Hernandez-Segura et al., Trends Cell Biol (2018) 28(6): pp. 436-453; Stahl et al., Front Immunol (2018) 9: pp. 2795; Belikov, Ageing Res Rev(2019)49:pp. 11-26; Campisi et al., Nature(2019)571(7764):pp. 183-192; Gorgoulis et al., Cell(2019)179(4):pp. 813-827; Schmeer et al., Cells(2019)8(11); Papatheodoridi et al., Hepatology(2020)71(1):pp. 363-374. Therefore, cellular senescence is considered to be an important physiological process in the development and progression of age-related diseases (Borghesan et al., Trends Cell Biol.(2020)30(10):pp. 777-791; Pignolo et al., Trends Mol Med(2020)26(7):pp. 630-638).

[0236] In some embodiments and settings, the Disclosure is intended to treat / prevent cellular senescence and diseases / conditions characterized by cellular senescence. In some embodiments and settings, the methods of the Disclosure include inhibiting cellular senescence. In some embodiments and settings, the methods of the Disclosure include inhibiting senescent cells. In some embodiments and settings, the methods include reducing the number of senescent cells and / or inhibiting the activity of senescent cells.

[0237] In some embodiments, reducing the number of senescent cells includes inhibiting the process of cellular senescence. That is, in some embodiments, reducing the number of senescent cells includes inhibiting the development of senescent cells from non-senescent progenitor cells. In some embodiments, reducing the number of senescent cells includes reversing the process of cellular senescence. That is, in some embodiments, reducing the number of senescent cells includes promoting the return of senescent cells to a non-senescent phenotype. In some embodiments, reducing the number of senescent cells includes reducing the number of senescent cells.

[0238] Cellular senescence is described, for example, by Childs et al., Nat Med (2015) 21(12): pp. 1424-1435 and by van Deursen, Nature (2014) 509(7501): pp. 439-446, both of which are fully incorporated here by reference. Cellular senescence is the arrest of cell division (p. 16 INK4a p21 CIP1 It is characterized by chromatin remodeling (including, and associated with, p53 activation), chromatin remodeling (e.g., DNA injury response (DDR), promyelocytic leukemia protein (PML) formation, and aging-related heterochromatin lesions (SAHF)), aging-related β-galactosidase activity, and the generation of a mixture of pro-inflammatory factors called aging-related secretory phenotype (SASP).

[0239] This disclosure indicates that senescent cells may exhibit one or more of the following characteristics compared to equivalent non-senescent cells of the same cell type / same tissue: p16 INK4a p21 CIP1and / or increased expression of p53; increased levels of DDR; increased number of PML bodies; increased number of SAHFs; increased expression and / or activity of senescence-related β-galactosidases; increased expression of one or more SASP factors (e.g., IL-1b or IL-8).

[0240] In certain aspects and embodiments, this disclosure relates to the treatment of diseases / conditions including and / or characterized by cellular senescence, i.e., diseases / conditions to which cellular senescence is pathologically linked. A disease / condition to which cellular senescence is “pathologically linked” is a disease / condition in which the number / proportion and / or activity of senescent cells are positively associated with the disease or condition.

[0241] A disease / condition in which cellular senescence is “pathologically linked” may be one in which an increase in the number / percentage and / or activity of senescent cells (compared to a non-pathological healthy state) is positively associated with the onset, development and / or progression of that disease / condition. A disease / condition in which cellular senescence is “pathologically linked” may be one in which an increase in the number / percentage and / or activity of senescent cells (compared to a non-pathological healthy state) is positively associated with the severity of one or more symptoms of that disease / condition. A disease / condition in which cellular senescence is “pathologically linked” may be one in which an increase in the number / percentage and / or activity of senescent cells (compared to a non-pathological healthy state) is a risk factor for the onset, development and / or progression of that disease / condition.

[0242] Diseases / states contemplated to be treated / presented by the present disclosure (e.g., age-related diseases / states) include, for example, geriatric syndrome, Alzheimer's disease, cancer, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, steatosis (e.g., of the liver), non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH), cardiovascular diseases, hypertension (e.g., systolic, diastolic), heart failure due to reduced or preserved ejection fraction, kidney diseases (e.g., chronic kidney disease), atherosclerosis, hypertension, macular diseases, age-related macular degeneration (AMD), cataracts, chronic obstructive pulmonary disease (COPD), arthritis, osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, rheumatoid arthritis, type 2 diabetes mellitus, chronic liver diseases, sarcopenia, constipation, impotence, vaginal dryness, hair loss, skin diseases, and skin fragility.

[0243] Geriatric syndrome is a common condition in elderly patients and includes, for example, frailty, cognitive impairment, delirium, dementia, incontinence, hearing impairment, visual impairment, sarcopenia, metabolic syndrome, malnutrition, gait disorders, falls, and pressure ulcers.

[0244] Further exemplary diseases / states contemplated to be treated / presented by the present disclosure include frailty, age-related increase in body fat mass, sarcopenia, age-related hyperlipidemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular diseases, age-related hypertension, age-related kidney diseases, and age-related skin diseases.

[0245] [[ID=I1]] When a disease / state is described herein as "age-related", it refers to a disease / state that occurs as a result of the age of the subject, distinct from other possible etiologies. For example, "age-related steatosis" refers to a specific subtype of steatosis that occurs as a result of the aging process and is distinct from, for example, steatosis that occurs as a result of diet.

[0246] In certain embodiments, the diseases / conditions treated / prevented by this disclosure are selected from: osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, frailty, cognitive impairment, mental confusion, dementia, incontinence, hearing impairment, visual impairment, malnutrition, gait disturbance, falls, and pressure ulcers.

[0247] In some aspects and embodiments, this disclosure is intended to address / prevent weakness. Frailty can be determined by the phenotypic criteria established by Fried et al., J Gerontol A Biol Sci Med Sci (2001) 56(3): M146~56 (fully incorporated here by reference): subjects having three or more of the following: low grip strength, low energy, slow walking speed, low physical activity and / or unintentional weight loss, which can then be determined by the frailty criteria of the Women's Health and Aging Studies (WHAS) or Cardiovascular Health Study (CHS), as summarized in Table 1 of Xue, Clin Geriatr Med (2011) February; 27(1): pp. 1~15 (fully incorporated here by reference).

[0248] In some aspects and embodiments, this disclosure aims to treat / prevent age-related changes in body composition. Age-related changes in body composition are described, for example, by Santanasto et al., J Gerontol A Biol Sci Med Sci. (2017) 72(4): pp. 513-519 and by St-Onge and Gallagher, Nutrition (2010) 26(2): pp. 152-155, both of which are fully incorporated here by reference. Age-related changes in body composition include: decreased muscle mass (i.e., sarcopenia), decreased bone mass (e.g., leading to osteoporosis), increased body fat, cartilage degeneration (e.g., leading to osteoarthritis), kidney changes (e.g., leading to renal dysfunction (e.g., age-dependent deterioration of glomerular filtration rate)), changes in the respiratory system (e.g., lungs, leading to chronic obstructive pulmonary disease (COPD)), changes in the digestive system (e.g., leading to constipation), changes in the bladder (e.g., leading to urinary incontinence), degeneration of teeth and / or gums (e.g., leading to periodontal disease), hair loss, skin fragility (e.g., leading to dryness and / or wrinkles), changes in the auditory system (e.g., leading to hearing loss), and changes in the reproductive organs (e.g., leading to impotence or vaginal dryness).

[0249] Age-related declines in muscle mass can include a decrease in skeletal muscle mass. Skeletal muscle undergoes age-related changes in mitochondria, leading to the formation of inefficient mitochondria that release more reactive oxygen species (Johnson et al., Trends Endocrinol Metab. (2013) 24(5): pp. 247-2456). Mitochondrial dysfunction is thought to then lead to the activation of apoptosis in skeletal muscle, resulting in skeletal muscle atrophy (Lenk et al., J Cachexia Sarcopenia Muscle. (2010) 1(1): pp. 9-21).

[0250] Age-related bone loss is described, for example, by Demontiero et al., Ther Adv Musculoskelet Dis. (2012) 4(2): pp. 61-76. Underlying mechanisms include bone resorption by osteoclasts and insufficient bone tissue formation by osteoblasts. Bone loss can lead to osteoporosis, which is defined as deterioration of bone mass and microarchitecture and increases the risk of fragility fractures (Raisz and Rodan, Endocrinol Metab Clin North Am. (2003) 32(1): pp. 15-24).

[0251] Aging is often characterized by an increase in total body fat mass, independent of general and physiological fluctuations in body weight and body mass index (BMI) (Zong et al., Obesity (2016) 24(11): pp. 2414-2421). In particular, the accumulation of muscular fat, visceral fat, and hepatic fat in the form of lipid droplets (LDs) shows an age-dependent increase (Reinders et al., Curr Opin Clin Nutr Metab Care. (2017) 20(1): pp. 11-15).

[0252] In some embodiments, the age-related changes in body composition according to this disclosure are selected from: age-related decrease in muscle mass, sarcopenia, age-related decrease in bone mass, osteoporosis, and age-related increase in body fat mass. In some embodiments, the age-related changes in body composition according to this disclosure are selected from: age-related decrease in muscle mass, sarcopenia, and age-related increase in body fat mass.

[0253] Aging is often associated with increased serum lipid levels. Older adults tend to have higher serum levels of triglycerides and cholesterol, and in some cases, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, or combined hyperlipidemia (a combination of hypertriglyceridemia and hypercholesterolemia)). Hyperlipidemia is then generally associated with, for example, atherosclerosis and cardiovascular disease.

[0254] Hypertriglyceridemia is defined, for example, by a blood triglyceride level of ≥150 mg / dL (≥1.7 mmol / L), as described by Berglund et al., J. Clin. Endocrinol. Metab. (2012) 97(9):2969-89. Hypercholesterolemia is defined, for example, by Bhatnagar et al., BMJ (2008) 337:a993. The UK NHS defines hypercholesterolemia as a blood total cholesterol level of ≥5 mmol / L or a blood low-density lipoprotein (LDL) level of ≥3 mmol / L. The US NIH defines hypercholesterolemia as a blood total cholesterol level of ≥240 mg / dL.

[0255] Aging is often associated with hepatic steatosis, as described, for example, by Nguyen et al., Cell Rep (2018) August 7; 24(6): pp. 1597-1609. Steadyosis refers to the abnormal retention of lipids in cells / tissues / organs. Steadyosis can be macrogranular or microvesicular and generally affects the liver. Aging steatosis can lead to age-related non-alcoholic fatty liver disease (NAFLD). NAFLD has been reviewed, for example, by Benedict and Zhang, World J Hepatol. (2017) 9(16): pp. 715-732 and by Albhaisi et al., version 1. F1000Res. (2018) 7: F1000 Faculty Rev-720, both of which are fully incorporated here by reference. NAFLD is characterized by steatosis of the liver, particularly of hepatocytes. NAFLD includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NAFL is characterized by steatohepatitis involving more than 5% of the parenchyma of the liver, with no evidence of hepatocyte damage. NAFL can progress to NASH (steatohepatitis), which is steatohepatitis complicated with inflammation and / or fibrosis.

[0256] In certain embodiments, the diseases / conditions addressed by this disclosure may include or be characterized by one or more of the following: frailty, decreased muscle mass, increased body fat mass, increased serum lipids (e.g., hyperlipidemia), increased serum triglycerides (e.g., hypertriglyceridemia), increased serum cholesterol (e.g., hypercholesterolemia), increased liver triglycerides (e.g., hepatic steatohepatia), and decreased serum β-hydroxybutyrate. It is understood that the decrease / increase is determined compared to a non-pathological state or the absence of the condition.

[0257] The therapeutic and prophylactic effects of this disclosure are achieved, for example, in cells, tissues / organs / organ systems / targets, through inhibition of IL-11-mediated signaling (i.e., antagonism of IL-11-mediated signaling).

[0258] IL-11 is upregulated with age across all tissues in male and female mice. It activates and phosphorylates ERK, inactivating LKB1 directly at the LKB1(Serine325) site and indirectly through P90RSK(LKB1(Serine428)). LKB1, as demonstrated by the inventors herein, was previously thought to be constitutively active and not regulated by phosphorylation. IL-11-mediated ERK phosphorylation and LKB1 inactivation lead to the dissociation of LKB1 from AMPK, which is then dephosphorylated and inactivated. Inactive AMPK can no longer activate members of the TSC complex that inhibit mTORC1. Thus, mTORC1 is activated. Activated mTORC1 phosphorylates and activates P70S6K and RPS6, stimulating many other aging-promoting pathways, including inhibition of autophagy, which impairs protein synthesis and protein equilibrium. This schema is outlined in Figure 16B. Therefore, inhibition of IL-11-mediated signaling has global therapeutic and prophylactic effects that reach a wide range of age-related challenges.

[0259] While not wishing to be constrained by theory, IL-11 activates mTOR by inhibiting AMPK through its upstream activity against LKB1, and the inventors have demonstrated that agents capable of inhibiting IL-11-mediated signaling have effects equivalent to or better than the putative anti-aging agents metformin and rapamycin combination, exerting potent anti-aging effects by increasing AMPK activity and decreasing mTOR activity.

[0260] Accordingly, in some embodiments, the diseases / conditions treated or prevented by this disclosure may be associated with increased IL-11, decreased AMPK, and / or increased mTOR function, gene and / or protein expression or activity in one or more affected tissues compared to a baseline healthy patient. In some embodiments, the diseases / conditions treated or prevented by this disclosure may be associated with gain-of-function mutations of IL-11 in one or more affected tissues. In fact, the “age” diseases / conditions or phenotypes outlined herein may, in some embodiments, be associated with gain-of-function mutations of IL-11 in one or more affected tissues.

[0261] In some embodiments, the disease / condition treated or prevented by the Disclosure may be one or more aging traits or associated therewith. “Aging traits” as described by Lopez-Otin et al., 2013, include: telomere reduction, genomic instability, mitochondrial dysfunction, cellular senescence, stem cell depletion, loss of protein balance, disregulated nutrient sensing, epigenetic changes, and altered intercellular communication. In some embodiments, the disease / condition treated or prevented by the Disclosure may be a trait selected from disregulated nutrient sensing, loss of protein balance, and / or cellular senescence or associated therewith.

[0262] The usefulness of the therapeutic and prophylactic methods disclosed herein extends to diseases / conditions caused by or exacerbated by the diseases / conditions described above, or to diseases / conditions described above that offer an inferior prognosis.

[0263] In some embodiments, the disease / condition treated / prevented by this disclosure may be characterized, for example, by increased expression of IL-11 and / or IL-11Rα (i.e., gene and / or protein expression) in the affected organ / tissue / subject compared to a normal organ / tissue / subject (i.e., in the absence of the disease / condition).

[0264] In some embodiments, the disease / condition may be associated with the upregulation of IL-11, for example, the upregulation of IL-11 in cells or tissues where symptoms of the disease appear or may occur, or the upregulation of extracellular IL-11 or IL-11Rα.

[0265] A treatment may be effective in reducing / delaying / blocking / reducing the development or progression of a disease / condition. A treatment may be effective in reducing / delaying / blocking / reducing the worsening of one or more symptoms of a disease / condition. A treatment may be effective in improving one or more symptoms of a disease / condition. A treatment may be effective in reducing and / or reversing the severity of one or more symptoms of a disease / condition. A treatment may be effective in reversing the effects of a disease / condition.

[0266] Prevention can refer to the prevention of the development of a disease / condition and / or the worsening of a disease / condition, for example, the prevention of progression of the disease / condition to a later / chronic stage. The aspects and embodiments of this disclosure relate to improving / increasing healthy life expectancy. This disclosure provides methods for improving / increasing the healthy life expectancy of subjects, and articles (pharmaceuticals, compositions) for use in such methods.

[0267] As used herein, “healthy life expectancy” can be defined as the period of life free from age-related diseases / conditions. Therefore, the healthy life expectancy of a given subject can refer to the period during which the subject is free from age-related diseases / conditions (e.g., age-related diseases as described herein). A subject may be considered free from a given disease / condition until they are diagnosed with the relevant disease condition.

[0268] Subjects with improved / increased / extended healthy life expectancy are understood to remain free from age-related disease / conditions for a longer period compared to a reference subject. In connection with this disclosure, subjects administered with agents capable of inhibiting IL-11-mediated signaling have increased healthy life expectancy compared to an equivalent untreated subject.

[0269] In some embodiments of this disclosure, the healthy lifespan of a subject can refer to the period during which the subject does not have (i.e., is not diagnosed with) any of the following: geriatric syndromes, Alzheimer's disease, cancer, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, steatosis (e.g., of the liver), non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), cardiovascular disease, hypertension (e.g., systolic and diastolic), heart failure due to reduced or preserved ejection fraction, kidney disease (e.g., chronic kidney disease), atherosclerosis, hypertension, macular degeneration, age-related macular degeneration (AMD), cataracts, chronic obstructive pulmonary disease (COPD), arthritis, osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, rheumatoid arthritis, diabetes mellitus, type II diabetes mellitus, chronic liver disease, sarcopenia, constipation, impotence, vaginal dryness, alopecia, skin diseases and skin fragility.

[0270] Alternatively, "healthy life expectancy" can be defined as the period of survival during which a subject does not show significant age-related deterioration in the function of the subject's tissue, organ, or organ system. Deterioration of function can occur as a result of age-related disease / condition. Subjects showing deterioration in the function of a given tissue / organ / organ system may indicate a level of the relevant function that is less than 1 times the level observed in comparable subjects who have not experienced the relevant deterioration, for example, ≤0.99, ≤0.95, ≤0.9, ≤0.85, ≤0.8, ≤0.75, ≤0.7, ≤0.65, ≤0.6, ≤0.55, ≤0.5, ≤0.45, ≤0.4, ≤0.35, ≤0.3, ≤0.25, ≤0.2, ≤0.15, or ≤0.1.

[0271] Depending on the various aspects of this disclosure, the method may include one or more of the following (for example, in relation to the treatment / prevention of diseases / conditions described herein): To reduce symptoms of weakness; To increase / maintain lean body mass; Inhibiting the age-related reduction in lean body mass; Reducing / maintaining body fat mass; To inhibit the age-related increase in body fat mass; To reduce age-related decline in metabolic function; To reduce age-related hyperlipidemia; To reduce age-related hypertriglyceridemia; To reduce age-related hypercholesterolemia; To reduce age-related steatosis (e.g., liver disease); To increase / maintain fatty acid oxidation and / or ketone production; To increase / maintain serum levels of β-hydroxybutyrate; Reducing the number / size and / or severity of age-related pathological lesions: Inhibiting the development of age-related pathological lesions; To reduce age-related fibrosis; To inhibit the development of age-related fibrosis; Inhibiting cellular senescence; To increase / maintain cardiac function; To inhibit the age-related deterioration of cardiac function; To increase / maintain kidney function; To inhibit the age-related deterioration of kidney function; To increase / maintain metabolic function; To inhibit the age-related deterioration of metabolic function; To increase / maintain liver function; To inhibit age-related deterioration of liver function; To increase / maintain lung function; To inhibit age-related deterioration of lung function; To increase / maintain skin function; and To inhibit the age-related deterioration of skin function.

[0272] Administration The administration of a drug capable of inhibiting IL-11-mediated signaling is preferably in a dose that is "therapeutically effective" or "prophylactically effective," which is sufficient to demonstrate a benefit to the subject.

[0273] The actual amount administered, as well as the rate and time course of administration, is expected to depend on the nature and severity of the disease and the properties of the drug. Prescribing treatment, such as determining dosage, is the responsibility of general practitioners and other physicians, typically taking into account the disease / condition being treated, the condition of the individual subject, the site of delivery, the method of administration, and other factors known to the physician. Examples of the above techniques and protocols can be found in Remington's Pharmaceutical Sciences, 20th edition, 2000, pub. Lippincott, Williams & Wilkins.

[0274] Multiple doses of the drug may be provided. One or more doses, or each of them, may be accompanied by the simultaneous or sequential administration of another therapeutic agent. Multiple doses may be separated by a predetermined time interval, which can be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 days, or 1, 2, 3, 4, 5, 6, 8, 10 or 12 months. For example, doses may be given once every 7, 14, 21 or 28 days (plus or minus 3, 2 or 1 day).

[0275] For therapeutic applications, agents capable of inhibiting IL-11-mediated signaling are preferably formulated as pharmaceuticals or medicinal products together with one or more other pharmaceutically acceptable components well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavoring agents, and sweeteners.

[0276] As used herein, the term “pharmaceutically acceptable” refers to compounds, components, materials, compositions, dosage forms, etc., that are suitable for use in contact with the tissue of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problems or complications, within the bounds of reasonable medical judgment, and in proportion to a reasonable benefit / risk ratio. Each carrier, adjuvant, excipient, etc., must also be “acceptable” in the sense of being compatible with the other components of the formulation.

[0277] Suitable carriers, adjuvants, and excipients can be found in standard pharmaceutical textbooks, such as Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

[0278] Formulations can be prepared by any method well known in the pharmaceutical industry. Such methods include the step of associating an active compound with a carrier constituting one or more auxiliary components. Generally, formulations are prepared by homogeneously and closely associating an active compound with a carrier (e.g., a liquid carrier, a finely divided solid carrier, etc.), and then, if necessary, shaping the product.

[0279] The formulation can be prepared for administration routes suitable for the disease / condition being treated, including topical, parenteral, systemic, intravenous, intra-arterial, intramuscular, subarachnoid, intraocular, intraconjunctival, subcutaneous, oral, intradermal, or injection. Injectable formulations may contain the selected drug in a sterile or isotonic medium. Topical formulations may be provided as a cream or lotion. The formulation and mode of administration can be selected depending on the drug and the disease being treated.

[0280] Detection of IL-11 and its receptor Some aspects and embodiments of this disclosure relate to the detection of the expression of IL-11 or IL-11 receptors (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) in a sample obtained from a subject.

[0281] In some aspects and embodiments, the disclosure relates to the upregulation (overexpression) of the expression of IL-11 or the IL-11 receptor (as a protein or oligonucleotide encoding IL-11 or the IL-11 receptor, respectively), and the detection of such upregulation as an indicator of suitability for treatment with agents capable of inhibiting the action of IL-11, or agents capable of blocking or reducing the expression of IL-11 or the IL-11 receptor.

[0282] Upregulated expression involves expression at levels higher than would normally be expected in a given type of cell or tissue. Upregulation can be determined by measuring the expression levels of the relevant factor in cells or tissues. The expression level in a cell or tissue sample from a subject can be compared to a reference level of expression for the relevant factor, e.g., a value or range of values ​​representing a normal level of expression for the relevant factor for the same or corresponding cell or tissue type. In some embodiments, the reference level can be determined by detecting the expression of IL-11 or the IL-11 receptor in a control sample, e.g., in corresponding cells or tissues from a healthy subject or healthy tissue from the same subject. In some embodiments, the reference level can be obtained from a standard curve or dataset.

[0283] Expression levels can be quantified for absolute comparison or for relative comparison. In some embodiments, upcontrol of IL-11 or its receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) can be considered present when the expression level in the test sample is at least 1.1 times the reference level. More preferably, the expression level can be selected from at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, at least 2.0, at least 2.1, at least 2.2, at least 2.3, at least 2.4, at least 2.5, at least 2.6, at least 2.7, at least 2.8, at least 2.9, at least 3.0, at least 3.5, at least 4.0, at least 5.0, at least 6.0, at least 7.0, at least 8.0, at least 9.0, or at least 10.0 times that of the reference level.

[0284] Expression levels can be determined by one of several known in vitro assay techniques, such as PCR-based assays, in situ hybridization assays, flow cytometry assays, or immunological or immunohistochemical assays.

[0285] As an example, a preferred technique includes a method for detecting the level of IL-11 or the IL-11 receptor in a sample by contacting the sample with a drug capable of binding to IL-11 or the IL-11 receptor and detecting the formation of a complex between the drug and the IL-11 or IL-11 receptor. The drug may be any suitable binding molecule, such as an antibody, polypeptide, peptide, oligonucleotide, aptamer, or small molecule, and may optionally be labeled to allow detection, for example, visualization, of the complex formed. Suitable labels and means for their detection are well known to those skilled in the art and include fluorescent labels (e.g., fluorescein, rhodamine, eosin and NDB, green fluorescent protein (GFP), rare earth chelates such as europium (Eu), terbium (Tb) and samarium (Sm), tetramethylrhodamine, Texas Red, 4-methylumbelliferone, 7-amino-4-methylcoumarin, Cy3, Cy5), isotope markers, radioisotopes (e.g., 32P, 33P, 35S), chemiluminescent labels (e.g., acridinium esters, luminol, isoluminol), enzymes (e.g., peroxidase, alkaline phosphatase, glucose oxidase, β-galactosidase, luciferase), antibodies, ligands and receptors. Detection techniques are well known to those skilled in the art and can be selected to correspond to the labeling agent. Suitable techniques include PCR amplification of oligonucleotide tags, mass spectrometry, detection of fluorescence or color after enzymatic conversion of the substrate by a reporter protein, or radioactivity detection.

[0286] The assay can be configured to quantify the amount of IL-11 or IL-11 receptor in a sample. The quantified amount of IL-11 or IL-11 receptor from the test sample can be compared to a reference value, and this comparison can be used to determine whether the test sample contains a higher or lower amount of IL-11 or IL-11 receptor than the reference value, up to a selected degree of statistical significance.

[0287] Quantification of detected IL-11 or IL-11 receptors can be used to determine upregulation, downregulation, or amplification of the gene encoding IL-11 or the IL-11 receptor. If the test sample contains fibrous cells, such upregulation, downregulation, or amplification can be compared to a reference value to determine if any statistically significant difference exists.

[0288] The sample obtained from the subject may be of any kind. Biological samples may be taken from any tissue or body fluid, such as blood samples, blood-derived samples, serum samples, lymph samples, semen samples, saliva samples, or synovial fluid samples. Blood-derived samples may be selected fractions of the patient's blood, such as selected cell-containing fractions or plasma or serum fractions. Samples may include tissue samples or biopsies; or cells isolated from the subject. Samples may be collected by known techniques, such as biopsy or needle aspiration. Samples may be stored and / or processed for subsequent determination of IL-11 expression levels.

[0289] The sample can be used to determine the upregulation of IL-11 or its receptor in the subject from which the sample was taken. In some preferred embodiments, the sample may be a tissue sample, e.g., a biopsy, taken from a tissue / organ affected by the disease / condition described herein. The sample may contain cells. Subjects may be selected for therapy / prevention according to this disclosure based on the determination that the subject has an upregulated level of expression of IL-11 or the IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130). Upregulated expression of IL-11 or the IL-11 receptor can serve as a marker for the disease / condition described herein, which is suitable for treatment with agents capable of inhibiting IL-11-mediated signaling.

[0290] Upregulation may occur in a given tissue or in selected cells from a given tissue. Upregulation of IL-11 or IL-11 receptor expression may also be determined in a circulating fluid, such as blood, or in a blood-derived sample. Upregulation may be of extracellular IL-11 or IL-11Rα. In some embodiments, expression may be upregulated locally or systemically.

[0291] After selection, drugs capable of inhibiting IL-11-mediated signaling can be administered to the target patient. Diagnosis and Prognosis The detection of upregulation of IL-11 or its receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) can also be used in a manner to diagnose the diseases / conditions described herein, to identify subjects at risk of developing the diseases / conditions described herein, and in a manner to prognose or predict a subject's response to treatment with agents capable of inhibiting IL-11-mediated signaling.

[0292] "To develop," "development," and other forms of "to develop" can refer to the onset of a disorder / disease, or the continuation or progression of a disorder / disease. In some embodiments, a subject may be suspected of having or suffering from a disease / condition described herein, for example, based on the presence of other symptoms indicative of the disease / condition in the subject's body or selected cells / tissues of the subject's body, or may be considered at risk of developing the disease / condition due to, for example, a genetic predisposition or exposure to environmental conditions known to be risk factors for the disease / condition. A determination of upregulation of IL-11 or IL-11 receptor expression can confirm a diagnosis or suspected diagnosis, or confirm that the subject is at risk of developing the disease / condition. This determination can also diagnose whether the disease / condition or predisposition is suitable for treatment with agents capable of inhibiting IL-11-mediated signaling.

[0293] Thus, a method for providing a prognosis for a subject having or suspected to have one of the diseases / conditions described herein can be provided, comprising determining whether the expression of IL-11 or the IL-11 receptor is upregulated in a sample obtained from the subject, and providing a prognosis for treatment of the subject with a drug capable of inhibiting IL-11-mediated signaling based on this determination.

[0294] In some embodiments, a method for diagnosing, prognosticating, or predicting a subject's response to treatment with a drug capable of inhibiting IL-11-mediated signaling does not require determining the expression of IL-11 or its receptor, but can be based on determining genetic factors in the subject that predict upregulation of expression or activity. Such genetic factors may include determining gene mutations, single nucleotide polymorphisms (SNPs), or gene amplifications in IL-11, IL-11Rα, and / or gp130, which correlate with and / or predict upregulation of expression or activity and / or IL-11-mediated signaling. The use of genetic factors that predict predisposition to disease status or response to treatment is known in the art; see, for example, Peter Starkel, Gut 2008;57:440-442; Wright et al., Mol. Cell. Biol. March 2010, Vol. 30, No. 6, pp. 1411-1420.

[0295] Genetic factors can be analyzed by PCR-based assays, such as quantitative PCR and competitive PCR, methods known to those skilled in the art. For example, by determining the presence of genetic factors in a sample obtained from a subject, a diagnosis can be confirmed, and / or the subject can be classified as being at risk of developing the diseases / conditions described herein, and / or the subject can be identified as suitable for treatment with agents capable of inhibiting IL-11-mediated signaling.

[0296] Some methods may include determining the presence of one or more SNPs associated with IL-11 secretion or susceptibility to the development of the diseases / conditions described herein. SNPs are typically bialleles and can therefore be readily determined using one of several conventional assays known to those skilled in the art (see, for example, Anthony J. Brookes. The essence of SNPs. Gene Vol. 234, No. 2, July 8, 1999, pp. 177-186; Fan et al., Highly Parallel SNP Genotyping. Cold Spring Harb Symp Quant Biol 2003. 68: pp. 69-78; Matsuzaki et al., Parallel Genotyping of Over 10,000 SNPs using one-primer assay on high-density oligonucleotide array. Genome Res. 2004. 14: pp. 414-425).

[0297] This method may include determining which SNP alleles are present in the sample obtained from the subject. In some embodiments, the determination of the presence of recessive alleles may be related to increased IL-11 secretion or susceptibility to the development of diseases / conditions described herein.

[0298] Therefore, one aspect of this disclosure provides a method for screening subjects, which includes: To obtain nucleic acid samples from the subject; One or more SNPs in the sample shown in Figure 33, Figure 34, or Figure 35 of WO2017 / 103108A1 (incorporated herein by reference), or one of the listed SNPs and r 2 Determine which alleles are located at the polymorphic nucleotide positions of SNPs that are in linkage disequilibrium with a linkage disequilibrium of ≥0.8.

[0299] The determination step may include determining whether recessive alleles are present at selected polymorphic nucleotide positions in the sample. This may include determining whether 0, 1, or 2 recessive alleles are present.

[0300] The screening method may be a method for determining the susceptibility of an individual to the development of any of the diseases / conditions described herein, or may form part of a diagnostic or prognostic diagnostic method described herein.

[0301] The method may further include the step of identifying a subject that has increased susceptibility to or risk of developing the diseases / conditions described herein, for example, if the subject is determined to have a recessive allele at a polymorphic nucleotide position. The method may further include the step of selecting a subject for treatment with a drug capable of inhibiting IL-11-mediated signaling, and / or administering a drug capable of inhibiting IL-11-mediated signaling to the subject in order to provide treatment for the diseases / conditions described herein in the subject, or to halt the development or progression of the diseases / conditions in the subject.

[0302] In some embodiments, methods for diagnosing the diseases / conditions described herein, identifying subjects at risk of developing the diseases / conditions described herein, and prognosticating or predicting the subject's response to treatment with agents capable of inhibiting IL-11-mediated signaling utilize indices that are neither detections of upregulation of IL-11 or IL-11 receptor expression nor detections of genetic factors.

[0303] In some embodiments, methods for diagnosing the diseases / conditions described herein, identifying subjects at risk of developing the diseases / conditions, and prognosticating or predicting the subjects' response to treatment with agents capable of inhibiting IL-11-mediated signaling are based on the detection, measurement, and / or identification of one or more indicators of the disease / condition.

[0304] Diagnostic or prognostic methods can be performed in vitro with samples obtained from subjects, or following processing of samples obtained from subjects. Once the samples are collected, the presence of a patient is not required to perform the in vitro diagnostic or prognostic methods, and therefore, these methods may not be practiced in human or animal bodies. As stated herein, the samples obtained from subjects may be of any kind.

[0305] Other diagnostic or prognostic tests may be used in conjunction with those described herein to enhance the accuracy of the diagnosis or prognosis, or to confirm the results obtained using the tests described herein.

[0306] subject The subject may be an animal or a human. The subject is preferably a mammal, more preferably a human. The subject may be a non-human mammal, but more preferably a human. The subject may be male or female. The subject may be a patient. The patient may have one of the diseases / conditions described herein.

[0307] The subjects may be those who require the therapeutic / preventive intervention described in this disclosure. The subjects may also be those who benefit from the therapeutic / preventive intervention described in this disclosure. Subjects may have been diagnosed with, suspected of having, or at risk of developing, any of the diseases / conditions described herein that require treatment.

[0308] In embodiments of this disclosure, the subject is preferably a human subject. In embodiments of this disclosure, the subject may be selected for treatment by the method based on the characterization for a specific marker of a disease / condition described herein.

[0309] Sequence identity Pairwise and multi-sequence alignments for determining the percentage of identity between two or more amino acid or nucleic acid sequences include, for example, ClustalOmega (Soding, J. 2005, Bioinformatics 21, pp. 951-960), T-coffee (Notredame et al., 2000, J. Mol. Biol. (2000) 302, pp. 205-217), Kalign (Lassmann and Sonnhammer, 2005, BMC Bioinformatics, 6(298)), and MAFFT (Katoh and Standley, 2013, Molecular Biology). This can be achieved in various ways known to those skilled in the art using publicly available computer software, such as the software described in (and Evolution, 30(4), pp. 772-780). When using such software, it is preferable to use default parameters, for example, regarding gap penalties and extension penalties.

[0310] array

[0311] [Table 2-1]

[0312] [Table 2-2]

[0313] [Table 2-3]

[0314] Numbered paragraphs The following numbered paragraphs (para) provide further descriptions of features and combinations of features intended in connection with the present invention: 1. A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling, for use in the treatment or prevention of age-related diseases / conditions. 2. Use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in treating or preventing age-related diseases / conditions. 3. A method for treating or preventing an age-related disease / condition, comprising the step of administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling to a target. 4. A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods of inhibiting cellular senescence and / or inhibiting the activity of senescent cells in subjects where such inhibition is required. 5. Use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in methods of inhibiting cellular senescence and / or inhibiting the activity of senescent cells in subjects where such inhibition is required. 6. A method for inhibiting cellular senescence and / or the activity of senescent cells in a subject requiring such inhibition, comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a drug capable of inhibiting interleukin-11 (IL-11) mediated signaling. 7. A drug for use according to paragraph 4, a use according to paragraph 5, or a method according to paragraph 6, wherein the subject has a disease or condition characterized by cellular senescence. 8. A drug, use or method for use according to paragraph 7, for a disease or condition characterized by cellular senescence that is an age-related disease or condition. 9. A drug, use or method for use according to paragraph 7 or paragraph 8 of a disease or condition characterized by cellular senescence, selected from: geriatric syndromes, Alzheimer's disease, cardiovascular disease, atherosclerosis, hypertension, macular degeneration, chronic obstructive pulmonary disease (COPD), osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, rheumatoid arthritis, diabetes mellitus, or sarcopenia. 10. Geriatric syndromes, Alzheimer's disease, cancer, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, steatosis (e.g., hepatic), non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), cardiovascular disease, hypertension (e.g., systolic and diastolic), heart failure due to reduced or preserved ejection fraction, kidney disease (e.g., chronic kidney disease), atherosclerosis, hypertension, macular degeneration, age-related macular degeneration A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling, for use in a manner of treating or preventing age-related diseases or conditions selected from: (AMD), cataracts, chronic obstructive pulmonary disease (COPD), arthritis, osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, rheumatoid arthritis, diabetes mellitus, type II diabetes mellitus, chronic liver disease, sarcopenia, constipation, impotence, vaginal dryness, alopecia, skin diseases and skin fragility. 11. Geriatric syndromes, Alzheimer's disease, cancer, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, steatosis (e.g., hepatic), non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), cardiovascular disease, hypertension (e.g., systolic and diastolic), heart failure due to reduced or preserved ejection fraction, kidney disease (e.g., chronic kidney disease), atherosclerosis, hypertension, macular degeneration, age-related macular degeneration (AMD), Use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in methods of treating or preventing age-related diseases or conditions selected from: cataracts, chronic obstructive pulmonary disease (COPD), arthritis, osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, rheumatoid arthritis, diabetes mellitus, type II diabetes mellitus, chronic liver disease, sarcopenia, constipation, impotence, vaginal dryness, alopecia, skin diseases and skin fragility. 12. A method for treating or preventing age-related diseases or conditions, comprising a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling, for the following conditions: geriatric syndromes, Alzheimer's disease, cancer, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, steatosis (e.g., of the liver), non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), cardiovascular disease, hypertension (e.g., systolic, diastolic). A method comprising the step of administering to a subject having an age-related disease or condition selected from: heart failure due to reduced or preserved ejection fraction, kidney disease (e.g., chronic kidney disease), atherosclerosis, hypertension, macular degeneration, age-related macular degeneration (AMD), cataracts, chronic obstructive pulmonary disease (COPD), arthritis, osteoarthritis, osteopenia, osteoporosis, Parkinson's disease, periodontitis, chronic rheumatoid arthritis, diabetes mellitus, type II diabetes mellitus, chronic liver disease, sarcopenia, constipation, impotence, vaginal dryness, alopecia, skin diseases and skin fragility. 13. A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling, for use in the treatment or prevention of weakness. 14. Use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of a medicament for use in treating or preventing weakness. 15. A method for treating or preventing weakness, comprising the step of administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling to a target. 16. A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods of treating or preventing age-related changes in body composition. 17. Use of agents capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in treating or preventing age-related changes in body composition. 18. A method for treating or preventing age-related changes in body composition, comprising the step of administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11) mediated signaling to a target. 19. Drugs, uses or methods for use according to any one of paragraphs 16-18, selected from: age-related changes in body composition, including: decreased muscle mass, decreased bone mass, increased body fat mass, cartilage degeneration, kidney changes, changes in the respiratory system, changes in the digestive system, changes in the bladder, tooth and / or gum degeneration, hair loss, skin fragility, changes in the auditory system and changes in the reproductive organs. 20. A drug capable of inhibiting interleukin-11 (IL-11) mediated signaling, for use in methods to extend the healthy lifespan of a target individual. 21. Use of drugs capable of inhibiting interleukin-11 (IL-11) mediated signaling in the manufacture of pharmaceuticals for use in methods to extend the healthy lifespan of subjects. 22. A method for extending the healthy lifespan of a subject, comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a drug capable of inhibiting interleukin-11 (IL-11) mediated signaling. 23. A drug, use, or method for use according to any one of paragraphs 1 to 22, wherein the drug is selected from the group consisting of an antibody or its antigen-binding fragment, polypeptide, peptide, nucleic acid, oligonucleotide, aptamer, or small molecule. 24. A drug, use, or method for use according to any one of paragraphs 1 to 23, wherein the drug is capable of blocking or reducing the binding of interleukin-11 (IL-11) to the interleukin-11 receptor (IL-11R). 25. A drug, use, or method for use according to any one of paragraphs 1 to 24, wherein the drug is capable of binding to interleukin-11 (IL-11) or the interleukin-11 receptor (IL-11R). 26. A drug, use, or method for use according to any one of paragraphs 1 to 25, wherein the drug is an antibody or an antigen-binding fragment thereof. 27. A drug, use, or method for use according to any one of paragraphs 1 to 26, wherein the drug is an anti-IL-11 antibody antagonist of IL-11 mediated signaling, or an antigen-binding fragment thereof. 28. Antibody or antigen-binding fragment: (i) Heavy-chain variable (VH) region incorporating the following CDR: HC-CDR1 having the amino acid sequence of SEQ ID NO: 34 HC-CDR2 having the amino acid sequence of SEQ ID NO: 35 HC-CDR3 having the amino acid sequence of SEQ ID NO: 36; and (ii) Light chain variable (VL) region incorporating the following CDR: LC-CDR1 having the amino acid sequence of SEQ ID NO: 37 LC-CDR2 having the amino acid sequence of SEQ ID NO: 38 LC-CDR3 having the amino acid sequence of SEQ ID NO: 39 A drug, use, or method of use for use, including any one of paragraphs 1 to 27. 29. Antibody or antigen-binding fragment: (i) Heavy-chain variable (VH) region incorporating the following CDR: HC-CDR1 having the amino acid sequence of SEQ ID NO: 40 HC-CDR2 having the amino acid sequence of SEQ ID NO: 41 HC-CDR3 having the amino acid sequence of SEQ ID NO: 42; and (ii) Light chain variable (VL) region incorporating the following CDR: LC-CDR1 having the amino acid sequence of SEQ ID NO: 43 LC-CDR2 having the amino acid sequence of SEQ ID NO: 44 LC-CDR3 having the amino acid sequence of SEQ ID NO: 45 A drug, use, or method of use for use, including any one of paragraphs 1 to 27. 30. A drug, use, or method for use according to any one of paragraphs 1 to 26, wherein the drug is an anti-IL-11Rα antibody antagonist of IL-11 mediated signaling, or an antigen-binding fragment thereof. 31. Antibody or antigen-binding fragment: (i) Heavy-chain variable (VH) region incorporating the following CDR: HC-CDR1 having the amino acid sequence of SEQ ID NO: 46 HC-CDR2 having the amino acid sequence of SEQ ID NO: 47 HC-CDR3 having the amino acid sequence of SEQ ID NO: 48; and (ii) Light chain variable (VL) region incorporating the following CDR: LC-CDR1 having the amino acid sequence of SEQ ID NO: 49 LC-CDR2 having the amino acid sequence of SEQ ID NO: 50 LC-CDR3 having the amino acid sequence of SEQ ID NO: 51 Drugs, uses, or methods for use, including, as described in any one of paragraphs 1-26 or paragraph 30. 32. A drug, use, or method for use according to any one of paragraphs 1-25, wherein the drug is a decoy receptor for IL-11. 33. A drug, use or method for use according to paragraph 32, wherein the IL-11 decoy receptor comprises: (i) an amino acid sequence corresponding to the cytokine-binding module of gp130, and (ii) an amino acid sequence corresponding to the cytokine-binding module of IL-11Rα. 34. A drug, use, or method for use according to any one of paragraphs 1 to 25, wherein the drug is a competitive inhibitor of IL-11. 35. Drugs, uses, or methods for use according to paragraph 34, where the drug is an IL-11 mutant protein. 36. Drugs, uses or methods for use according to paragraph 35, in which the IL-11 mutant protein is W147A. 37. A drug, use, or method for use according to any one of paragraphs 1 to 23, which is capable of blocking or reducing the expression of interleukin-11 (IL-11) or the interleukin-11 receptor (IL-11R). 38. A drug, use or method for use according to paragraph 37, wherein the drug is an antisense oligonucleotide capable of blocking or reducing the expression of IL-11. 39. An antisense oligonucleotide capable of blocking or reducing IL-11 expression is an IL-11 targeting siRNA containing the sequence of SEQ ID NO: 12, 13, 14, or 15, for use, use, or method as described in paragraph 38. 40. A drug, use or method for use according to paragraph 37, wherein the drug is an antisense oligonucleotide capable of inhibiting or reducing the expression of IL-11Rα. 41. An antisense oligonucleotide capable of blocking or reducing the expression of IL-11Rα is an siRNA targeting IL11RA containing the sequence of SEQ ID NOs. 16, 17, 18, or 19, for use, use, or method as described in paragraph 40. 42. A drug, use, or method for use according to any one of paragraphs 1 to 41, comprising administering the drug to a subject in which the expression of interleukin 11 (IL-11) or the receptor for IL-11 (IL-11R) is upregulated.

[0315] This disclosure includes combinations of the embodiments and preferred features described herein, except where such combinations are clearly unacceptable or obviously avoidable. Features disclosed in the foregoing statements, or in the following claims, or in the accompanying drawings, and which are represented in their specific forms, or as appropriate in means for performing the disclosed functions, or in methods or processes for obtaining the disclosed results, can be used separately or in any combination of such features to implement the disclosure in its various forms.

[0316] To avoid any doubt, any theoretical explanations provided herein are provided for the purpose of improving the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.

[0317] None of the section headings used herein are for structural purposes only and should not be construed as limiting the subject inventions described herein. Throughout this specification, including subsequent claims, unless the context otherwise requires, variations of the words “comprise,” “include,” “comprises,” “comprising,” and “including” are understood to mean that they include the expressed integer or step, or group of integers or steps, but do not exclude any other integer or step or group of integers or steps.

[0318] It should be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” refer to multiple subjects unless otherwise explicitly stated in the text. Ranges may be expressed herein as “about” one particular value and / or “about” another particular value. Where such ranges are expressed, another embodiment includes one particular value and / or the other particular value. Similarly, where values ​​are expressed as approximations, the use of the antecedent “about” is expected to be understood as meaning that a particular value forms another embodiment. The term “about” with respect to numbers is optional and means, for example, + / - 10%.

[0319] The methods disclosed herein may be performed in vitro, ex vivo, or in vivo, or products may exist. The term “in vitro” encompasses experiments with materials, biomolecules, cells and / or tissues under laboratory conditions or culture, while the term “in vivo” encompasses experiments and procedures with intact multicellular organisms. In some embodiments, methods performed in vivo may be performed on non-human animals. “Ex vivo” refers to things that exist or occur outside a living organism, e.g., outside a human or animal body, and may be on tissues (e.g., entire organs) or cells taken from a living organism.

[0320] Where nucleic acid sequences are disclosed herein, their reverse complements are also explicitly intended. For standard molecular biology techniques, see Sambrook, J., and Russell, DWMolecular Cloning, Laboratory Manual, 3rd edition 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

[0321] The aspects and embodiments of this disclosure will be discussed with respect to the accompanying drawings. Further aspects and embodiments will become apparent to those skilled in the art. All documents pointed out in this text are incorporated herein in full by reference. This disclosure is described with the exemplary embodiments below, but many equivalent modifications will become apparent to those skilled in the art in consideration of this disclosure. Thus, the exemplary embodiments of this disclosure shown above are illustrative and not limiting. Various modifications can be made to the embodiments described without departing from the spirit and scope of this disclosure.

[0322] Embodiments and experiments illustrating the principles of this disclosure will be discussed with respect to the attached figures. [Examples]

[0323] In the following examples, the inventors demonstrate that antagonism of IL-11-mediated signaling is beneficial for treating and preventing age-related diseases, including weakness, and age-related changes in body composition. Example 1: Analysis of the ability of IL-11-mediated signaling antagonists to treat weakness and age-related changes in body composition. The inventors sought to investigate whether inhibiting IL-11-mediated signaling using neutralizing antibodies could reduce frailty and age-related changes in body composition in aged mice.

[0324] 46-week-old C57B1 / 6J mice were obtained from Jackson Laboratory and randomized 1:1 to receive either X203 or isotype-controlled IgG antibody. X203 is a mouse anti-mouse IL-11 IgG, described, for example, by Ng et al., Sci Transl Med. (2019) 11(511)pii:eaaw1237 (also published as Ng et al., "IL-11 is a therapeutic target in idiopathic pulmonary fibrosis." bioRxiv 336537; doi: https: / / doi.org / 10.1101 / 336537). X203 is also called "Enx203". X203 includes a VH region by sequence number 92 of WO2019 / 238882A1 (sequence number 22 in this disclosure) and a VL region by sequence number 94 of WO2019 / 238882A1 (sequence number 23 in this disclosure).

[0325] From 55 weeks of age (equivalent to approximately 45 years of age in humans, i.e., middle age) to 110 weeks of age (equivalent to approximately 75 years of age in humans), mice were administered 40 mg / kg of X203 or isotype-matched control IgG every 3 weeks via intraperitoneal injection.

[0326] At 110 weeks of age, frailty was investigated using the mouse frailty index described in Rizzo et al., Curr Protoc Mouse Biol. (2018) 8(2):e45, which is fully incorporated here by reference. In this protocol, mice are individually observed and evaluated for the presence and severity of 27 different features, each rated as 0, 0.5, or 1 based on the level of severity. The frailty index score is calculated as a cumulative score of all measurements. Core body temperature was recorded as a separate measure of frailty because it is known that core body temperature decreases with increasing frailty in mice (Reynolds et al., Mechanisms of Ageing and Development (1985) 30(2): pp. 143-152). Data were analyzed by two-way ANOVA.

[0327] The results are shown in Figures 1 and 2. Treatment with X203 was found to cause a significant reduction in the frailty index and was associated with significantly higher body temperature. Previous studies on frailty (e.g., Sanchez-Alavez et al. (2011) Age 33(1):89-99) have also found that male mice have a lower body temperature compared to female mice.

[0328] Mice also underwent body composition assessment by ultrasound-MRI at baseline (55 weeks of age) and at 108–109 weeks. This allowed for the calculation of changes in body fat mass and lean (muscle) mass in the X203 and IgG control treatment groups. At 110 weeks of age, gastrocnemius and soleus muscles were also harvested from the mice and their weights were recorded. Data were analyzed by two-way ANOVA.

[0329] The results are shown in Figures 3A, 3B, 4A, and 4B. Mice treated with X203 were found to have a significantly smaller increase in body fat mass than mice treated with the IgG control antibody (Figure 3A). Treatment with X203 was also found to be associated with significantly greater lean body mass compared to treatment with the IgG control antibody. Consistent with these findings, the weight of the gastrocnemius and soleus muscles (as a percentage of their body weight) in mice treated with X203 was greater than that of mice treated with the IgG control antibody (Figures 4A and 4B).

[0330] Example 2: Further analysis of the ability of IL-11-mediated signaling antagonists to treat age-related diseases. 2.1 Analysis of behavioral correlations between frailty and aging C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 gm / kg via IP injection every three weeks from 55 weeks to 110 weeks of age.

[0331] At 110 weeks, mice are analyzed for grip strength using a grip strength meter. Decreased grip strength is a robust marker of age-related frailty in mice (see Fischer et al., Aging (2016) 8: pp. 2370–2391, fully incorporated here by reference).

[0332] The mouse grasps the wire mesh attached to the meter with both forelimbs, and then its tail is gently pulled on a horizontal plane parallel to the meter's base plate. The gripping force is recorded as the maximum force shown.

[0333] Mice treated with X203 exhibit greater grip strength than mice treated with an IgG control antibody. 2.2 Analysis of aging lesions C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 gm / kg via IP injection every three weeks from 55 weeks to 110 weeks of age.

[0334] At 110 weeks, mice are euthanized, and sections are prepared from the heart, lungs, liver, spleen, kidneys, and skeletal muscle tissue. These sections are triple-stained with hematoxylin-eosin or Masson's and analyzed by light microscopy. The tissue sections are evaluated for age-related lesions as described in Snider et al., Geroscience (2019) 40: pp. 97-103 and Snyder et al., Geroscience (2019) 41: pp. 455-465 (fully incorporated here by reference). Analysis is performed by a veterinary pathologist blinded to the treatment group.

[0335] Mice treated with X203 show fewer, smaller, and / or less developed senile lesions compared to mice treated with an IgG control antibody. 2.3 Analysis of Organ Fibrosis Aging is associated with progressive fibrosis in multiple organs, particularly the heart, lungs, kidneys, and skeletal muscles (see, for example, Murtha et al., Aging Dis. (2019) 10: pp. 419-428, O'Sullivan et al., J.Am.Soc.Nephrol. (2017) 28: pp. 407-420, and Etienne et al., Skelet.Muscle (2020) 10: p. 4, all of which are fully incorporated here by reference).

[0336] C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 gm / kg via IP injection every three weeks from 55 weeks to 110 weeks of age.

[0337] At 110 weeks, broad tissue collagen content in cardiac, lung, renal, and skeletal muscle tissue is assessed by a hydroxyproline assay. Tissue sections from these tissues are further subjected to Masson's triple staining and analyzed by light microscopy (blinded to the treatment group).

[0338] Mice treated with X203 showed less fibrosis in the analyzed tissues compared to mice treated with an IgG control antibody. 2.4 Analysis of cellular senescence markers The accumulation of senescent cells is a characteristic of aging, and molecular markers of cellular senescence include aging-related β-galactosidase (SA-β-gal) activity and the cell cycle regulator p16. INK4a p21 CIP1 This includes the level on page 53 (which is fully incorporated here by reference; see Wang et al., Front. Genet. (2018) 9:247).

[0339] C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 gm / kg via IP injection every three weeks from 55 weeks to 110 weeks of age.

[0340] At 110 weeks, tissue was collected from mouse cells of the relevant tissue, and p16 INK4a p21 CIP1 We will analyze the gene and / or protein expression of p53, as well as SA-β-gal activity.

[0341] Mice treated with X203 show lower levels of cellular senescence markers compared to mice treated with an IgG control antibody. 2.5 Analysis of markers of cardiac and renal function Impairment of cardiac and renal function is a pathological characteristic of aging (see, for example, Murtha et al., Aging Dis. (2019) 10: pp. 419-428, de Lucia et al., J. Gerontol. A Biol. Sci. Med. Sci. (2019) 74: pp. 455-461, and Feridooni et al., J. Physiol. (2017) 595: pp. 3721-3742, all of which are fully incorporated here by reference). Age-related impairment of cardiac function generally manifests as left ventricular remodeling / hypertrophy and impaired diastolic function, and a reduction in systolic function may also occur.

[0342] C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 mg / kg via IP injection every three weeks from 55 weeks to 110 weeks of age. Renal function was assessed by analysis of serum blood urea nitrogen (BUN) and creatinine levels using a urea assay kit (ab83362, Abcam) and a creatinine assay kit (ab65340, Abcam) according to the manufacturer's instructions for use. BUN and serum creatinine levels were also analyzed in 12-week-old male and female C57B1 / 6J mice to determine baseline levels. Data were analyzed by two-way ANOVA.

[0343] The results are shown in Figures 9 and 10. Figure 9 shows that male and female mice treated with X203 exhibited a 79% and 42% reduction in BUN levels, respectively, compared to mice treated with an IgG control antibody (mean BUN levels of 12-week-old male (51.3 mg / dl) and female (31.8 mg / dl) mice were used as baseline).

[0344] Figure 10 shows that male and female mice treated with X203 showed a 60% and 43% reduction in creatinine levels, respectively, compared to mice treated with an IgG control antibody (mean creatinine levels of 12-week-old male (0.92 mg / dl) and female (0.77 mg / dl) mice were used as baseline).

[0345] Therefore, mice treated with X203 showed improved renal function compared to mice treated with an IgG control antibody. 2.6 Analysis of metabolic function C57B1 / 6J mice were randomized to receive X203 or IgG control antibody at a dose of 40 mg / kg via IP injection every three weeks from 55 weeks to 110 weeks of age. Serum triglyceride, liver triglyceride, serum cholesterol, and serum β-hydroxybutyrate levels were measured using a triglyceride assay kit (ab65336, Abcam), a cholesterol assay kit (ab65390, Abcam), and a β-hydroxybutyrate colorimetric assay kit (700190; Cayman Chemicals) according to the manufacturer's instructions. Serum triglyceride, liver triglyceride, serum cholesterol, and serum β-hydroxybutyrate levels were also analyzed in 12-week-old male and female C57B1 / 6J mice to determine baseline levels. Data were analyzed by two-way ANOVA.

[0346] The results are shown in Figures 11-14. Figure 11 shows that male and female mice treated with X203 exhibited a 65% and 47% reduction in serum triglyceride levels, respectively, compared to mice treated with an IgG control antibody (mean serum triglyceride levels of 12-week-old male (54 mg / dl) and female (37 mg / dl) mice were used as baseline).

[0347] Figure 12 shows that male and female mice treated with X203 exhibited a 71% and 54% reduction in liver triglyceride levels, respectively, compared to mice treated with an IgG control antibody (mean liver triglyceride levels of 12-week-old male (165 mg / g) and female (130 mg / g) mice were used as baseline).

[0348] Figure 13 shows that male and female mice treated with X203 exhibited a 45% and 51% reduction in serum cholesterol levels, respectively, compared to mice treated with an IgG control antibody (mean serum cholesterol levels of 12-week-old male (149 mg / dl) and female (90 mg / dl) mice were used as baseline).

[0349] Figure 14 shows that male and female mice treated with X203 showed a 66% and 26% reduction in serum β-hydroxybutyrate levels, respectively, compared to mice treated with an IgG control antibody (mean serum β-hydroxybutyrate levels of 12-week-old male (0.159 mM) and female (0.236 mM) mice were used as baseline).

[0350] Therefore, treatment with X203 was found to reduce age-related hypertriglyceridemia, stiliosis (hepatic fat accumulation), and hypercholesterolemia. Treatment with X203 was found to increase levels of circulating β-hydroxybutyrate, a peripheral marker of fatty acid oxidation and ketone production. In summary, these data suggest that antagonism of IL-11-mediated signaling reduces age-related decline in metabolic function.

[0351] Example 3: Evaluation of IL-11-mediated signaling and aging 3.1 IL-11 protein levels in young and aged mice The inventors evaluated the expression of IL-11 protein in the livers of 28-month-old and 3-month-old C57B1 / 6J mice.

[0352] In short, liver was collected from mice, homogenized in radioimmunoprecipitation assay (RIPA) lysis and extraction buffer (ThermoFisher Scientific) containing protease and phosphatase inhibitors (Roche), and then centrifuged to clear the lysate. Protein concentration was determined by the Bradford assay (Bio-Rad). Equal volumes of protein lysate were separated by SDS-PAGE, transferred to a PVDF membrane, blocked with 3% BSA for 1 hour, and incubated overnight with X203 (1:2000) or anti-GAPDH (1:1000, CST). Protein bands were visualized using an ECL detection system (Pierce) with appropriate secondary antibodies: anti-mouse HRP and anti-rabbit HRP (1:5000, CST). Proteins were visualized using an ECL detection system (Pierce) with appropriate secondary antibodies.

[0353] The results are shown in Figure 5. IL-11 protein levels were found to be higher in the livers of 28-month-old mice compared to 3-month-old mice. In further experiments, the inventors evaluated the expression of IL-11 protein in the liver, ventricles, kidneys, gastrocnemius, and soleus muscles of 110-week-old and 12-week-old male and female C57B1 / 6J mice. Total protein was extracted from the liver, ventricles, kidneys, gastrocnemius, and soleus muscles in RIPA lysis and extraction buffer and analyzed by Western blotting as described above.

[0354] The results are shown in Figure 8. IL-11 protein levels were found to be higher in the liver, ventricles, kidneys, gastrocnemius, and soleus muscles of 110-week-old mice compared to 12-week-old mice.

[0355] 3.2 Effect of IL-11-mediated signaling antagonism on the expression of senescence markers by cells in an in vitro model of senescence induction The inventors then investigated the effect of antagonizing IL-11-mediated signaling on the expression of senescence and inflammation markers by senescent cells in vitro, using X203 or X209.

[0356] X209 is a mouse anti-mouse IL-11RαIgG, as described, for example, by Widjaja et al., Gastroenterology (2019) 157 (3:777-792). X209 is also known as "Enx209" and includes the VH region by Sequence ID No. 7 of WO2019 / 238884A1 (Sequence ID No. 24 in this disclosure) and the VL region by Sequence ID No. 14 of WO2019 / 238884A1 (Sequence ID No. 25 in this disclosure).

[0357] Sensed liver mouse cells were generated from cells of the mouse hepatocyte cell line AML12, as described by Tripathi et al. in Star Protocols (2020) 1:100064 (which is fully incorporated here by reference).

[0358] In short, AML12 cells were grown to a 50% concentration, and senescence was induced by treating the cells with a sublethal concentration of H2O2 (0.75 mM) for 1 hour each day for a total of 7 days, followed by a 23-hour recovery period (as described by Tripathi et al., Star Protocols (2020) 1:100064). From day 2 onward, 2 μg / ml of X209 / X203 or isotype-matched control IgG was added to the culture during the 23-hour recovery period.

[0359] On day 7, total RNA was isolated, and the expression levels of the p21(Cdkn1a), Il1b, Il11, and Tgfb genes were evaluated by qRT-PCR. Briefly, total RNA was extracted from the cell lysate using Trizol (Invitrogen) followed by purification with an RNeasy column (Qiagen). cDNA was synthesized using the iScript® cDNA synthesis kit (Bio-Rad) according to the manufacturer's instructions. Gene expression analysis was performed using the StepOnePlus real-time PCT system (Applied Biosystems) over 40 cycles with TaqMan (Applied Biosystems) or fast SYBR green (Qiagen). The expression data for p21(Cdkn1a), Il1b, Il11, and Tgfb were normalized to Gapdh expression, and 2 -ΔΔCt The rate of change was calculated using the method.

[0360] The results are shown in Figures 6A-6D and 7A-7D. Treatment with X209 was found to significantly reduce the gene expression of p21(Cdkn1a), Il1b, Il11, and Tgfb in AML12 cells that had undergone a senescence induction program (Figures 6A-6D).

[0361] Treatment with X203 was found to significantly reduce Tgfb gene expression in AML12 cells that had undergone senescence induction (Figure 7D), and Il11 expression also tended to decrease (Figure 7C).

[0362] 3.3 Effect of IL-11-mediated signaling antagonism on the expression of cellular aging markers in an in vitro model of senescence induction using human cells Primary human hepatocytes or AML12 cells are grown to a 50% concentration, and senescence is induced by treating the cells with a sublethal concentration of H2O2 (0.75 mM) for 1 hour each day for a total of 7 days, followed by a 23-hour recovery period. From day 2 onward, 2 μg / ml of X2O9 / X2O3 or isotype-matched control IgG is added to the culture during the 23-hour recovery period.

[0363] After 7 days, total RNA is isolated from the cells and isolated to evaluate the expression of p21(Cdkn1a), Il1b, Il11, and Tgfb, as well as p16 and p53, as described in Example 3.2. The cells are also subjected to phenotypic evaluation of cell hypertrophy and nuclear expansion. The cells are also analyzed for chromatin condensation, DNA damage, replication capacity, ROS generation and oxidative stress, SASP gene and protein expression, energy phenotypic analysis and mitochondrial activity / damage, cellular glycolysis, as well as autophagy and nutrient sensing pathway activity (mTOR, AMPK, etc.).

[0364] Treatment with an antibody antagonist of IL-11-mediated signaling was shown to reduce levels of cellular senescence markers compared to treatment with an IgG control antibody, indicating that antagonism of IL-11-mediated signaling can inhibit the induction of cellular senescence.

[0365] 3.4 Effect of IL-11-mediated signaling antagonism on the expression of cellular aging markers in an in vitro model of senescence induction using human cells Primary human hepatocytes or AML12 cells are grown to a 50% concentration, and aging is induced by treating the cells with a sublethal concentration of H2O2 (0.75 mM) for 1 hour each day for a total of 7 days, followed by a 23-hour recovery period.

[0366] From day 7, treat the cells with 2 μg / ml of X209 / X203 or isotype-matched control IgG. After 14 days, total RNA is isolated from the cells and isolated to evaluate the expression of p21(Cdkn1a), Il1b, Il11, and Tgfb, as well as p16 and p53, as described in Example 3.2. The cells are also subjected to phenotypic evaluation of cell hypertrophy and nuclear expansion. The cells are also analyzed for chromatin condensation, DNA damage, replication capacity, ROS generation and oxidative stress, SASP gene and protein expression, energy phenotypic analysis and mitochondrial activity / damage, cellular glycolysis, as well as autophagy and nutrient sensing pathway activity (mTOR, AMPK, etc.).

[0367] Treatment with an antibody antagonist of IL-11-mediated signaling was shown to reduce levels of cellular senescence markers compared to treatment with an IgG control antibody, suggesting that antagonism of IL-11-mediated signaling can reverse the induction of cellular senescence.

[0368] Example 4: In vitro evaluation of the effects of IL-11-mediated signaling on the aging pathway. Cellular senescence is one of the nine "characteristics of aging," or pathways that accelerate the aging process (Lopez-Otin et al., 2013, Cell 153(6): pp. 1194-1217).

[0369] The inventors investigated the effects of IL-11-mediated signaling on key characteristics of aging: nutrient sensing (Liu and Sabatini 2020, Nature Reviews. Molecular Cell Biology 21(4): pp. 183-203), decreased protein equilibrium (Kaushik and Cuervo 2015, Nature Medicine 21(12): pp. 1406-1415), and cellular senescence (Dolgin 2020, Nature Biotechnology 38(12): pp. 1371-1377). The aging pathways associated with these characteristics are: insulin / IGF-1 signaling (IIS), the mammalian target of rapamycin 1 (mTORC1), AMP-activated kinase (AMPK), and the MEK / ERK pathway.

[0370] 4.1 Effects of IL-11 on the aging pathway in human cardiac fibroblasts Primary human cardiac fibroblasts were stimulated with IL-11 (10 ng / ml) for 15 minutes, 2 hours, 4 hours, 6 hours, or 24 hours, and the levels of phosphorylated LKB1 (p-LKB1), LKB1, phosphorylated mTOR (p-mTOR), and mTOR were measured by Western blotting.

[0371] Stimulation with IL-11 increases the levels of phosphorylated LKB1 and phosphorylated mTOR (Figure 15). This data suggests that IL-11-mediated signaling plays a role in the inactivation of LKB1 through phosphorylation, which then leads to the activation of mTORC1. This is a novel finding, as to the inventors' knowledge, LKB1 was only thought to be constitutively active and not regulated by phosphorylation.

[0372] 4.2 IL-11 stimulates phosphorylation of LKB1 To determine the mechanism by which IL-11 stimulates LKB1 phosphorylation, A549 cells were engineered to overexpress human LKB1 (AA8-LKB1 in Figure 16A) and treated with IL-11. Western blot analysis revealed that IL-11 stimulates ERK-mediated phosphorylation of LKB1 serine 325 (S325) and P90RSK-mediated phosphorylation of LKB1 serine 428 (S428).

[0373] The inventors identified that IL-11-mediated signaling activates ERK and P90RSK, biphosphateming LKB1, which leads to its inactivation and promotes key characteristics of aging. A schematic diagram outlining the role of IL-11 is shown in Figure 16B. Examples disclosed herein confirm that inhibition of IL-11-mediated signaling by neutralizing antibodies or deletion of Il11ra blocks ERK activation, stimulates LKB1 / AMPK, and inhibits mTORC1 / P70S6K while reducing aging markers (P16 and p21), thereby confirming that inhibition / inactivation of IL-11 equally targets multiple critical aging processes (metabolism, inflammation, protein translation, and senescence).

[0374] Human hepatic astrocytes (Figure 17A) and human hepatocytes (Figure 17B) were engineered to overexpress wild-type LKB1 and double mutants S325A and S428A (DM-LKB1). Figures 17A and 17B confirm that IL-11 stimulation induces phosphorylation at S428 (ERK site) and S325 (P90RSK site) in WT LKB1 cells. As expected, phosphorylation is not observed in double mutant LKB1 cells.

[0375] The inventors believe that the undetectable absence of S325 phosphorylation in cells that do not overexpress LKB1 (absence) is due to the low sensitivity of the antibody. 4.3 Effects of rapamycin, wartmannin, or U0126 on IL-11 stimulated human cardiac fibroblasts Primary human cardiac fibroblasts were stimulated with IL-11 for 24 hours in the presence of DMSO, rapamycin (mTOR inhibitor), wartmannin (phosphoinositide 3-kinase (PI3K) inhibitor), or U0126 (MEK1 / 2 inhibitor), and levels of p-LKB1 and p-AMPK were measured by Western blotting (Figure 18).

[0376] When IL-11-stimulated fibroblasts are treated with rapamycin, wartmannin, or U0126, p-LKB1 levels decrease while p-AMPK levels increase. This data indicates that each of rapamycin, wartmannin, or U0126 partially inhibits IL-11-mediated phosphorylation of LKB1 and subsequent dephosphorylation of AMPK, thus confirming that IL-11 promotes the MEK / ERK, AMPK, and mTORC1 pathways.

[0377] 4.4 Effects of IL-11-mediated signaling antagonism on aging pathways in human cardiac fibroblasts Primary human cardiac fibroblasts were stimulated with or without IL11 or TGFβ1 (BL). Figure 19 shows the levels of various markers determined by Western blotting.

[0378] Firstly, this data further confirms the role of IL-11 as an activator of ERK, which phosphorylates and inactivates LKB1 directly and indirectly through P90RSK. As described in Example 4.1, LKB1 was previously thought to be constitutively active and not regulated by phosphorylation. IL-11-induced p-ERK and p-p90RSK phosphorylate and inactivate LKB1, which then leads to the inactivation (dephosphorylation) of AMPK. Inactive AMPK can no longer activate members of the TSC complex that inhibit mTORC1. Thus, mTORC1 is activated (phosphorylated). Activated mTORC1 phosphorylates and activates P70S6K and S6-ribosomal protein (RPS6 or S6RP) to stimulate many other aging-promoting pathways, including inhibition of autophagy, which impairs protein synthesis and protein equilibrium.

[0379] Both X203 (anti-IL-11 antagonist antibody) and X209 (anti-IL-11Rα antagonist antibody) significantly reduce the phosphorylation levels of the markers ERK, p90RSK, LKB1, mTOR, p70S6K, and S6RP. Treatment with X203 or X209 essentially reverses the effects of IL-11 / TGFβ1 stimulation on these markers to levels observed in unstimulated controls.

[0380] 4.5 Effects of IL-11-mediated signaling antagonism on aging pathways in human hepatocytes Primary human hepatocytes (stimulated or unstimulated with IL-11, BSA, or palmitate) were treated with X203 (anti-IL-11 antagonist antibody) and X209 (anti-IL-11Rα antagonist antibody). Figure 20 shows that treatment with X203 or X209 reduces the levels of phosphorylated markers p-ERK, p-p90RSK, p-LKB1, p-mTOR, p-p70S6K, and p-S6RP, but stimulates AMPK and acetyl coenzyme A carboxylase (ACC), as evidenced by the increase in p-AMPK and p-ACC levels. Treatment with X203 or X209 essentially reverses the effect of palmitate stimulation on these markers to levels observed in the unstimulated control.

[0381] 4.6 Effects of IL-11 on aging pathways in primary human hepatic stellate cells and human hepatocytes in the presence of U0126 Primary human hepatic stellate cells and human hepatocytes were stimulated with IL-11 for 24 hours in the presence of DMSO or U0126. As discussed in Example 4.4, the inventors observed that IL-11 treatment stimulated p-mTOR, p-70S6K, and p-S6RP. Consistent with the inventors' hypothesis, administration of U0126 to IL-11-stimulated cells blocked ERK-mediated inactivation of LKB1 / AMPK, which terminates IL-11-induced mTORC1 / P70S6K activation (Figures 21 and 22, respectively).

[0382] 4.7 Relative effects of IL-11 and IL-6 on the aging pathway in primary human hepatic stellate cells and human hepatocytes. Primary human hepatic stellate cells (HSCs) and human hepatocytes were stimulated for 24 hours with increasing concentrations of IL-11 or IL-6 (1.25–20 ng / ml). Unlike IL-11, IL-6 did not induce LKB1 inactivation or AMPK activation even at the highest concentration (Figure 23). The effects of IL-11 on these markers were observable in both HSCs and hepatocytes at a low concentration of 1.25 ng / ml.

[0383] 4.8 Effects of X209 and X203 in in vitro models of aging Anti-aging experiments were performed as shown in Figure 24A. Briefly, aged AML12 cells were generated by treating cells with sublethal concentrations of H2O2, as described by Tripathi et al. (2020) STAR Protocols 1(2):100064. IgG / X209 (2 μg / ml) was added to the culture for 10 days during a 23-hour recovery period. Relative mRNA expression of Cdkn2a (p16), Cdkn1a (p21), Il1β, Il8, and Il11, as measured by qPCR, is shown in Figures 24B, 24C, 24D, 24E, and 24F, respectively. Cells antagonized by X209 of IL-11-mediated signaling showed reduced levels of aging markers (P16 and p21) and inflammatory markers (IL-1β, IL-11, and IL-6).

[0384] The aging reversal experiment was performed as shown in Figure 25A. Briefly, aged AML12 was prepared for 7 days as described above, but at the end of the 72-hour aging induction period, IgG / X203 / X209 (2 μg / ml) was added to the culture. X203 and X209 antagonists of IL-11-mediated signaling significantly reduced the aging marker p21 (Figure 25B) and the inflammatory markers IL-1b (Figure 25C) and IL-11 (Figure 25D).

[0385] In summary, in an in vitro model of aging (AML12 cells), anti-IL-11 or anti-IL-11RA antagonists inhibit and even reverse cellular senescence. Example 5: Detection of age-related IL-11 upregulation in vivo 5.1 Upregulation of IL-11 in tissues of aged EGFP reporter mice IL11:EGFP Reporter Mouse (Il11-Egfp + / -(Widjaja et al., 2021, Science Translational Medicine 13(597))) was created and brought to 110 weeks of age. Figure 26 shows immunofluorescence images of the kidneys of "aged" IL11:EGFP reporter mice compared to wild-type 110-week-old mice. EGFP staining was not detected in the age-matched control kidneys from wild-type mice.

[0386] IL-11 expression in ventricular and atrium (Figure 27), lung (Figure 28), and spleen (Figure 29) cells was observed in aged (110-week-old) IL11:EGFP reporter mice. EGFP staining was absent (or almost absent) in age-matched control or young (10-week-old) IL11:EGFP reporter mice. IL-11 was upregulated in the tissues of aged mice, and these findings support the role of IL-11 in promoting the aging pathway.

[0387] 5.2 Upregulation of IL-11 in abdominal fat in aged WT mice Western blot analysis (Figure 30) demonstrates that IL-11 is upregulated in abdominal adipose tissue of 110-week-old wild-type mice.

[0388] Example 6: In vivo study in IL11RA1 knockout mice 6.1 Effects of Il11ra1 deletion on the aging pathway Il11ra1-KO male mice were generated and allowed to reach 10-12 weeks of age (young) and 110 weeks of age (elderly). Figure 31 demonstrates that the livers of elderly Il11ra1-deficient mice have lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to wild-type mice and young Il11ra1-deficient mice, thus confirming the role of IL-11 in accelerating the aging pathway. The same results were observed in the gastrocnemius muscle (Figure 32), soleus muscle (Figure 33), and abdominal fat (Figure 34) of elderly Il11ra1-deficient mice.

[0389] 6.1 Effects of Il11ra1 deletion on phenotype Phenotypic studies revealed that aged Il11ra1-KO mice had lower body weight (Figure 35), a lower percentage of body fat (Figure 36), and a higher percentage of lean muscle mass (Figure 37) compared to wild-type controls. Furthermore, aged Il11ra1-KO mice showed significantly reduced frailty (Figure 38) and higher body temperature (Figure 39) compared to wild-type controls.

[0390] Deletion of Il11ra1 led to aged mice with less abdominal fat and more muscle (soleus and gastrocnemius) compared to wild-type controls (Figures 40A, 40B, and 40C).

[0391] Fibrosis of abdominal fat, gastrocnemius muscle, soleus muscle, liver, atria, ventricles, kidneys, and lungs was evaluated based on collagen content in aged Il11ra1-KO mice compared to wild-type controls (Figures 41A-41D and 42A-42D). Aged Il11ra1 KO mice had less fibrosis across these tissues.

[0392] Example 6 demonstrates that mice deleting Il11ra1 at 110 weeks of age mirror the phenotype observed with X203 administration (Example 1 and Figures 1, 2, 3, 4A and 4B), namely, improved multimorbidity with better serum levels of fat and glucose, less histofibrosis, better renal function, reduced tissue inflammation, reduced obesity and less frailty. It further demonstrates that Il11ra1-KO mice have a more similar aging signaling profile across tissues to younger mice.

[0393] Example 7: Effects of IL-11 antagonism (X203) on the aging pathway in vivo Figures 43 and 44 demonstrate that the livers of 110-week-old mice treated with neutralizing IL-11 antibody (X203) have lower ERK / LKB1 / mTORC1 activity, higher AMPK activity, and lower expression of key aging markers (p16 and p21) compared to aged and young (12-week-old) mice treated with IgG controls. The same results are observed in the gastrocnemius muscle (Figures 45 and 46), soleus muscle (Figures 47 and 48), and abdominal fat (Figures 49 and 50) of aged mice treated with X203.

[0394] In summary, neutralizing IL-11 antibodies restore LKB1 / AMPK activity, reduce mTORC1 activity, and inhibit the expression of key aging markers p16 and p21 in the liver, skeletal muscle (soleus and gastrocnemius), and abdominal fat of aged mice.

[0395] Example 8: Effects of IL-11 antagonist (X203) on inflammatory markers in vivo Altered intercellular communication, particularly increased chronic inflammation and IL-6 upregulation, are key characteristics of aging that can be targeted to prevent, treat, and / or reverse the aging process (Furman et al., 2019, Nature Medicine 25(12):1822-32; Ferrucci and Fabbri, 2018, Nature Reviews. Cardiology 15(9):505-22; Ershler and Keller, 2000, Annual Review of Medicine 51:245-70).

[0396] 8.1 Effects of X203 on serum IL-6 levels IL-6 is strongly associated with aging (Maggio et al., 2006, J Gerontol A Biol Sci Med Sci. 61(6): pp. 575-584; Ershler and Keller 2000, Annual Review of Medicine 51: pp. 245-70). Figure 50 shows the effect of treatment with anti-IL11 (X203) or IgG isotype controls on serum IL-6 levels in aged (110-week-old) male and female mice. X203-neutralizing IL-11 antibody significantly reduces serum IL-6 protein levels in aged mice.

[0397] 8.2 Effects of X203 on inflammatory markers in the liver, kidneys, and muscles Administration of neutralizing anti-IL-11(X203) versus IgG to aged mice reduced inflammatory markers (CCL2, CCL5, TNFα, IL-1β, IL-11, and IL-6), which corresponds to age-related altered intercellular communication characteristics across tissues including the liver (Figure 52), kidney (Figure 53), and skeletal muscle (Figure 54). The effect on IL-6 was even more pronounced in the liver and kidney at the qPCR level.

[0398] In summary, the data disclosed herein demonstrate that antagonism of IL-11-mediated signaling (e.g., by anti-IL-11 therapy) reduces several characteristics of aging: nutrient sensing, decreased protein balance, cellular senescence, and altered intercellular communication (inflammation). This is achieved by simultaneously targeting multiple aging modules in parallel: ERK, AMPK, and mTORC1.

[0399] Furthermore, the data discloses the following: Administration of the MEK1 / 2 inhibitor U0126 to IL11-stimulated cells inhibits ERK-mediated inactivation of LKB1 / AMPK, which terminates IL11-induced mTORC1 / P70S6K activation.

[0400] Administration of anti-IL11(X203) versus IgG control to 55-110 week old mice results in less ERK activation, recovery of LKB1 / AMPK activity, and reduced mTORC1 activity and aging markers (p16 / p21). This is observed across tissues.

[0401] • 110-week-old IL11RA1-deficient mice mirrored the effects observed with X203 administration and exhibited a more similar signaling profile across tissues to younger mice. Administration of X203 versus IgG to aged mice resulted in improved polymorbidity with better serum levels of fat and glucose, less histofibrosis, better renal function, reduced tissue inflammation, reduced obesity, and less frailty.

[0402] Administration of X203 versus IgG to aged mice enhances inflammatory markers (CCL2, CCL5, TNFa, IL1b, IL11, and IL6)—characteristics of age-related altered intercellular communication—across tissues including the liver, kidney, and skeletal muscle. The effect on IL-6, which is strongly associated with aging, is particularly pronounced in the liver and kidney at the QPCR level, and IL-6 levels are systematically lower in the serum of aged mice after anti-IL11 administration (Maggio et al., 2006; Ershler and Keller, 2000).

[0403] • 110-week-old Il11ra1-deficient mice exhibit reduced polymorbidity, less histofibrosis, better renal function, reduced tissue inflammation, reduced obesity, and less frailty compared to littermates and controls, due to superior serum levels of fat and glucose.

[0404] In an in vitro model of aging (AML12 cells), anti-IL11 or anti-IL11RA inhibits and even reverses cellular senescence. Using a certified frailty scoring system (Sukoff Rizzo et al., 2018), treatment of mice with anti-IL11 for 55–110 weeks was associated with statistically significantly less frailty compared to controls.

[0405] · Using the validated frailty scoring system (Sukoff Rizzo et al., 2018), IL11RA1 KO mice have significantly less frailty statistically compared to wild-type littermate controls.

[0406] Example 9: Materials and Methods Used in Examples 5-8 Chemical Substances Hydrogen peroxide (H2O2, 31642, Sigma), palmitate (P5585, Sigma), rapamycin (9904, CST), U0126 (9903, CST). U0126 is a highly selective inhibitor of MEK1 and MEK2, a kind of MAPK / ERK kinase, wortmannin (9951, CST).

[0407] Cell Culture Cells were grown and maintained at 37 °C and 5% CO2. The growth medium was renewed every 2-3 days, and cells were passaged at 80% confluence using standard trypsinization techniques. All experiments were performed at low cell passages (<P3). Cells were serum-starved in basal medium overnight before stimulation. As outlined in the figure legends, cells were stimulated under different treatment conditions and durations. Stimulated cells were compared to unstimulated cells grown for the same duration under the same conditions but without stimulation.

[0408] Primary Human Cardiac Fibroblasts (HCF) Primary HCF (6330, ScienCell) were grown and maintained in FM-2 complete medium containing fibroblast medium 2 (2331, ScienCell), fibroblast growth supplement 2 (FGS-2, 2382, ScienCell), 5% fetal bovine serum and 1% penicillin-streptomycin (P / S, 0353, ScienCell).

[0409] Primary Human Hepatic Stellate Cells (HSC) HSC (5300, ScienCell) were cultured in stellate cell complete medium (5301, ScienCell) on plates coated with poly-L-lysine (2 μg / cm 2 , 0403, ScienCell).

[0410] Primary human hepatocytes Primary human hepatocytes (5200, ScienCell) were maintained at 37°C and 5% CO2 in hepatocyte medium (5201, ScienCell) supplemented with 2% fetal bovine serum and 1% penicillin-streptomycin.

[0411] AML12 AML12 (ATCC) was cultured in DMEM:F12 medium (30-2006, ATCC) supplemented with 10% FBS, 10 μg / ml insulin, 5.5 μg / ml transferrin, 5 ng / ml selenium, and 40 ng / ml dexamethasone.

[0412] Aging induction As described (Tripathi, Yen and Singh, 2020 STAR Protocols 1(2):100064), aged AML12 cells were produced by treating cells with a sublethal concentration of H2O2 (0.75 mM) for 1 hour each day for 7 days, followed by a 23-hour recovery period. For prophylactic testing, AML12 cells were treated with 2 μg / ml of IgG or X209 during the recovery period of the senescence induction phase (days 1 to 7); cells were collected on day 10 for total RNA collection. For reversal testing, senescence was first induced for 7 days, followed by treatment with 2 μg / ml of IgG, X203, or X209 for 3 days; cells were collected on day 10 for total RNA collection.

[0413] Animal models In vivo administration of anti-IL11(X203) Male and female C57B1 / 6J mice at 46 weeks of age were purchased from Jackson Laboratory. Mice were randomized in a 1:1 ratio to receive 40 mg / kg of X203 or isotype-controlled IgG antibody (11E10) every 3 weeks starting at 55 weeks of age (IP). Mice were sacrificed at 110 weeks of age for blood and tissue collection. Male and female C57B1 / 6J mice at 12 weeks of age were purchased from Invivos (Singapore) for use as controls.

[0414] Il11ra1-deficient mouse (Il11ra1 KO, B6.129S1-Il11ra tm1Wehi (J, Jackson's Laboratory) For blood and tissue collection, male and female Il11ra1 at 110 weeks of age. + / + (Wild type) and Il11ra1 - / - Mice were sacrificed; male and female mice of each genotype, aged 10–12 weeks, were used as controls.

[0415] Ultrasound MRI analysis for body composition Total fat mass and lean body mass were measured two days prior to slaughter by EchoMRI analysis using a 4-in-1 Body Composition Analyzer for Live Small Animals.

[0416] Weakness scoring Endpoint frailty scoring was performed two days prior to euthanasia using a certified frailty scoring system (Sukoff Rizzo et al., 2018, Current Protocols in Mouse Biology 8(2):e45).

[0417] Immunoblotting Western blotting was performed on total protein extracts from primary human cardiac fibroblasts (HCFs), hepatic stellate cells (HSCs), hepatocytes, liver, gastrocnemius muscle, soleus muscle, and abdominal fat. Cell or tissue lysates were homogenized with RIPA lysis and extraction buffer (89901, Thermo Scientific) containing a protease and phosphatase inhibitor (Roche). Protein lysates were separated by SDS-PAGE, transferred to a PVDF membrane, and blocked with 3% BSA for 1 hour to extract phospho-ACC (11818, CST), ACC (3676, CST), phospho-AMPK (2535, CST), AMPK (5832, CST), phospho-ERK1 / 2 (4370, CST), ERK1 / 2 (4695, CST), GAPDH (2118, CST), and phospho-LKB1 S428 (3482, CST), phospho-LKB1 (S325), LKB1 (3047, CST), phospho-mTOR (2971, CST), mTOR (2972, CST), p16 (ab232402, Abcam), p21 (64016, CST), phospho-p70S6K (9205, CST), p70S6K (2708, CST), phospho-S6 ribosomal protein (4858, CST), or S6 ribosomal protein (2217, CST) were incubated overnight. All primary antibodies were diluted 1:1000 in 1% BSA. Protein bands were visualized using an ECL detection system (Pierce) with anti-rabbit HRP (1:2000 in 3% BSA, 7074, CST).

[0418] Hydroxyproline assay The total hydroxyproline content in mouse liver was measured using the Quickzyme Total Collagen Assay Kit (QZBtotco15, Quickzyme Biosciences).

[0419] Enzyme-linked immunosorbent assay (ELISA) The levels of IL-6 in mouse serum were quantified using the Mouse IL-6 Quantikine ELISA Kit (M6000B; R&D Systems).

[0420] RT-qPCR Total RNA was extracted from AML12 or rapidly frozen tissue using Trizol (Invitrogen) and the RNeasy mini-kit (Qiagen). PCR amplification was performed using the iScript cDNA synthesis kit (Biorad). Gene expression analysis was performed on two replicate samples over 40 cycles using TaqMan (Applied Biosystems) for Il11 (Mm00434162) or fast SYBR green (Qiagen) technology with StepOnePlus™ (Applied Biosystems) for Ccl2, Ccl5, Gapdh, Il1β, Il6, Il8, p16, p21, and Tnfα. Expression data were normalized to GAPDH mRNA expression, with a change factor of 2. -ΔΔCt The calculation was performed using the method.

[0421] [Table 3]

[0422] Immunofluorescence staining 110-week-old wild-type and IL11:EGFP reporter mice (IL11-EGFP + / -Kidneys, hearts, lungs, and spleens were harvested from (Widjaja et al., 2021, Science Translational Medicine 13(597)), fixed in 4% paraformaldehyde, dehydrated with 15% and 30% sucrose, and embedded in OCT cryoblock. Sections (7 μm) were prepared using standard methods by mouse-on-mouse blocking (MKB-2213-1, Vector Labs) and fixation in methanol:acetone (1:1) and 0.1% Triton-X100 combined with 5% normal goat serum. Kidney sections were stained for EGFP (GFP, ab290, Abcam (1:500)) and αSMA (αSMA, ab7817, Abcam (1:200)); cardiac (atrial and ventricular) sections were stained for EGFP (GFP, sc-9966, Santacruz (1:100)) and αSMA (αSMA, ab5694, Abcam (1:500)); and spleen sections were stained for EGFP (GFP, sc-9966, Santacruz (1:100)). Tissue sections were then incubated with appropriate secondary antibodies conjugated with a fluorophor: goat anti-rabbit IgG AF647 (A27040, ThermoFisher Scientific (1:500)) and goat anti-mouse IgG AF555 (A28180, ThermoFisher Scientific (1:500)), followed by autofluorescence quenching with 0.1% Sudan Black B in 70% ethanol.

[0423] References The following quote is fully incorporated by reference. Burkewitz, Kristopher, Yue Zhang, and William B. Mair. 2014. “AMPK at the Nexus of Energetics and Aging.” Cell Metabolism 20 (1): 10-25. Dolgin, Elie. 2020. “Send in the Senolytics.” Nature Biotechnology38 (12): 1371-77. Ershler, W. B., and E. T. Keller. 2000. “Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty.” Annual Review of Medicine 51: 245-70. Fernandes, Stephanie A., and Constantinos Demetriades. 2021. “The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging.” Frontiers in Aging 2: 38. Ferrucci, Luigi, and Elisa Fabbri. 2018. “Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty.” Nature Reviews. Cardiology 15 (9): 505-22. Furman, David, Judith Campisi, Eric Verdin, Pedro Carrera-Bastos, Sasha Targ, Claudio Franceschi, Luigi Ferrucci, et al. 2019. “Chronic Inflammation in the Etiology of Disease across the Life Span.” Nature Medicine25 (12): 1822-32. Kaushik, Susmita, and Ana Maria Cuervo. 2015. “Proteostasis and Aging.” Nature Medicine 21 (12): 1406-15. Liu, Grace Y., and David M. Sabatini. 2020. “mTOR at the Nexus of Nutrition, Growth, Ageing and Disease.” Nature Reviews. Molecular Cell Biology 21 (4): 183-203. Lopez-Otin, Carlos, Maria A. Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer. 2013. “The Hallmarks of Aging.” Cell 153 (6): 1194-1217. Maggio, Marcello, Jack M. Guralnik, Dan L. Longo, and Luigi Ferrucci. 2006. “Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway.” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences61 (6): 575-84. Shaw, Reuben J., Katja A. Lamia, Debbie Vasquez, Seung-Hoi Koo, Nabeel Bardeesy, Ronald A. Depinho, Marc Montminy, and Lewis C. Cantley. 2005. “The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin.” Science 310 (5754): 1642-46. Slack, Cathy, Nazif Alic, Andrea Foley, Melissa Cabecinha, Matthew P. Hoddinott, and Linda Partridge. 2015. “The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity.” Cell 162 (1): 72-83. Sukoff Rizzo, Stacey J., Laura C. Anderson, Torrian L. Green, Tracy McGarr, Gaylynn Wells, and Shawn S. Winter. 2018. “Assessing Healthspan and Lifespan Measures in Aging Mice: Optimization of Testing Protocols, Replicability, and Rater Reliability.” Current Protocols in Mouse Biology 8 (2): e45. Tripathi, Madhulika, Paul Michael Yen, and Brijesh Kumar Singh. 2020. “Protocol to Generate Senescent Cells from the Mouse Hepatic Cell Line AML12 to Study Hepatic Aging.” STAR Protocols 1 (2): 100064. Widjaja, Anissa A., Jinrui Dong, Eleonora Adami, Sivakumar Viswanathan, Benjamin Ng, Leroy S. Pakkiri, Sonia P. Chothani, et al. 2021. “Redefining IL11 as a Regeneration-Limiting Hepatotoxin and Therapeutic Target in Acetaminophen-Induced Liver Injury.” Science Translational Medicine 13 (597). https: / / doi.org / 10.1126 / scitranslmed.aba8146. Zhang, Yan, Jinjin Zhang, and Shixuan Wang. 2021. “The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging.” Ageing Research Reviews 70 (September): 101376.

Claims

1. An agent capable of inhibiting interleukin-11 (IL-11) mediated signal transduction for use in a method for treating or preventing an age-related disease / condition selected from: age-related inflammation, frailty, age-related increase in body fat mass, sarcopenia, age-related hyperlipidemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related hepatic steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

2. An agent capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in a method for treating or preventing frailty.

3. An agent capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in a method for treating or preventing age-related changes in body composition.

4. An agent capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in a method for extending the healthy lifespan of a subject.

5. The agent for use according to any one of claims 1 to 4, wherein the agent is selected from the group consisting of: an antibody or an antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer or a small molecule.

6. The method for use according to any one of claims 1 to 5, wherein the agent is capable of blocking or reducing the binding of interleukin-11 (IL-11) to the receptor for interleukin-11 (IL-11R).

7. The agent for use according to any one of claims 1 to 6, wherein said agent is capable of binding to interleukin 11 (IL-11) or the receptor for interleukin 11 (IL-11R).

8. The agent for use according to any one of claims 1 to 7, wherein the agent is an antibody or an antigen-binding fragment thereof.

9. The agent for use according to any one of claims 1 to 8, wherein said agent is an anti-IL-11 antibody antagonist of IL-11 mediated signaling or an antigen-binding fragment thereof.

10. The agent for use according to any one of claims 1 to 9, wherein said agent is an anti-IL-11Rα antibody antagonist of IL-11 mediated signaling or an antigen-binding fragment thereof.

11. The agent for use according to any one of claims 1 to 7, wherein said agent is a decoy receptor for IL-11.

12. The agent for use according to any one of claims 1 to 7, wherein said agent is a competitive inhibitor of IL-11.

13. The agent for use according to any one of claims 1 to 5, wherein said agent is capable of blocking or reducing expression of interleukin 11 (IL-11) or the receptor for interleukin 11 (IL-11R).

14. The agent for use according to claim 13, wherein said agent is an antisense oligonucleotide capable of blocking or reducing the expression of IL-11.

15. The agent for use according to claim 13, wherein said agent is an antisense oligonucleotide capable of blocking or reducing the expression of IL-11Rα.

16. 16. The agent for use according to any one of claims 1 to 15, wherein the method comprises administering the agent to a subject in which expression of interleukin 11 (IL-11) or the receptor for IL-11 (IL-11R) is upregulated.